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Abstract 
The overall aim was to produce a magnetolipopolyplex, a multimodal-imaging agent, for the 
detection of cancer. Iron oxide nanoparticles, which are used as negative contrast agents in 
magnetic  resonance  imaging  were  encapsulated  into  biocompatible  liposomes  alongside 
plasmid DNA and targeting peptides. The plasmid DNA provides the potential for optical 
imaging and PET through the inclusion of the red fluorescent protein reporter gene and the 
human  sodium  iodide  symporter,  which  can  be  radiolabelled.  The  inclusion  of  targeting 
peptides in the formulation of the magnetolipopolyplexes allows for its site-specific delivery.  
Initially, poly(L)lysine (PLL) was bio-conjugated to the surface of commercially available iron 
oxide nanoparticles (MNPs) coated with dextran, rendering the surface charge of the MNPs 
positive and thus allowing for the electrostatic binding of negatively charged plasmid DNA 
(pDNA) to the surface. Two plasmids were produced; one coding for the red fluorescent 
protein (RFP gene) for optical imaging and the other with both RFP and the human sodium 
iodide symporter (hNIS) which can be radiolabelled for PET imaging. Once the pDNA was 
electrostatically bound to the PLL on the surface of the MNP, the functionalised MNP was 
encapsulated  into  a  cationic  liposome  in  order  to  produce  a  biocompatible  means  of 
delivering the liposome both in vivo and in vitro. Unfortunately, poor results were obtained for 
the  in  vitro  transfections,  which  were  attributed  to  their  large  size  and  negative  surface 
charges.  
To overcome the issues faced by the formulation method and in vitro transfections studies, 
an alternative method of magnetolipopolyplex formulation was carried out. Here, negatively 
charged MNPs, coated with either carboxymethyldextran or citric acid, were added to pre-
formulated  cationic  liposomes.  The  negative  surface  charge  of  the  MNP  allowed  the 
successful  diffusion  of  the  MNPs  through  the  positively  charged  lipid  membrane  to  form 
magnetoliposomes.  To  these  magnetoliposomes  co-condensed  pDNA  and  K16  peptides 
was  also  added,  ultimately  forming  magnetolipopolyplexes.  Dynamic  light  scattering  and 
zetapotential  characterisation  data  confirmed  the  successful  formulation  of  the 
magnetolipopolyplexes  and  subsequent  in  vitro  transfection  studies  were  carried  out  to 
establish  the  transfection  efficiency  of  the  magnetolipopolyplexes  by  measuring  the  RFP   4 
expression  of  the  pDNA.  SQUID  magnetometry  data  was  obtained  to  determine  the 
concentration of the MNPs taken up into the cells following the incubation of the cells with 
the magnetlipopolyplexes.  
The  encapsulation  of  MNPs,  pDNA  and  peptides  into  liposomes  demonstrates  the 
successful formulation of a multimodal-imaging agent with the potential for optical, PET and 
MRI imaging modalities.  
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Abbreviations  
C/D  CH300/DOPE 
(cc)DEX@MNP  Chemicell Dextran functionalised Nanoparticles 
(cc)CDEX@MNP  Chemicell Carboxymethyldextran functionalised 
Nanoparticles 
CDEX@MNP  Carboxymethyldextran functionalised Nanoparticles 
Cy3  Cyanine-3 
DAPI  4',6-diamidino-2-phenylindole  
D/D  DOTMA/DOPE 
DEX@MNP  Dextran functionalised Nanoparticles 
DLS  Dynamic Light Scattering 
DOPE  1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
DOTAP  1,2-dioleoyl-3-trimethylammoniumpropane 
DOTMA  1,2-di-O-octadecenyl-3-trimethylammoniumpropane 
DT/D  DOTAP/DOPE 
D:P@N  Magnetopolyplex 
EPR  Enhanced Permeability and Retention 
FITC  Fluorescein isothiocyanate 
FTIR   Fourier Transform Infrared Spectroscopy 
ICP-AES  Inductively Coupled Plasma–Atomic Emission Spectroscopy 
L  Liposome 
LB  Lysogeny Broth 
L:N  Magnetoliposome 
L:P:D  Lipopolyplex 
L:P:D:N  Magnetolipopolyplex (where PLL co-condensed with pDNA 
and added to the formulated L:N)  
L:D:P@N  Magnetolipopolyplex (where PLL conjugated to the surface of 
the MNP) 
ML  Magnetoliposome   23 
(mm)DEX@MNP  Micromod Dextran functionalised Nanoparticles 
(mm)CDEX@MNP  Micromod Carboxymethyldextran functionalised 
Nanoparticles 
MNP  Magnetic Nanoparticle 
MRI  Magnetic Resonance Imaging 
MWCO  Molecular Weight Cut Off 
N  Nanoparticle 
PBS  Phosphate Buffer Solution 
pDNA  Plasmid DNA 
PEG  Poly(ethylene) Glycol 
Pen/strep  Penicillin/Streptomycin 
PET  Positron Emission Tomography 
PLL  Poly(L)lysine 
P@N  Poly(L)lysine Conjugated Nanoparticle 
RES  Reticulo-endothelial System 
RFP  Red Fluorescent Protein 
ROS  Reactive Oxygen Species 
SQUID  Superconducting Quantum Interference Device 
TAE  Buffer containing Tris Base, Acetic Acid and EDTA 
TEM  Transmission Electron Microscopy 
TP  Targeting Peptide 
XRD  X-ray Diffraction 
ZP   Zetapotential 
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Thesis Aim 
The purpose of this work was to formulate magnetolipopolyplexes (L:P:D:Ns), which contain 
iron  oxide  MNPs,  plasmid  DNA,  shielding  lipids  and  targeting  peptides  for  use  as  a 
multimodal diagnostic agent for cancer. The iron oxide MNPs serve as a negative contrast 
agent for MRI and the plasmid DNA codes for both a fluorescent protein (RFP) for optical 
imaging and the human sodium iodide symporter (hNIS), which can be radiolabelled for use 
as a PET imaging agent. Targeting peptides were also included in the formulation, providing 
cell-specific delivery of the L:P:D:Ns.  
Chapter  1  provides  an  introduction  into  the  use  of  iron  oxide  MNPs  in  biomedicine, 
diagnostic techniques used to image cancer, the use of liposomes for delivery of DNA and 
MNPs  to  the  site  of  interest,  challenges  faced  in  vivo  and  cancer  imaging  techniques 
including MRI and PET. Chapter 2 discusses the methods used to functionalise the MNPs, 
the  encapsulation  of  the  pDNA,  MNPs  and  targeting  peptides  into  liposomes  and  the 
methods  used  to  image  the  L:P:D:Ns  in  vitro.  Chapters  3  and  4  are  focussed  on  the 
formulation, characterisation and the in vitro transfection studies of magnetolipopolyplexes in 
a variety of cell lines.  
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1.0 Introduction 
1.1 Background 
1.1.1 What is Cancer?  
Cancer  is  defined  as  the  uncontrolled  proliferation  of  mutated  cells  in  the  body.  Cancer 
Research UK recorded 311,487 cancer diagnoses in 2011, with breast, lung, prostate and 
bowel accounting for over half these and one out of four deaths in the UK a result of cancer. 
The World Health Organisation recorded 7.6 million cancer related deaths across the world 
in 2008. 
1  
The uncontrolled growth and defects of the mutated cells are due to abnormalities arising in 
the regulatory pathways that dictate normal cell division and replication.
2 There are over one 
hundred different types of cancer recognised today, with further subtypes found in certain 
cancers. Hanahan and Weinberg proposed that the causes for all these cancer types could 
be  attributed  to  six  essential  factors,  which  account  for  the  breakdown  in  regulatory  cell 
growth pathways, Figure 1. 
3  
 
Figure 1: The Six Key Factors which Contribute to the Onset of Cancer (Reproduced from Reference 3 with 
permission from Elsevier Ltd) 
Cell
58
AcquiredGSautonomywasthefirstofthesixcapabili-
ties to be clearly defined by cancer researchers, in large
part because of the prevalence of dominant oncogenes
that have been found to modulate it. Three common
molecular strategies for achieving autonomy are evi-
dent, involving alteration of extracellular growth signals,
of transcellular transducers of those signals, or of intra-
cellular circuits that translate those signals into action.
While most soluble mitogenic growth factors (GFs) are
made by one cell type in order to stimulate proliferation
of another—the process of heterotypic signaling—many
cancer cells acquire the ability to synthesize GFs to
which they are responsive, creating a positive feedback
signaling loop often termed autocrine stimulation (Fedi
etal.,1997).Clearly,themanufactureofaGFbyacancer
cell obviates dependence on GFs from other cells within
the tissue. The production of PDGF (platelet-derived
growth factor) and TGF￿ (tumor growth factor ￿) by
glioblastomas and sarcomas, respectively, are two illus-
trative examples (Fedi et al., 1997).
The cell surface receptors that transduce growth-
stimulatory signals into the cell interior are themselves
targets of deregulation during tumor pathogenesis. GF
receptors, often carrying tyrosine kinase activities in
their cytoplasmic domains, are overexpressed in many
cancers. Receptor overexpression may enable the can-
cer cell to become hyperresponsive to ambient levels Figure 1. Acquired Capabilities of Cancer
of GF that normally would not trigger proliferation (Fedi We suggest that most if not all cancers have acquired the same set
et al., 1997). For example, the epidermal GF receptor of functional capabilities during their development, albeit through
various mechanistic strategies. (EGF-R/erbB) is upregulated in stomach, brain, and
breast tumors, while the HER2/neu receptor is overex-
pressed in stomach and mammary carcinomas (Slamon
etal.,1987;YardenandUllrich,1988).Additionally,gross We describe each capability in turn below, illustrate with
overexpression of GF receptors can elicit ligand-inde- a few examples its functional importance, and indicate
pendent signaling (DiFiore et al., 1987). Ligand-indepen- strategies by which it is acquired in human cancers.
dent signaling can also be achieved through structural
alteration of receptors; for example, truncated versions
Acquired Capability: Self-Sufficiency
of the EGF receptor lacking much of its cytoplasmic
in Growth Signals domain fire constitutively (Fedi et al., 1997).
Normal cells require mitogenic growth signals (GS) be- Cancer cells can also switch the types of extracellular
fore they can move from a quiescent state into an active matrix receptors (integrins) they express, favoring ones
proliferative state.These signals are transmittedinto the that transmit progrowth signals (Lukashev and Werb,
cell by transmembrane receptors that bind distinctive 1998;GiancottiandRuoslahti,1999).Thesebifunctional,
classes of signaling molecules: diffusible growth fac- heterodimeric cell surface receptors physically link cells
tors, extracellular matrix components, and cell-to-cell toextracellularsuperstructuresknownastheextracellu-
adhesion/interaction molecules. To our knowledge, no lar matrix(ECM). Successfulbinding tospecific moieties
type of normal cell can proliferate in the absence of of the ECM enables the integrin receptors to transduce
such stimulatory signals. Many of the oncogenes in the signals into the cytoplasm that influence cell behavior,
cancer catalog act by mimicking normal growth signal- ranging from quiescence in normal tissue to motility,
ing in one way or another. resistance to apoptosis, and entrance into the active
Dependence on growth signaling is apparent when cell cycle. Conversely, the failure of integrins to forge
propagating normal cells in culture, which typically pro- these extracellular links can impair cell motility, induce
liferate only when supplied with appropriate diffusible apoptosis, or cause cell cycle arrest (Giancotti and Ru-
mitogenic factors and a proper substratum for their inte- oslahti, 1999). Both ligand-activated GF receptors and
grins. Such behavior contrasts strongly with that of tu- progrowth integrins engaged to extracellular matrix
mor cells, which invariably show a greatly reduced components can activate the SOS-Ras-Raf-MAP kinase
dependenceonexogenousgrowthstimulation.Thecon- pathway (Aplin et al., 1998; Giancotti and Ruoslahti,
clusion is that tumor cells generate many of their own 1999).
growth signals, thereby reducing their dependence on ThemostcomplexmechanismsofacquiredGSauton-
stimulation from their normal tissue microenvironment. omy derive from alterations in components of the down-
This liberation from dependence on exogenously de- stream cytoplasmic circuitry that receives and pro-
rived signals disrupts a critically important homeostatic cesses the signals emitted by ligand-activated GF
mechanism that normally operates to ensure a proper receptors and integrins. The SOS-Ras-Raf-MAPK cas-
cade plays a central role here. In about 25% of human behavior of the various cell types within a tissue.  26 
1.1.2 Current Challenges Associated with Cancer Diagnosis and Therapy 
There are currently many challenges associated with the way in which cancers are both 
detected  and  treated.  Perhaps  the  most  significant  issue  is  the  late  diagnosis  and 
subsequent late treatment of cancer, which is associated with an increased occurrence of 
the metastatic spread of cancer cells. 
4,5 Menon et al. estimated that around 60% of patients 
diagnosed with breast, ovarian, lung, colon and prostate cancers already have metastases 
at the time of cancer diagnosis.
 6  
Conventional  methods  for  treating  cancer  are  also  a  key  challenge  with  popular 
chemotherapeutic  techniques  involving  the  intravenous  administration  of  cytotoxic  agents 
which target rapidly dividing cells such as cancer cells. However, there are many side effects 
associated with these treatments including alopecia and gastrointestinal problems as a result 
of the chemotherapy targeting the rapidly dividing ‘normal’ cells such as hair and gut cells.
 4-
5,7 
1.1.3 The Use of Nanotechnology in Cancer Diagnosis and Therapy 
To overcome the issues faced by conventional diagnostic and therapeutic techniques, new, 
targeted approaches are being developed with the goal of selectively targeting cells that are 
in the early stages of mutation.
 In order to maximise the efficacy per dose two synergistic 
goals must be taken into consideration; ensuring the in vivo selectivity of the compound and 
evading biological clearance processes that hinder its progress in reaching the target. 
8  
Nanotechnology  is  the  study  of  devices  that  are  in  the  size  range  of  a  few  atoms  to  a 
subcellular  size,  1-1000  nm.
8 Nanomedicine  can  provide  a  wide  range  of  applications  in 
cancer including, diagnosis, imaging and targeted therapy. It also offers a multifunctional 
platform whereby a range of diagnostic and therapeutic agents can be co-administered to 
offer  ‘theranostic’  treatment.    Nanomedicine  is  considered  the  next  generation  of  cancer 
treatment offering targeted and customisable diagnosis and therapy, molecular diagnosis of 
tumour phenotypes and the ability to simultaneously diagnose and treat cancer via a range 
of  modalities.  These  modalities  can  include  metallic  nanoparticles  for  MRI  contrast, 
liposomes for drug and gene delivery and radiolabels for nuclear imaging. 
4-5,8-12 
   27 
1.2 Iron Oxide Nanoparticles in Medicine 
 
1.2.1 Introduction to Magnetic Nanoparticles 
Magnetic  nanoparticles  (MNPs)  are  an  attractive  prospect  in  medicine,  particularly  in 
diagnostic techniques, owing to their ability to operate at either cellular or molecular levels of 
biological interactions as a result of their small size.
13 Characteristics exhibited by MNPs, 
such  as  superparamagnetism  and  enhanced  magnetic  moments,  only  increase  their 
attractiveness as the next generation of contrast agents. As research progresses further, 
their size, morphology, composition and surface chemistry can be modified to improve both 
the magnetisation and in vivo behaviour of the nanoparticles.
13-14  
There are numerous different compositions of MNPs, but by far the most commonly used 
material is iron oxide; either in magnetite form (Fe3O4) or the more stable maghemite (γ-
Fe2O3).
14 Iron oxide MNPs synthesised for biomedical use typically have an inorganic core 
(e.g. magnetite) with a coating that is both biocompatible and stable  under physiological 
conditions.
13 Characteristic properties such as biocompatibility, superparamagnetism and a 
large magnetic moment allow iron oxide particles to be excellent MRI contrast agents – it is 
for this reason that iron oxide particles are the most commonly used material in biomedical 
fields.
10,15 One form of iron oxide MNP that is currently approved by the Food and Drug 
Administration (FDA) is Feridex, which is used for the imaging of liver cancer. Endorem and 
Resovist are two iron oxide MNPs that have been previously FDA approved as MRI contrast 
agents for imaging liver cancer, but have subsequently been removed from clinical use. 
16,17  
Iron oxide MNPs have been shown to be biologically safe. The reticuloendothelial system 
(RES) within the liver and spleen clears the blood via uptake within Kupffer cells where the 
iron is metabolised into elemental iron and is either excreted or incorporated into the body’s 
iron  store  where  it  is  taken  up  into  haemoglobin.
13  However,  the  production  of  reactive 
oxygen species (ROS) can be caused by an elevated amount of elemental iron present in 
the cytoplasm which is undesirable in vivo.
13,18 
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1.2.2 Properties of Iron Oxide Nanoparticles 
1.2.2.1 Crystal Structures of Magnetite and Maghemite 
Magnetite (Fe3O4) and maghemite (γ-Fe2O3) are two forms of iron oxide nanoparticles that 
are used in the biomedical field. In both magnetite and maghemite structures the oxygen 
ions occupy a cubic close packed arrangement but there is a difference in the distribution of 
the iron ions in the two forms.
19 Magnetite has an inverse spinel structure where the iron (III) 
ions  randomly  occupy  both  tetrahedral  and  octahedral  sites  with  the  iron  (II)  ions  solely 
occupying the octahedral sites.
13,20  
Maghemite  possesses  a  similar  structure  to  that  of  magnetite  but  with  vacancies  in  the 
octahedral lattice where 66% of the sites are filled with iron (III) ions. When the MNP is over 
20nm the structure is ordered with two iron (III) ions next to each other following a vacancy, 
when the MNP is below this size there is no vacancy ordering.
19 Magnetite nanoparticles are 
very unstable and prone to oxidation to form the more metastable maghemite, which forms 
stable colloidal solutions.
20 The crystal structures of magnetite and maghemite can be seen 
in Figure 2. 
  
Figure 2: The Crystal Structure of Magnetite (i) and Maghemite (ii) (Reproduced from Reference 21 with permission 
from the Royal Society of Chemistry) 
 
1.2.2.2 Magnetic Properties of Magnetite and Maghemite 
In  their  bulk  structures  both  magnetite  and  maghemite  possess  ferrimagnetic  magnetic 
properties.
19  The  magnetic  properties  of  a  material  are  defined  by  the  ratio  of  applied 
magnetic  field  (H)  and  the  induced  magnetisation  (M),  which  provides  the  magnetic 
susceptibility  (χ).
13  When  iron  oxide  structures  are  formed  they  can  possess  different 
magnetic  moments  which  can  exist  in  different  states.  Ferrimagnetism  has  an  overall 
magnetic moment that arises from the magnetic moments aligning in opposite directions with 
one having a larger precedence than the other, which is illustrated in Figure 3.  
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magnetoreceptors. Iron cycling, which generally starts from
Fe(II)-containing primary rocks (e.g. pyrite), is common and
active in many parts of ecosystems, such as marine
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Figure 3: Alignment of Individual Magnetic Moments in Ferrimagnetism 
 
At small nanometer sizes both magnetite and maghemite cease to be ferrimagnetic and 
instead  are  said  to  be  superparamagnetic.  The  magnetism  in  superparamagnetic  MNPs 
arises from the spin of unpaired electrons present in the crystal lattice where thermal energy 
permits the spin of these unpaired electrons to randomly flip direction. These MNPs only 
exhibit magnetic properties when an external magnetic field is present, which introduces 
magnetic energy to the MNPs and overcomes the thermal energy, aligning the spins parallel 
to the direction of the external magnetic field. Upon the removal of the external magnetic 
field the spins are no longer aligned and the MNPs do not possess magnetic properties. The 
lack of magnetisation in the absence of an external magnetic field is a desirable property of 
superparamagnetic MNPs as it prevents aggregation of the MNPs in vivo. 
22-25 
1.2.3 Synthetic Routes to Iron Oxide Nanoparticles 
Perhaps the most important issue faced by the synthesis of the nanoparticles is controlling 
their  size  and  morphology.  The  method  of  formation  can  dictate  the  shape,  size  and 
morphology and it can also determine the level of impurity within a particle.
10  There are 
several  synthetic  routes  towards  preparing  iron  oxide  nanoparticles,  with  the  two  most 
common being co-precipitation and thermal decomposition. 
1.2.3.1 The Co-precipitation Method 
Co-precipitation  is  the  most  common  method  for  producing  solution-phase  iron  oxide 
nanoparticles.
14 By co-precipitating aqueous ions of Fe
3+ and Fe
2+ in a ratio of 0.5 and in a 
basic  solution  such  as  NH4OH,  it  provides  a  simple  method  for  forming  magnetite 
nanoparticles.
20,26,27 The overall reaction is shown in Equation 1: 
Fe
2+ + 2Fe
3+ + 8OH
- → Fe3O4 + 4H2O             (1)
 
 
Ferrimagnetism   30 
The co-precipitation reaction is typically carried out in an inert atmosphere in the presence of 
a  coating  agent  (e.g.  a  polymer  such  as  Dextran)  as  the  magnetite  produced  is  highly 
susceptible to oxidation into the metastable maghemite form (γ-Fe2O3).
20,26 The reaction itself 
is carried out at a high pH and it has been found that by controlling the pH and ionic strength 
it is possible to control the size of the nanoparticles; at a higher pH and ionic strength the 
mean size of nanoparticles produced is smaller.
15 This reaction is particularly popular due to 
its ease and relatively low cost; however, it does not offer the size control that is perhaps 
offered  by  higher-temperature  reactions  such  as  thermal  decomposition.
27  Babic  et  al. 
reported the use of the co-precipitation method to produce small (6 nm) magnetite particles 
coated with poly(L)lysine for use in stem cell labelling, showing a successful production of 
monodisperse nanoparticles with a biocompatible coating.
28 
1.2.3.2 The Thermal Decomposition Method 
As previously mentioned, high temperature syntheses such as thermal decomposition offer a 
better control over the size and shape of the particles. Carried out in an organic phase, 
thermal decomposition offers excellent crystallinity, narrow size distribution and an ability to 
control the size of the nanoparticles.
15,29 In a typical reaction an iron precursor (e.g. Fe(CO)5 
or Fe(acac)3) is injected into a hot organic solution producing iron nanoparticles which are 
later oxidised in air or via an oxidising agent.
15 
 
Despite the many advantages of this method, it is still hindered by the fact that the particles 
themselves are produced in an organic solvent. In order to obtain aqueous nanoparticles 
suitable for biomedical use, a laborious washing and phase transfer process must be carried 
out, which can result in a loss of the final product. Park et al. reported the ability to produce 
iron oxide nanoparticles by injecting iron pentacarbonyl (Fe(CO)5) into a solution of dioctyl 
ether and oleic acid at 373K. The Fe(CO)5 was thermally decomposed in order to produce 
iron nanoparticles, which were then oxidised using trimethylamine N-oxide in order to yield 
monodisperse, highly crystalline iron oxide nanoparticles.
30 
1.2.4 Biocompatibility of Magnetic Nanoparticles 
As a result of their high interfacial surface energy, it is essential to provide a coating for the 
MNPs.  Agglomeration  in  vivo  is  undesirable  owing  to  issues  of  toxicity,  clotting  and  the   31 
alteration  of  the  MNP’s  characteristics.
  Aside  from  preventing  agglomeration  in  vivo, 
functionalising the MNP can provide essential biocompatibility, increase the blood half life 
and can provide  targeting mechanisms.
13 A key feature for functionalising the MNPs is to 
evade their rapid clearance from the body by the reticuloendothelial system (RES), upon 
administration MNPs are subject to a number of obstacles that they must overcome in order 
to reach the site of interest, Section 1.4. Biocompatability issues can also be overcome by 
functionalising MNPs; Babincova et al. reported no measurable toxicity index (LD50) when 
administering  dextran  coated  MNPs  in  vivo  for  hyperthermia  measurements.
31  The 
encapsulation  of  MNPs  in  liposomes  to  form  magnetoliposomes  has  also  been  widely 
explored in the literature proving a facile and biocompatible method of delivering MNPs for 
MRI imaging, Section 1.3.2. The surface of MNPs can also be modified to allow for the 
specific targeting of MNPs to tumours via targeting agents such as peptides and antibodies 
allowing for improvements in in vivo toxicity and concentration at the site of interest, Section 
1.5. 
 
1.3 Introduction to Liposomes in Medicine 
Liposomes can be classified as ‘spherical, self-closed structures formed by one or several 
concentric  lipid  bilayers  with  an  aqueous  phase  in  the  core  whose  medical  applications 
include drug delivery, gene delivery and the ability to act as a contrast agent for MRI through 
the encapsulation of MNPs.
32-34 Hydrophillic and hydrophobic compounds such as drugs can 
be encapsulated into their aqueous core and lipid membrane respectively, which provides a 
method of delivery that can evade the body’s clearance mechanisms.
35  
Perhaps the most desirable property associated with liposome encapsulation is their ability 
to  incorporate  a  wide  range  of  compounds  into  the  structure  such  as  chemotherapeutic 
drugs  and  MNPs.
35  Current  clinically  available  liposome  preparations  feature  the 
encapsulation of a therapeutic agent, an example of which is Doxil, which encapsulates the 
chemotherapeutic cancer drug Doxorubicin into liposomes functionalised with polyethylene 
glycol (PEG). Doxil has been used for the treatment of solid tumours in patients with breast-
carcinoma,  ovarian  cancer  and  Refractory  Kaposi’s  Sarcoma.
36-38  By  encapsulating   32 
Doxorubicin into liposomes there has been an increase in the survival rates in breast cancer 
patients and there also is a marked improvement on the toxicity and subsequent side effects 
that are characteristic of the Doxorubicin drug when administered un-encapsulated.
39 Other 
clinically  important  liposome/drug  formulations  include;  DanoXome  which  encapsulates 
Daunorubicin  and  is  used  in  the  treatment  of  Kaposi’s  sarcoma  and  Onco  TCS  which 
incorporates Vincristine for the treatment of non-Hodgkin’s lymphoma.
32 
1.3.1 Formulation of Liposomes 
Several  methods  are  reported  in  the  literature  for  formulating  liposomes.  These  include 
reverse-phase evaporation,
 40,41 freeze thawing,
 18 sonication and extrusion.
42-44 In a typical 
procedure, the lipids are dissolved in an organic solvent (e.g. chloroform), which is then 
evaporated and the nanoparticles added along with a buffer (e.g. PBS or H2O), completing 
the formulation of the liposome.
41,45-48  
Extrusion is a common method for producing size-controllable monodisperse liposomes. It 
works by pushing the lipid dispersion through a polycarbonate membrane with specific pore 
sizes,  producing  liposomes  with  a  characteristic  size.  There  are  several  advantages 
associated with this method, primarily its reproducibility. The technique also does not require 
the removal of organic solvents, which is a complication faced by other methods such as 
reverse-phase evaporation.
43,47,49  
Another  popular  method  employed  in  order  to  form  liposomes  is  sonication,  with  much 
evidence to support this in the literature.
41,46,50 In this method, the lipid dispersion is prepared 
in the typical manner: dH2O or PBS buffer is added and the mixture subjected to acoustic 
energy via a bath or tip sonicator, which in turn forms unilamellar vesicles.
34,43 The size of 
the  liposomes  can  be  controlled  by  the  length  of  time  the  lipid  mixture  is  subjected  to 
sonication. This method offers an advantage over extrusion, as the latter is particularly time 
consuming. One disadvantage, however, is the reproducibility of the method compared to 
that of extrusion.
43 
1.3.2 Magnetoliposomes  
The incorporation of iron oxide MNPs into a liposome to form a ‘magnetoliposome’ (ML) was 
first  noted  by  Margolis  et  al.  in  1983.
51 There are numerous advantages associated with   33 
using  this  delivery  system,  namely  the  biocompatibility  offered  by  the  liposome  and  an 
increased in vivo stability that is not offered by the MNPs alone
.42 The incorporation of MNPs 
into  liposomes  to  form  MLs  has  also  been  shown  to  have  both  structural  and  biokinetic 
advantages  over  the  sole  administration  of  MNPs.
52  A  key  structural  advantage  is  the 
potential to load both MNPs and therapeutic drugs into a single liposome modality, which 
provides both diagnostic and therapeutic capabilities. The biocompatibility is improved upon 
encapsulation owing to the lipid coating reducing the cytotoxicity associated with free MNPs 
and by preventing aggregation of the MNPs in the blood stream.
42,53 The incorporation of 
MNPs into liposomes to form MLs is not without its drawbacks and a key limitation is the 
poor stability due to the thin hydrophobic lipid film, which can cause issues with in  vivo 
administration.
53,54 Figure 4 shows the proposed structures for MLs with the encapsulation of 
a single MNP (i) and multiple MNPs (ii). 
(i)  (ii) 
Figure 4: The Proposed Structures of MLs Containing (i) a Single MNP and (ii) Multiple MNPs (Reproduced from 
Reference 55 with permission from Elsevier Ltd) 
 
1.3.3 Formulation of Magnetoliposomes 
The typical formulation of MLs follows the same methods of liposome formulation seen in 
Section 1.3.1 with the addition of MNPs prior to the sonication and extrusion methods used 
to form the liposomes.  
Martina et al. reported the formulation of ‘superparamagnetic liposomes’ using an extrusion 
method.  Iron  oxide  (maghemite)  MNPs  were  loaded  into  liposomes  made  of  egg 
phosphodicholine  (EPC)  and  1.2-diactyl-sn-glycero-3-phosphoenthanolamine-N-
[methoxy(poly)ethylene glycol))-2000] DSPEPEG2000 in order to produce a ML with a final size 
of 195 ± 33 nm, which were shown to be non-toxic to the J774 macrophage cell line, and to 
this statement. Keblinski et al. [18] have shown that the theoretical
temperature difference between a nanoparticle surface and the
bulk phase due to EMF heating is almost negligible. This was fur-
ther veriﬁed by Gupta et al. [19] for Fe3O4 nanoparticles heated
by RFs. In this work quantum dots were mixed or covalently an-
chored to the nanoparticles as temperature probes to compare bulk
verse local temperature.
In this work we describe an in situ spectroﬂuorometric-based
approach to determine the effect of RF heating on the temperature
of liposomal bilayers in a Fe3O4 nanoparticle–liposome dispersion
containing MLs. The approach is based on the anisotropy, hri, of a
lipid bilayer probe molecule, diphenylhexatriene (DPH), and the
proportionality among anisotropy, bilayer viscosity, and lipid
phase state, which depend on temperature [20]. Nanoparticle–
liposome dispersions were prepared with dipalmitoylphosphati-
dylcholine (DPPC) and contained 25 mol% cholesterol and
0.2 mol% DPH. While cholesterol is known to stabilize liposomes,
in this work it was added speciﬁcally to broaden the main phase
transition or melting temperature region [21,22]. This provided a
large heating window for anisotropy measurements. Calculated
(via hri) and measured temperatures were compared to differenti-
ate between local and bulk heating relative to MLs as a function of
time during on/off RF cycles.
2. Materials and methods
2.1. Chemicals
Dipalmitoylphosphatidylcholine (DPPC) and cholesterol were
purchased from Avanti Polar Lipids, and diphenylhexatriene
(DPH) from Sigma Chemical Company. The aqueous Fe3O4 nano-
particle solution was purchased from Ferrotec GmbH (EMG 705
ferroﬂuid, 3.9 vol.%). Previous work has shown that in this solution
the particles are well dispersed with an average diameter of
12.5 ± 3.4 nm [23]. Sterile deionized water was obtained from a
Millipore Direct-3Q puriﬁcation system. All materials were used
as received with the exception of dilution.
2.2. Preparation of Fe3O4 nanoparticle–liposome dispersions
Samples were prepared by reverse phase evaporation [24]
(Buchi Rotavapor R-215, Zurich, Switzerland), similar to the proce-
dure by Wijaya and Hamad-Schifferli [23]. The following compo-
nents were added to a 25 ml round bottom ﬂask: 320 ll of
10 mM DPPC in chloroform, 80 ll of 10 mM cholesterol in chloro-
form, 40 ll of 0.2 mM DPH in tetrahydrofuran, and 40 ll of ferro-
ﬂuid. To this, 4 ml of DI water and 16 ml of chloroform were
added and an emulsion was formed by bath sonication for 5 min
at 50  C, which is above the DPPC melting temperature (Tm) of
42  C [25]. The sample was cooled at room temperature for
30 min. The solvent phase was then removed by rotary evaporation
at 25  C and 100 RPM under 300 mbar for 30 min followed by
200 mbar for 2 h. The ﬁnal dispersions contained 0.8 mM DPPC
and 1 mM Fe3O4, which was equivalent to approximately
0.23 mg Fe3O4 ml
 1, equivalent to 0.23% mass fraction Fe3O4 in
water and 287.5 g Fe3O4 mol
 1 DPPC.
Nanoparticle encapsulation efﬁciency was estimated using a
centrifugation procedure employed by Pradhan et al. [10]. Brieﬂy,
0.9 wt.% NaCl was added to the samples (in DI water) at a volume
ratio of 1:1. This led to the aggregation of unencapsulated nanopar-
ticles via charge screening. The solution was then centrifuged at
1000 g for 10 min at 4  C. The supernatant containing MLs and (if
present) empty liposomes was removed and the precipitate was
resuspended in DI water, digested in nitric acid, and analyzed by
inductively coupled plasma mass spectrometry (ICP-MS, Thermo
Electron X Series, Waltham, MA). Encapsulation was calculated
based on the 57Fe isotope.
2.3. Cryogenic transmission electron microscopy (cryo-TEM)
The nanoparticle–liposome dispersions were prepared for cryo-
TEM at 25  C using a Vitrobot (FEI Company). A quantifoil grid with
2 lm carbon holes on 200 square mesh copper (Electron Micros-
copy Sciences, Hatﬁeld, PA) was immersed in the sample, blotted
to reduce ﬁlm thickness, and vitriﬁed in liquid ethane. The sample
was transferred to liquid nitrogen for storage and imaging, which
was performed in a cooled stage (Model 915, Gatan Inc., Pleason-
ton, CA) at 200 kV using a JEOL JEM-2100F TEM (Peabody, MA).
Size analysis was performed using ImageJ software [26]. The aver-
age size reported was based on all liposomes observed in the cryo-
TEM micrographs.
2.4. RF heating
RF heating was performed using a 1 kW Hotshot™ (Ameritherm
Inc., Scottsville, NY) operating from 50 to 250 A and 291 to
287 kHz, respectively. The speciﬁc absorption rates (SAR) of the
nanoparticles were measured using a 3-turn copper coil with a
4.5 cm outer diameter. To determine SAR values, sample tempera-
tures were measured as a function of nanoparticle concentration
and electromagnetic ﬁeld strength, Hf, which was varied between
1   10
5 and 5   10
5 kA m
 1 s
 1. SAR (W g
 1) values were calcu-
lated from the initial slope of adiabatic temperature rise of the
samples:
DT=Dt   SARmNP=   cpmV   1 
Fig. 1. Magnetoliposome structures consisting of (top) a single nanoparticle
encapsulated within a supported lipid bilayer and (bottom) multiple nanoparticles
encapsulated within a liposome.
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ferroﬂuid, 3.9 vol.%). Previous work has shown that in this solution
the particles are well dispersed with an average diameter of
12.5 ± 3.4 nm [23]. Sterile deionized water was obtained from a
Millipore Direct-3Q puriﬁcation system. All materials were used
as received with the exception of dilution.
2.2. Preparation of Fe3O4 nanoparticle–liposome dispersions
Samples were prepared by reverse phase evaporation [24]
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dure by Wijaya and Hamad-Schifferli [23]. The following compo-
nents were added to a 25 ml round bottom ﬂask: 320 ll of
10 mM DPPC in chloroform, 80 ll of 10 mM cholesterol in chloro-
form, 40 ll of 0.2 mM DPH in tetrahydrofuran, and 40 ll of ferro-
ﬂuid. To this, 4 ml of DI water and 16 ml of chloroform were
added and an emulsion was formed by bath sonication for 5 min
at 50  C, which is above the DPPC melting temperature (Tm) of
42  C [25]. The sample was cooled at room temperature for
30 min. The solvent phase was then removed by rotary evaporation
at 25  C and 100 RPM under 300 mbar for 30 min followed by
200 mbar for 2 h. The ﬁnal dispersions contained 0.8 mM DPPC
and 1 mM Fe3O4, which was equivalent to approximately
0.23 mg Fe3O4 ml
 1, equivalent to 0.23% mass fraction Fe3O4 in
water and 287.5 g Fe3O4 mol
 1 DPPC.
Nanoparticle encapsulation efﬁciency was estimated using a
centrifugation procedure employed by Pradhan et al. [10]. Brieﬂy,
0.9 wt.% NaCl was added to the samples (in DI water) at a volume
ratio of 1:1. This led to the aggregation of unencapsulated nanopar-
ticles via charge screening. The solution was then centrifuged at
1000 g for 10 min at 4  C. The supernatant containing MLs and (if
present) empty liposomes was removed and the precipitate was
resuspended in DI water, digested in nitric acid, and analyzed by
inductively coupled plasma mass spectrometry (ICP-MS, Thermo
Electron X Series, Waltham, MA). Encapsulation was calculated
based on the 57Fe isotope.
2.3. Cryogenic transmission electron microscopy (cryo-TEM)
The nanoparticle–liposome dispersions were prepared for cryo-
TEM at 25  C using a Vitrobot (FEI Company). A quantifoil grid with
2 lm carbon holes on 200 square mesh copper (Electron Micros-
copy Sciences, Hatﬁeld, PA) was immersed in the sample, blotted
to reduce ﬁlm thickness, and vitriﬁed in liquid ethane. The sample
was transferred to liquid nitrogen for storage and imaging, which
was performed in a cooled stage (Model 915, Gatan Inc., Pleason-
ton, CA) at 200 kV using a JEOL JEM-2100F TEM (Peabody, MA).
Size analysis was performed using ImageJ software [26]. The aver-
age size reported was based on all liposomes observed in the cryo-
TEM micrographs.
2.4. RF heating
RF heating was performed using a 1 kW Hotshot™ (Ameritherm
Inc., Scottsville, NY) operating from 50 to 250 A and 291 to
287 kHz, respectively. The speciﬁc absorption rates (SAR) of the
nanoparticles were measured using a 3-turn copper coil with a
4.5 cm outer diameter. To determine SAR values, sample tempera-
tures were measured as a function of nanoparticle concentration
and electromagnetic ﬁeld strength, Hf, which was varied between
1   10
5 and 5   10
5 kA m
 1 s
 1. SAR (W g
 1) values were calcu-
lated from the initial slope of adiabatic temperature rise of the
samples:
DT=Dt   SARmNP=   cpmV   1 
Fig. 1. Magnetoliposome structures consisting of (top) a single nanoparticle
encapsulated within a supported lipid bilayer and (bottom) multiple nanoparticles
encapsulated within a liposome.
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be successful as a MRI contrast agent.
48 Bulte et al. reported the success of incorporating 
dextran coated magnetite MNPs into liposomes via extrusion, to yield 240 ± 40 nm vesicles, 
which  showed  good  results  in  vitro  when  incubated  with  human  peripheral  blood 
mononuclear cells resulting in a transverse relaxivity of 16.6 s
-1.
47 
Bulte et al. also reported the formation of PEGylated MLs via a sonication method, which 
showed success as a potential contrast agent.
 Liposomes were formulated with DC15:OPG 
(dipentadecanoylphosphatidylglycerol)  and  DMPE-PEG2000  (dimyristoyl-phosphatidyl- 
ethanolamine-N-polyethylene  glycol2000)  with  the  encapsulation  of  lauric  acid  stabilized 
magnetite (Fe3O4) to produce an ML with a diameter of 40 nm. The MLs showed long blood 
half lives and good T1 and T2 relaxivities (3 and 240 s
-1/ mM at 1.5T and 37°C) 
52  
1.3.4 Role of plasmid DNA and Peptides in Cancer and their Incorporation in 
Liposomes 
Gene therapy plays a key role in the treatment of diseases such as cancer via the delivery of 
DNA-based formulations to introduce a gene that is toxic to the cancer cells.
56 Plasmid DNA 
(pDNA) is a double stranded circular structure of DNA that has the advantage of replicating 
autonomously from the main genome of a cell, making it popular in cloning techniques and 
genetic engineering as it can be modified to express genes of interest.
57 The ability to modify 
pDNA has led to its extensive use in gene therapy and typically plasmids from E. Coli are 
used, which are modified to replace the gene encoding for bacterial infection with a gene of 
interest  whilst  retaining  their  replication  origin  so  that  they  may  independently  replicate 
separately to the host cell.
58,59 
 
In order to successfully deliver pDNA to the target cells it is essential that it be incorporated 
into a delivery vector as free pDNA is susceptible to enzymatic degradation from nucleases 
and rapidly cleared from the body.
 The large size, hydrophilicity and strong negative charge 
also hinders the delivery of free pDNA.
56,60 To circumvent the issues faced by the delivery of 
free pDNA it can be incorporated into a variety of non-viral delivery vectors whereby it acts 
as  a  transfection  agent.  A  transfection  agent  is  defined  as  electrostatically  charged 
macromolecule that can bind pDNA for its delivery into a cell and these include peptides, 
lipids and dendrimers.
61 A key challenge of gene delivery with non-viral vectors is ensuring   35 
sufficient amounts at the target site with the avoidance of toxic dosing at non-target sites.
62 A 
number of cationic delivery systems have been investigated owing to the improved rate of 
transfection achieved with positively charged vectors. Positively charged vectors have better 
association with the negatively charged cell membrane facilitating the entry of the vector into 
the cell.
32,63 
One popular method of gene delivery is the incorporation of pDNA into a liposome to form a 
lipoplex, which was first suggested in 1987.
 Typically lipoplexes are made from a mixture of 
cationic  lipids  such  as  DOTMA  (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-tri-  methylammonium 
chloride)  and  the  neutrally  charged  DOPE  (1,2-dioleoyl-sn-glycero-3-
phosphatidylethanolamine). DOTMA is classed as a cytofectin, which consists of a cationic 
head group attached to a hydrophobic lipid chain via a linker and it is this cationic head 
group that is responsible for the overall positive charge of the lipoplex.
 DOPE has been 
shown to promote fusion with the endosomal membrane and mediate endosomal escape.
64 
The combination of DOTMA:DOPE in a 1:1 ratio forms a commercially available compound 
called Lipofectin.
65 
Lipoplexes  enter  the  cell  via  a  process  called  endocytosis,  which  is  defined  as  the 
introduction of extracellular macromolecules (i.e. a lipoplex) across the cell membrane. The 
macromolecule  associates  with  the  cell’s  surface  whereby  the  plasma  membrane 
invaginates the molecule until it forms an intracellular vesicle containing the macromolecule, 
an  endosome.  The  endosome  is  subsequently  destablised  and  the  macromolecule  is 
released into the cytoplasm whereby the pDNA can be released and delivered to the cell’s 
nucleus where the gene is expressed, see Figure 5.
32,66,67    36 
 
Figure 5: A Figure Showing the Mechanism of Endocystosis for Lipoplexes (Reproduced from Reference 68 with 
permission from Cambridge University Press) 
 
An advantage associated with the lipoplex delivery of pDNA is the ease of uptake in the cell 
via  endocytosis  whereby  the  lipoplex  destabilises  the  endosomal  membrane  to  allow 
subsequent release of the pDNA into the cytoplasm. Another key feature of packaging the 
pDNA inside a liposome is their easy surface modification to avoid rapid clearance in vivo, 
protecting  the  pDNA.  Once  inside  the  cell  the  liposome  can  deliver  its  contents  by  the 
destabilising of the lipid membrane through the reduced pH inside the cell providing (pH 7.7 
to pH 5) a facile mechanism for the release of the pDNA.
 32,69 
Disadvantages  associated  with  lipoplex  formulations  are  found  when  they  are  in  the 
presence  of  serum  in  vivo,  which  causes  instability  in  the  liposome  structure  and  the 
subsequent release and degradation of the pDNA. Lipoplexes are also found to be rapidly 
cleared by the reticuloendothelial system (RES), which prevents successful delivery of the 
pDNA to the site of interest.
56,69  
An alternative method of gene delivery is the condensation of pDNA by a cationic peptide to 
form  a  polyplex.  Cationic  peptides  can  be  used  to  condense  pDNA  via  the  formation  of 
electrostatic bonds, which offers protection of the pDNA from enzymatic degradation and 
thus allows for the intra cellular pDNA delivery in vitro and in vivo.
32,56,60,67,70,71 Benefits of 
polyplex delivery over lipoplex delivery include ease of synthesis and in vivo stability.
56 In   37 
order to successfully deliver the pDNA to the cell a number of obstacles must be overcome 
that include; rapid clearance in vivo, internalisation in the cell membrane and endosomal 
escape.
67 There are several types of peptides that facilitate the delivery of pDNA into cells 
and these include; pDNA condensing peptides such as polylysine and polyargenine, cell 
penetrating peptides which can carry their cargo across the cellular membrane and peptides 
containing specific nuclear localisation sequences which allow for gene expression via the 
targeting of pDNA to the nucleus.
56 The length of the peptide is of particular importance 
when considering the transfection ability of the polyplex; if the peptide chain is too long the 
pDNA is not released for delivery into the nucleus and if it is too short then condensation of 
the  pDNA  is  prevented.  Welser  et  al.  reported  that  the  optimal  peptide  for  pDNA 
condensation was found to be a linear lysine chain sixteen lysines in length (K16), although 
success has also been seen in branched argenine chains of the same length.
71 
A disadvantage of using cationic peptides is their toxic effect on the cells, it has been noted 
in the literature that there is a close link between low levels of pDNA transfection and the 
cytotoxicity of the peptide/pDNA structure.
73 Another disadvantage seen with the polyplex 
delivery  of  pDNA  is  its  inability  to  destabilise  the  endosome  upon  entering  the  cell  via 
endocytosis, thus preventing it’s release into the cytoplasm and the subsequent delivery of 
the pDNA.
32 
To overcome the issues faced by the lipoplex and polyplex delivery mechanisms, a second 
generation of delivery vector has been developed called a lipopolyplex (L:P:D); a lipid based 
complex where pDNA is condensed by a cationic peptide and subsequently encapsulated 
into a liposome. The cationic peptides can be modified to contain two sections; a cationic 
pDNA condensing chain, e.g. poly-L-lysine chains such as K16, and a targeting group that 
allows for the specific cellular delivery of the pDNA, see Section 1.5. 
70,71,73-77 Figure 6 shows 
the proposed structure for the lipopolyplex (L:P:D)structures.   38 
 
Figure 6: A Figure Showing the Proposed Structure of a Lipopolyplex
 (Reproduced from Reference 75 with 
permission from the American Chemical Society) 
 
Lipopolyplexes offer advantages over lipoplexes and polyplexes as the peptide provides a 
mechanism for condensing the pDNA thus protecting the pDNA from nuclease attack. It also 
increases  the  in  vivo  stability  whilst  the  lipid  shielding  aids  its  uptake  intracellularly  by 
endocystosis  whereby  it  can  effectively  destabilise  the  endosome  for  release  into  the 
cytoplasm. The ability to introduce a targeting moiety into the lipopolyplex also effectively 
ensures the site-specific delivery of pDNA and sufficient levels of pDNA at the target site.
70 
Mustapa et al. reported the formulation  of  lipopolyplex  complexes  that  incorporated  both 
pDNA and peptides whereby the pDNA (pCl-Luc) contained the bioluminescent luciferase 
reporter  chain  and  the  peptides  were  designed  with  an  integrin-targeting  moiety.  These 
lipopolyplex  formulations  demonstrated  good  levels  of  transfection  indicating  successful 
internalisation and subsequent disassembly in order to deliver the pDNA with minimal effect 
to cell viability.
76 
1.4 Improving the In Vivo Circulation Time of Nanocomplexes 
An important consideration when administering diagnostic and therapeutic agents in vivo is 
their blood half life as after intravenous (IV) injection there are a variety of obstacles they 
must overcome in order to prevent clearance from the body. 
13,78-80 Macrophages are found 
in  many  tissues  and  organs  of  the  body  and  are  responsible  for  the  rapid-clearance  of 
‘foreign’  particles  such  as  MNPs  and  liposome  dispersions.  Their  ability  to  undergo 
Targeting 
head  
group of 
peptide 
Co-condensed pDNA 
(yellow)  
and K16 peptide tail 
(red) 
Lipid bilayer   39 
phagocytosis of foreign particles has led to numerous macrophage directed studies of both 
diagnostic and therapeutic agents, however, this excellent uptake in these cells is a marked 
hindrance  when  targeting  sites  of  disease  such  as  tumours.
81  Following  IV  injection 
opsonisation  takes  place  where  plasma  proteins  are  adsorbed  onto  the  surface  of  the 
injected particles. After opsonisation the administered particles become easily recognisable 
by  the  reticuloendothelial  system  (RES)  and  are  then  removed  from  circulation  by 
macrophage cells, Figure 7.
13 
 
Figure 7: A Figure to Show the fate of MNPs in vivo (Reproduced from Reference 2 with permission from Elsevier 
Ltd) 
 
Both the size and surface charge of the administered particle can play a large part in the 
blood-half life, for example strongly anionic surface charges have shown to be cleared much 
faster than their neutrally charged counterparts.
79 As for the size of the particles, they must 
be large enough to circumvent clearance by the RES but also small enough that they can 
evade clearance by other mechanisms, with larger particles being cleared more rapidly than 
smaller ones. It is also extremely important that the size, charge and stability in biological 
fluids such as serum are considered as this can alter the size and charge of administered 
particles. 
13,79-83 
The circulation time in vivo can also be vastly improved by modifying the surface coating of 
the particle with a polymeric coating.
13,79-80,83 Coating the MNP or liposome with a polymeric 
coating  can  prevent  in  vivo  agglomeration  whilst  evading  clearance  by  the  RES, 
subsequently augmenting the blood half life. It is extremely important to consider the effect 
that  the  polymeric  coating  will  have  on  the  system  with  key  considerations  such  as; 
molecular weight of the polymer, biodegradability properties and hydrophilicity.
13  
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These ligands include oligosaccharides, oligo-
peptides,  folic  acid,  antibodies  and  their  frag-
ments. The coupling of monoclonal antibodies
has at least two disadvantages: the overall dimen-
sions of the antibodies (a20 nm), which cause
particles to diffuse poorly through biological bar-
riers, and their immunogenicity. Therefore, the
coupling of  antibody  fragments or  small  non-
antigenic ligands to nanoparticles has been also
investigated, for example, folic acid (B vitamin
essential  for  cell  division  processes)  for  tumor
targeting [23]. 
Magnetic nanoparticles as contrast 
agents for MRI
In actual practice, tissues may be differentiated
on MR images. But, in many clinical situations,
these  intrinsic  differences  are  small  and  exo-
genous contrast media are currently used for a
better delineation of tissues. The first generation
of  these contrast agents consisted of high-spin
paramagnetic  ions,  usually  Gd3+ in  very  stable
nontoxic chelate form obtained through compl-
exation by low molecular weight chelating mole-
cules,  such  as  diethylenetriaminepentaacetic
acid.  Gd-chelates  have  a  nonselective  extra-
cellular distribution before their excretion by the
kidney. Hydrogen atoms of water in proximity to
such chelates experience a  faster  T1-relaxation.
Consequently, differences in agent concentration
result in contrast enhancement on T1-weighted
images (‘positive’ contrast) [6].
Magnetic nanoparticles have also been devel-
oped  as  contrast  agents  for both  standard  and
functional  MRI  [24,25].  The  superparamagnetic
behavior of these subdomain magnetic cores is
similar  to  that  of  paramagnetic  substances,  in
that they lose their magnetization when the mag-
netic field is removed, but differs by the value of
the magnetic moment, which is markedly higher.
Therefore, their relaxivity (ability to increase the
relaxation rates of surrounding proton spins) is
much higher than that of Gd-chelates. In most
situations,  they  are  used  for  their  significant
capacity to produce predominantly T2-relaxation
effects, which result in signal reduction on T2-
weighted  images (‘negative’  contrast).  Basically,
the  phenomenon  may  be  described  from  the
large  magnetic  field  heterogeneity  around  the
nanoparticle through which water molecules dif-
fuse [26]. Diffusion induces dephasing of the pro-
ton  magnetic  moments,  resulting  in  T2-
shortening. Such contrast agents are also called
susceptibility agents owing to their effect on the
magnetic field. T2-shortening is a remote effect,
whereas  the  T1-shortening  process  requires  a
close  interaction  between  water  molecules  and
Gd-chelates [6].
This new generation of contrast agent is often
called (ultrasmall)  superparamagnetic  iron oxide
([U]SPIO).  They  consist  of  nonstoichiometric
iron oxide cores (3–10 nm in diameter), whose
composition and physicochemical properties vary
continuously from magnetite Fe3O4 to maghemite
J-Fe2O3. For i.v. administration, they are generally
synthesised in a one-step process by alkaline copre-
cipitation or iron (II) and iron (III) precursors in
aqueous solutions of hydrophilic macromolecules,
essentially dextran [201]. The role of these macro-
molecular corona is the limitation of the magnetic
core growth during the synthesis, their steric stabi-
lization  in  water  (and  later  in  physiological
medium) and in vivo the reduction of the opsoni-
zation  process.  These  colloidal  contrast  agents
would be more realistically described as made of
several magnetic cores, more or less aggregated and
embedded  in  the  hydrophilic  macromolecules.
The overall hydrodynamic diameter, as measured
by  photon  correlation  spectroscopy,  is  largely
higher than the magnetic core dimensions. Inter-
actions  between  magnetic  cores  and  macro-
molecules are weak (essentially Van der Waals and
hydrogen interactions) [27] and generally prevent
any efficient derivatization of dextran corona with-
out  macromolecule  depletion  [202].  Stability
improvement  may  be  achieved  when  dextran
macromolecules are cross-linked in a second step
for enhancing the mechanical entrapment of mag-
netic cores (cross-linked iron oxide [CLIO] [28]) or
when  dextran  macromolecules  are  chemically
bonded to magnetic cores through the use of cou-
pling agents [29] (versatile USPIO [VUSPIO] [30]).
Figure 1. The main steps of the mononuclear phagocyte 
system-mediated clearance of nonstealth particles.
 
Opsonization Recognition Macrophage
Endocytosis
Lysosome
Opsonin
Receptor
Nanomedicine  40 
Poly(ethylene  glycol)  (PEG)  is  a  particularly  popular  and  important  choice  of  polymeric 
coating owing to its biocompatibility, lack of toxicity and stability in both aqueous and organic 
media. Studies have shown that the incorporation of PEG into compounds administered in 
vivo have no specific affinity for particular organs and its accumulation in tumour tissue can 
be dictated by its targeting and the presence of hyperpermeable tumour vasculature, which 
facilitates the uptake of compounds via the enhanced permeability retention effect (EPR).
80 
The increased stability of PEG in vivo and its effectiveness at evading clearance by the RES 
have led to its classification as a ‘stealth’ polymer rendering the administered compounds 
unrecognisable to clearance mechanisms.
13,17,84  
The modification of liposome formulations to contain PEGylated lipids has been shown to 
vastly increase their in vivo circulation times and significantly reduce the rate of clearance. 
PEGylated  liposomes  have  been  shown  to  vastly  improve  the  delivery  of  liposomes 
containing  both  therapeutic  and  diagnostic  agents.  The  commercially  available  Doxil  is 
formulated by the incorporation of Doxorubicin into PEGylated lipids that show a prolonged 
in vivo circulation time for the treatment of metastatic breast cancer.
85  
The size of PEG shielding incorporated into the liposome formulation can also play a key 
part in in vivo circulation times and cellular uptake and it has been shown that larger weights 
of  PEG  can  have  reduced  uptake  into  cells.
86 Mitchell  et  al.  reported  the  formulation  of 
PEGylated multifunctional liposomes that incorporated DODEG4, a short n-EG spacer lipid. 
The shorter length of PEG demonstrated an improved cellular internalisation in tumour cells 
compared to the longer length DSPE-PEG2000 lipids with no notable effect to the blood half 
life and in vivo distribution.
87 
1.5 In Vitro and In Vivo Targeting Techniques 
Specific  targeting  of  the  diagnostic  or  therapeutic  compound  in  vivo  can  increase  the 
selective toxicity whilst reducing the amount that reaches non-target sites, which permits the 
increase of administered dose.
4,89 Specific targeting of these compounds can be achieved by 
either passive or active targeting.
12-13,88-89  
Passive targeting of tumours seeks to exploit their general features, which include leaky 
bloody vessels that results from their rapid growth and vascularisation and poor lymphatic   41 
drainage  mechanisms.  The  leaky  vasculature  permits  the  entry  and  subsequent 
accumulation of extracellular compounds such as MNPs and liposomes via the EPR effect, 
Figure 8.
4,13,88 Passive targeting has shown success with compounds with sizes ranging from 
10 nm to 500 nm.
13 
 
Figure 8: A Schematic Representation Showing the Process of Passive Targeting (Reproduced from Reference 4 
with permission from Annual Reviews) 
 
There are several limitations associated with passive targeting including in vivo circulation 
times, multiple-drug resistance and diffusion limitations. As discussed in Section 1.4 there 
are numerous factors, which play a part in the in vivo circulation time, and a key factor for 
ensuring the success of passive targeting is the compounds ability to evade the RES. Finally 
the lack of control can hinder passive targeting owing to the inability for the administered 
compound to diffuse into tumour successfully. These issues can however be overcome by 
active targeting.
4,12-13,88  
Tumour cells can express significant biomarkers and signatures that can be targeted by 
functionalising the surface of the MNP or liposome complex with targeting agents, which 
include  peptides,  aptamers,  antibodies  and  proteins.  When  using  a  targeting  agent  it  is 
essential that the targeting agent has a high specificity to the biomarker expressed on the 
surface  of  the  cancer  cell.  It  is  also  necessary  that  this  biomarker  is  overexpressed  on 
ANRV317-BE09-09 ARI 7 June 2007 17:40
Passive Targeting
Rapid vascularization in fast-growing cancerous tissues is known to result in leaky,
defective architecture and impaired lymphatic drainage. This structure allows an
EPR effect (63, 64, 66, 73), resulting in the accumulation of nanoparticles at the
tumor site (Figure 7). For such a passive targeting mechanism to work, the size and
surface properties of drug delivery nanoparticles must be controlled to avoid up-
take by the reticuloendothelial system (RES) (100). To maximize circulation times
and targeting ability, the optimal size should be less than 100 nm in diameter and
the surface should be hydrophilic to circumvent clearance by macrophages. A hy-
drophilic surface of the nanoparticles safeguards against plasma protein adsorption
andcanbeachievedthroughhydrophilicpolymercoatingssuchasPEG,poloxamines,
poloxamers, polysaccharides, or through the use of branched or block amphiphilic
copolymers (101–104). The covalent linkage of amphiphilic copolymers (polylactic
acid, polycaprolactone, polycyanonacrylate chemically coupled to PEG) is generally
preferred, as it avoids aggregation and ligand desorption when in contact with blood
components.
Figure 7
Schematic diagrams
showing enhanced
permeability and retention
of nanoparticles in tumors.
Normal tissue vasculatures
are lined by tight
endothelial cells, thereby
preventing nanoparticle
drugs from escaping or
extravasation, whereas
tumor tissue vasculatures
are leaking and
hyperpermeable allowing
preferential accumulation of
nanoparticles in the tumor
interstitial space (called
passive nanoparticle tumor
targeting).
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tumour cells compared to normal tissue cells. The binding of the targeting agents to the 
surface  of  the  cell  can  induce  the  internalisation  of  the  compound  thus  releasing  the 
nanocarrier inside the cell, Figure 9. Internalisation of the targeted compounds can also be 
augmented by the EPR once they have reached the target location.
13,88 Advantages of active 
targeting include the minimisation of toxicity at non-target sites, increased concentrations of 
administered compound in target cells and the ability to increase the dosage leading to more 
effective imaging or therapy.
82  
 
Figure 9: A Schematic Representation Showing the Process of Active Targeting (Reproduced from Reference 4 with 
permission from Annual Reviews 
 
The first targeting agents were monoclonal antibodies (mAbs), which showed a site-specific 
molecular recognition for the delivery of nanocarriers. An example of a FDA approved mAb 
targeting  system  is  Herceptin,  which  shows  specificity  to  the  HER2/neu  receptor  that  is 
generally found in breast cancer and is responsible for the proliferation of cancer cells.
13 Huh 
et al. reported the attachment of the Herceptin mAb to the surface of DMSA-coated MNPs 
which  showed  in  vivo  specificity  when  targeting  the  HER2/neu  expressing  NIH3/t6.7  cell 
line.
90  
Kenny  et  al.  demonstrated  the  successful  in  vivo  delivery  of  a  multimodal  liposome 
functionalised with integrin targeting peptides specific for the ApoE, neurotensin and tetanus 
ANRV317-BE09-09 ARI 7 June 2007 17:40
H+
H+
H+
H+
H+
H+
H+
H+
H+
1. Internalization
2. Early endosomes
3. Acidified endosomes
4. Endosomal release
5. Recycling endosomes
6. Membrane fusion
Ligand
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Figure 8
Nanoparticle drug delivery
and targeting using
receptor-mediated
endocytosis. The
nanoparticle drug is
internalized by tumor cells
through ligand-receptor
interaction. Depending on
the design of the cleavable
bond, the drug will be
released intracellularly on
exposure to lysosomal
enzymes or lower pH.
clustersandbindpreferablytothemultivalentformsoftheligand.Furthermore,con-
focal microscopy demonstrated selective uptake and endocytosis of folate-conjugated
nanoparticles by tumor cells bearing folate receptors. Interest in exploiting folate re-
ceptor targeting in cancer therapy and diagnosis has rapidly increased, as attested by
manyconjugatedsystems,includingproteins,liposomes,imagingagents,andneutron
activation compounds (119, 120).
Nanoparticle Drugs
Nanotechnology is beginning to change the scale and methods of drug delivery
(Figure 9). Therapeutic and diagnostic agents can be encapsulated, covalently at-
tached, or adsorbed onto nanoparticles. These approaches can easily overcome drug
solubility issues, which has signiﬁcant implications because more than 40% of active
substances being identiﬁed through combinatorial screening programs are poorly
soluble in water (122). Conventional and most current formulations of such drugs
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toxins expressed by neuroblastoma tumour cells. They reported good bio-distribution and 
cellular  viability  with  multimodal  functionalities  that  included  an  MRI  contrast  agent  and 
pDNA delivery.
91  
The epidermal growth factor receptor (EGFR) is overexpressed in a wide range of human 
cancers and for this reason it is used as a key target for the delivery of both imaging agents 
and chemotherapeutic drugs. Targeting peptides that are specific for EGFR can be used as 
a targeting moiety and benefit from low immunogenicity and facile incorporation into delivery 
vectors.
92,93  Song  et  al.  reported  the  formulation  of  a  liposomal  delivery  vector  that 
incorporated a peptide targeting moiety specific for EGFR, which provided specific targeting 
in vitro and in vivo in human cancer cell lines.
126 
 
1.6 Characterisation Techniques 
1.6.1 X-Ray Powder Diffraction (XRD) 
XRD is a powerful analytical technique that allows information regarding the crystal structure 
of a material to be determined. A cathode-ray tube produces X-rays, which are filtered in 
order to produce monochromatic radiation. This monochromatic radiation is directed towards 
the sample and the interaction of the beam with the sample gives constructive interference 
when Bragg’s law is obeyed (Equation 2): 
nλ = 2dsinθ                     (2) 
where n is an integer, λ the wavelength of the incident wave, d the spacing between the 
planes and θ the angle between the incident ray and the scattering planes.  
Bragg’s law provides a relationship between the lattice spacing in a sample, the angle of 
diffraction and the wavelength of the incident wave. A detector measures the diffracted X-
rays and by obtaining a number of 2θ angles, information on the lattice structure can be built 
up. The diffraction peaks can be analysed to give the ‘d-spacings’ which ultimately allow for 
identification of the material, as each material has a set of unique d-spacings. This method is 
an essential tool for characterising the crystal structure of NPs, giving essential information   44 
on their crystallography and size. XRD cannot, however, identify between the magnetite and 
maghemite forms of iron oxide, owing to their similar crystal structures (inverse spinel) and 
therefore alternative techniques such as Mössbauer must be considered.
93 
1.6.2 Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR spectroscopy can be used to determine whether or not successful bioconjugation of 
PLL to the surface of the MNPs has taken place by providing a means for elucidating the 
functional groups present on the surface of the MNP. 
In a typical infrared spectroscopy measurement, IR radiation is directed at the sample. Some 
of  the  radiation  is  transmitted  through  the  sample  producing  a  spectrum  that  gives 
information  on  functional  groups  in  the  sample,  for  example  if  there  is  a  carboxylic  acid 
group present. This spectrum provides a ‘molecular fingerprint’, which is characteristic of the 
particular  compound.
 FTIR  is  preferable  over  standard  infrared  measurements  due  to  its 
improved sensitivity and lowered noise levels. It is also a fast, accurate and reproducible 
technique.
94  
 
1.6.3 Dynamic Light Scattering (DLS)  
Dynamic light scattering (DLS) is used to measure the size of particles suspended in solution. 
It works by measuring the Brownian motion, which is the random motion of particles as they 
move through a solution. The size of the particle is a key factor on determining its Brownian 
motion, smaller particles move at a faster speed than those with larger sizes and thus have a 
faster Brownian motion. The instrument works by shining a laser beam through the sample 
and measuring the ‘intensity at which the light fluctuates when detected using an optical 
arrangement’.  The  rate  at  which  these  fluctuations  occur  depends  on  the  size  of  the 
particles; the smaller the particle, the faster it moves in solution and thus more fluctuation in 
intensity of scattered light. A schematic representation of the DLS instrumentation can be 
seen in Figure 10. The resulting measurement gives a value of the particle’s hydrodynamic 
diameter (HD) which is determined by the Stokes-Einstein equation (Equation 3) where the 
velocity  arising  from  the  Brownian  motion  is  defined  as  D,  the  translational  diffusion   45 
coefficient  is  k,  δ(H)  is  the  hydrodynamic  diameter,  k  is  Boltzmann’s  constant,  T  is  the 
absolute temperature and η is velocity. 
95-96 
δ(H) = kT/ 3πηD                  (3) 
 
Figure 10: A Figure Showing the Schematic Representation of a DLS instrument (Reproduced from Malvern 
Instruments, Reference 96) 
 
1.6.4 Zetapotential (ZP) 
A colloidal suspension is defined as the dispersion of one state of matter (gas, liquid or solid) 
in another, most typically the dispersion of particles in a solution, for example an aqueous 
solution containing magnetolipopolyplexes. This dispersion of particles in a solution exhibits 
a physical property called zeta potential (ζ potential), which is defined as the ‘potential at the 
surface of shear between the charged surface and the electrolyte solution’.  By measuring 
the zeta potential information on both the surface charge of the particles in solution and also 
their stability in this solution can be determined.  
Particles present in colloidal suspension are subjected to the exertion of both attractive and 
repulsive forces, Van de Waals and the electrical double layer respectively. The presence of 
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a  charged  particle  in  solution  leads  to  the  presence  of  counter-ions  in  solution,  which 
surround  the  charged  particle  and  this  is  defined  as  the  electrical  double  layer.  As  the 
particles undergo Brownian motion these two forces dictate whether or not coagulation of the 
particles occurs. In order to coagulate, the particles must overcome the repulsive forces that 
are present due to the electrical double layer thus leading to the particles binding irreversibly. 
If  sufficient repulsive forces exist the particles remain well dispersed in solution and are 
therefore deemed as being ‘stable’ confirming that the larger surface charge on the particle 
the larger the force exhibited by the electrical double layer.  
This electrical double layer surrounding the particle can be split into two sections, the Stern 
region, the inner region where the counter ions are strongly bound to the particle, and the 
diffuse region, the less tightly bound outer region. As the particle moves in solution the Stern 
region remains bound to the surface as do some counter ions present in the diffuse layer, 
however a boundary exists in which some of the counter ions remain with the bulk solution. 
The zeta potential is the measure of potential at this boundary between the charged surface 
of the particle and the solution as illustrated in Figure 11, hence, the higher the surface 
charge the more stable the solution as larger repulsive forces exist between the particles. It 
is said that stable solutions exist above +30 mV for positively charged particles and below -
30 mV for those that are negatively charged.  
 
Figure 11: A Schematic Representation of the Principle of Zetapotential (Reproduced from Malvern Instruments, 
Reference 97) 
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By knowing the surface charge it is possible to not only deduce the stability and surface 
charge particles in solutions, i.e. in the case of the magnetolipopolyplexes but it can also be 
a measure of whether a bioconjugation reaction or electrostatic addition has been successful. 
A schematic representation of the ZP instrumentation can be seen in Figure 12. In the case 
of conjugating poly(L)lysine to the surface of a dextran coated MNP you would expect to see 
the surface charge change from the neutral charge you would see with dextran to a positive 
charge  that  would  be  present  upon  successfully  conjugating  the  PLL  as  a  result  of  the 
positive amine groups present. 
95,97 
 
Figure 12: A Figure Showing the Schematic Representation of a Zetapotential Instrument (Reproduced from 
Malvern Instruments, Reference 97) 
 
1.6.5 Inductively Coupled Plasma – Atomic Emission Spectroscopy (ICP-AES) 
ICP-AES is a technique that is primarily used in order to detect trace metals in blood and 
food. However, it can also be used in order to give an accurate concentration of a particular 
element in a sample.  
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The instrument functions by passing the sample into a plasma flame whereby the analyte 
atoms in the sample are converted to their excited state. Energy dissipating from the atoms 
is emitted at characteristic wavelengths of electromagnetic radiation that provide qualitative 
multi-elemental analysis of the given sample. In addition to this, it is possible to determine 
the  concentrations  of  the  elements  present  in  solution  by  measuring  the  intensity  of  the 
emitted radiation. 
98-99 
ICP-AES offers many advantages over other types of emission spectrometry, including a 
reduced  susceptibility  to  chemical  interference  (owing  to  the  higher  temperatures  in  the 
ionisation  process)  and  multi-elemental  analysis.  Perhaps  one  of  the  most  important 
advantages is the extremely low limit of detection; with this method it is possible to measure 
as  low  as  nanomolar  concentrations.  The  low  detection  limits  coupled  with  the  ability  to 
determine the concentration of a given element in a sample provide a useful technique for 
analysing the iron concentration. If it is possible to determine the concentration of iron in 
solution,  it  means  that  upon  imaging  the  sample  using  MRI,  the  exact  relaxivity  can  be 
calculated, thereby providing essential information of the viability of the sample as a contrast 
agent.
99 
1.6.6 Transmission Electron Microscopy (TEM) 
TEM  functions  by  using  some  of  the  same  principles  to  that  of  a  light  microscope,  but 
instead of a beam of light, electrons are used. These electrons have a significantly shorter 
wavelength than that of light and, therefore, the resolution is around one thousand times 
higher than that offered by a light microscope, which is ideal for studying the size and shape 
of MNPs. By using electron diffraction it is possible to identify the phases present in the 
sample, i.e. the crystalline structure. 
The TEM instrument works by a source (e.g. LaB6) emitting an electron beam down the 
column of the microscope, which is under a vacuum. Electromagnetic lenses then focus 
these electrons into a thin beam so that it is directed at the sample. Some of the electrons 
pass  through  the  sample  and  some  are  reflected  (scattered),  the  number  of  electrons 
passing through the sample is determined by its density. The electrons that pass through hit   49 
a fluorescent screen that allows an image of the sample to be built up.
100 Figure 13 shows a 
schematic diagram of a standard TEM instrument. 
 
Figure 13: A Schematic Representation of a TEM Instrument 
 
1.6.7 Superconducting Quantum Interference Device (SQUID) Magnetometry 
The  superconducting  quantum  interference  device  (SQUID)  is  an  extremely  sensitive 
magnetometer that measures magnetic fields. It can be used to obtain information of the 
magnetic properties of MNPs such as whether or not they are superparamagnetic. The high 
level of sensitivity means that the SQUID can detect extremely small amounts of iron oxide 
MNPs  and  therefore  can  be  used  to  measure  the  amount  of  iron  oxide  MNPs  present 
intracellularly. 
A SQUID instrument functions by passing current through a superconductor that has been 
designed to form two Josephson junctions. Named after Brian Josephson, the Josephson 
Junction consists of two superconductors weakly connected by a thin insulating material, 
which allows highly coherent coupled electrons called Cooper pairs to tunnel through the thin 
insulating material.
101-103 By passing current through the Josephson junctions this gives rise 
to  a  phenomena  called  flux  quantisation  whereby  the  magnetic  flux  is  the  measure  of 
magnetic  field  for  a  given  area.  Upon  introducing  a  sample  there  is  an  alteration  in  the   50 
current and as a result, an alteration in the flux quantisation which gives rise to information 
regarding the field and ultimately the magnetic properties of the sample.
104  
1.7 Imaging Techniques 
 
1.7.1 Diagnostic Techniques for Cancer and the Benefits of Multimodality 
In order to provide detailed early cancer diagnosis it is essential to have detailed images at 
the molecular level. Criteria for molecular imaging involves the ability of imaging agent to 
avoid rapid clearance, high sensitivity and resolution imaging techniques and high-affinity 
biocompatible  probes  that  provide  excellent  imaging  contrast.  Figure  14  shows  the  pre-
requisites for in vivo molecular imaging. 
78,105 
 
Figure 14: A Schematic Illustrating the Pre-Requisites to Successful Molecular Imaging (Reproduced from 
Reference 78 with permission from the Radiological Society of North America) 
 
Popular imaging modalities used in cancer diagnosis include clinical techniques such as MRI 
(Section  1.7.2)  and  positron  emission  tomography  (PET)  (Section  1.7.3)  and  laboratory 
based techniques such as optical imaging (Section 1.7.4). 
Non-invasive multimodal imaging is considered to be the next generation in cancer diagnosis 
combining two or more molecular imaging techniques typically using a single imaging agent 
that  is  dual  or  triple  labelled  with  either  optical,  nuclear  or  MRI  agents,  of  particular 
prominence is dual PET-MRI imaging. This multimodal approach to imaging covers a wide 
appear daunting at ﬁrst glance, recent ad-
vances in drug discovery technology
(combinatorial techniques, rational de-
sign, high-throughput testing, robotics,
target identiﬁcation, and validation
through genomic sciences) have helped
move this process forward rapidly. For
example, the data points (to describe the
effect of one compound on one target)
generated by large screening programs in
industry were roughly 200,000 in the
early 1990s, 5 million in the mid-1990s,
and over 50 million today. Many such
“hits” (ie, compounds that elicit desired
effects or properties) are subsequently
validated in more complex biologic sys-
tems. Current therapeutic drugs are di-
rected against approximately 500 molec-
ular targets (45% of which are receptors;
30%, enzymes; and 25%, other targets).
Estimates of potential future drug targets
are in excess of 5,000–10,000. In other
words, there are at least 10 times more
targets that will be discovered and ex-
ploited than are being used today. While
the use of these powerful methods have
essentially changed therapeutic drug de-
velopment, there has been limited im-
pact on the design of imaging probes to
date. There are many reasons for this,
primarily the smaller market size for im-
aging drugs as compared with that for
therapeutic drugs and the lack of active
interactions between imaging and chem-
istry departments. As imaging receives
further recognition as a key enabling
technology for in vivo molecular target
assessment, such essential interdiscipli-
nary interactions will increase, undoubt-
edly leading to the discovery of many
novel imaging agents.
High-afﬁnity ligands developed ratio-
nally, combinatorially, or by chance
must have the ability to reach the in-
tended target at sufﬁcient concentration
and for a sufﬁcient length of time to be
detectable in vivo. Rapid excretion, non-
speciﬁc binding, metabolism, and deliv-
ery barriers all counteract this process
and must be overcome. Delivery barriers
are typically the most challenging to deal
with, particularly for larger biotechnol-
ogy drugs. However, even low-molecular-
weight agents may not be easily internal-
ized into cells, a requirement for imaging
of intracellular targets. A number of strat-
egies have been developed to circumvent
existing delivery barriers, while current
research is concentrated on the develop-
ment of even more efﬁcient methods. Ex-
amples include the use of peptide-de-
rived membrane translocation signals
that result in active shuttling of imaging
drugs into cells (1), peg-ylation to de-
crease both immunogenicity and rapid
recognition (2), use of long-circulating
drugs to achieve a more homogenous dis-
tribution (3), and/or local delivery com-
bined with pharmacologic or physical
methods to improve targeting (4,5). An-
other aspect unique to in vivo molecular
imaging is the frequent inability to elim-
inate unbound afﬁnity ligands, which
may markedly contribute to background
noise. In in vitro assays, this step is easily
dealt with by washing off unbound ligands
and then recording speciﬁc signals, with
resultant high target-to-background ratios.
Unfortunately, in the in vivo situation, on
the contrary, options are limited to optimi-
zation of pharmacokinetics (ie, waiting for
nonspeciﬁc agents to be washed out). This
may be aided by removing some of the
ligand from circulation (into the reticu-
loendothelial system) by means of the
addition of speciﬁc “chase” compounds
shortly before imaging (6).
Utilization and future development
of efﬁcient ampliﬁcation strategies (in-
creasing the imageable signal) remain
critical components of much of molec-
ular imaging research. Figure 3 summa-
rizes generic cellular targets, including
DNA, messenger RNA (mRNA), and pro-
teins. Although the numbers of DNA
and mRNA targets per cell are limited
(requiring extreme levels of signal am-
pliﬁcation for visualization), the imag-
ing of proteins and/or protein function
is much more feasible (referred to as
“imaging downstream”). A number of
chemical and biologic ampliﬁcation
strategies have been developed to facil-
itate molecular imaging at the protein
level: These strategies make use of
(a)i m p r o v i n gt a r g e tc o n c e n t r a t i o n( b y
means of pretargeting [7], avidin-biotin
ampliﬁcation systems [8], and improv-
ing kinetics [9]), (b)u n i q u ec e l l u l a r
functions (trapping of converted li-
gands [10,11]), or (c)t h ea b i l i t yo f
probes to change their physical behav-
ior after target interactions (ﬂuores-
cence dequenching [12], increasing R2
[13] or R1 [14] at magnetic resonance
[MR] imaging). The use of some or all of
the strategies, together with the selec-
tion of a downstream target of gene
expression, will typically sufﬁce for im-
aging at the protein level.
Molecular information can be ob-
tained with some but not all of our pres-
ently used “high-end” imaging technol-
ogies (Fig 3). Despite recent advances in
imaging technology, further improve-
ments in current imaging modalities and
exploration of new modalities are still at
the center stage of molecular imaging re-
search. For example, the development of
optical imaging technology (including
diffuse optical tomography, phase-array
detection, photon counting, near-infra-
red ﬂuorescence imaging), high-spatial-
resolution MR and nuclear imaging tech-
niques (eg, micro-MR, micro–positron
emission tomography [PET]) play an im-
portant role in the ﬁeld (discussed later in
this article). Improved spatial resolution
now allows imaging of mouse models of
human disease, and imaging ﬁndings
and concepts can thus be directly trans-
lated into a clinical context.
Figure 1. Schematics show prerequisites to in vivo molecular imaging. Potential targets can be
at the DNA, RNA, or protein level (also see the text and Fig 2).
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range of disciplines including engineering, molecular biology, chemistry and medicine and 
aims to overcome the shortcomings of each modality by combining multiple techniques.
105-106  
Mitchell  et  al.  reported  the  success  of  using  a  PEGylated  liposome  as  a  multimodal 
diagnostic  agent  that  incorporated  the  MRI  contrast  agent  gadolinium,  a  radiolabel  for 
nuclear imaging and a fluorescent lipid for optical imaging. These PEGylated lipids showed 
good biodistribution and cellular uptake in tumour cells with little effect on cell viability.
87 
1.7.2 Magnetic Resonance Imaging (MRI) 
Magnetic  Resonance  Imaging  (MRI)  is  considered  to  be  an  excellent  technique  when 
imaging cancer owing to its high spatial resolution, excellent soft tissue contrast and its non-
invasive nature.
107-108 
An  MRI  instrument  obtains  high-resolution  images  of  the  body  by  exploiting  the  natural 
magnetic properties of water present within the body and hence, the abundance of hydrogen 
nuclei.  In  the  absence  of  an  external  magnetic  field  hydrogen  nuclei  exhibit  random 
orientations,  however,  upon  the  application  of  a  magnetic  field  the  nuclei  align  in  the 
direction of the applied field, see Figure 15. When an RF ‘pulse’ is applied these nuclei flip in 
a 90-degree orientation to the magnetic field and the removal of this RF pulses causes the 
nuclei to return to their alignment along the applied field axis. A signal is produced upon the 
removal of the RF pulse, which allows an image to be built up.
109 
(i) 
(ii) 
Figure 15: A Figure Showing the Nuclei in the Body in (i) the Absence of an External Magnetic Field and (ii) the 
Presence of an External Magnetic Field (Reproduced from Reference 109 with permission from BMJ Publishing 
Group LTD) 
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When additional energy (in the form of a radio
wave) is added to the magnetic field, the
magnetic vector is deflected. The radio wave
frequency (RF) that causes the hydrogen nuclei
to resonate is dependent on the element
sought (hydrogen in this case) and the
strength of the magnetic field. 
The strength of the magnetic field can be
altered electronically from head to toe using a
series of gradient electric coils, and, by altering
the local magnetic field by these small
increments, different slices of the body will
resonate as different frequencies are applied. 
When the radiofrequency source is switched
off the magnetic vector returns to its resting
state, and this causes a signal (also a radio
wave) to be emitted. It is this signal which is
used to create the MR images. Receiver coils
are used around the body part in question to
act as aerials to improve the detection of the
emitted signal. The intensity of the received
signal is then plotted on a grey scale and cross
sectional images are built up.
Multiple transmitted radiofrequency pulses can
be used in sequence to emphasise particular
tissues or abnormalities. A different emphasis
occurs because different tissues relax at
different rates when the transmitted
radiofrequency pulse is switched off. The time
taken for the protons to fully relax is measured
in two ways. The first is the time taken for the
magnetic vector to return to its resting state and
the second is the time needed for the axial spin
to return to its resting state. The first is called T1
relaxation, the second is called T2 relaxation. 
An MR examination is thus made up of a series
of pulse sequences. Different tissues (such as
fat and water) have different relaxation times
and can be identified separately. By using a 
“fat suppression” pulse sequence, for example, 
the signal from fat will be removed, leaving
only the signal from any abnormalities lying
within it. 
Most diseases manifest themselves by an
increase in water content, so MRI is a sensitive
test for the detection of disease. The exact
nature of the pathology can be more difficult to
ascertain: for example, infection and tumour
can in some cases look similar. A careful
analysis of the images by a radiologist will
often yield the correct answer. 
There are no known biological hazards of MRI
because, unlike x ray and computed tomography,
MRI uses radiation in the radiofrequency range
which is found all around us and does not
damage tissue as it passes through.
Pacemakers, metal clips, and metal valves can
be dangerous in MRI scanners because of
potential movement within a magnetic field.
Metal joint prostheses are less of a problem,
although there may be some distortion of the
image close to the metal. MRI departments
always check for implanted metal and can
advise on their safety. Safety information is
also available on the internet on 
http://kanal.arad.upmc.edu/MR_Safety/
Abi Berger, science editor, BMJ
HOW DOES IT WORK?
Magnetic resonance imaging
When the body is placed in a strong magnetic
field, such as an MRI scanner, the protons’
axes all line up. This uniform alignment creates
a magnetic vector oriented along the axis of
the MRI scanner. MRI scanners come in
different field strengths, usually between 0.5
and 1.5 tesla.
T1 weighted axial pelvis T2 weighted axial pelvis
The hydrogen proton can be likened to the
planet earth, spinning on its axis, with a 
north-south pole. In this respect it behaves like
a small bar magnet. Under normal
circumstances, these hydrogen proton “bar
magnets” spin in the body with their axes
randomly aligned. 
Magnetic resonance imaging (MRI) uses the
body’s natural magnetic properties to produce
detailed images from any part of the body. For
imaging purposes the hydrogen nucleus (a
single proton) is used because of its
abundance in water and fat.
Right femoral head
Right femoral head
Cortical bone
Pelvic fat
Subcutaneous fat
Right acetabulum
Gluteus muscle
Uterus
Recto sigmoid
Anterior
Bladder
Bladder
Anterior
No external magnetic field 
present 
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The MRI signal is dependent on a variety of key factors, which include both the properties of 
the tissue and the imaging parameters. These include; longitudinal and transverse relaxation 
times (T1 and T2), hydrogen spin density, the tissue motion and the magnetic susceptibility. 
The longitudinal relaxation time (T1) is the rate of recovery of the nuclei along the X axis (the 
main magnetic field) and the transverse relaxation time (T2) can be expressed as the rate at 
which the nuclei dephase along the Y axis (the 90-degree orientation resulting from the RF 
pulse).
110,124 
The  image  is  built  up  from  the  T1  and  T2  relaxation  times  of  water,  which  are  largely 
dependent on the physiological environment and composition of cells thus allowing contrast 
between tissues within an image. However, there may be little change in relaxation/contrast 
seen between healthy and cancerous tissue in early stages of disease and thus contrast 
agents are normally needed to delineate small tumour lesions.
111-112  
Contrast agents work by shortening the relaxation times in the tissues and are dependent on 
their concentration in the tissue, as well as the density and movement of the protons in the 
tissue.
111 The shortening of the T1 and T2 relaxation times with a contrast agent is classified 
as the relaxivity and can be expressed as r1 and r2. By using contrast agents it is possible to 
shorten the relaxation times, increasing the contrast between tissues, thus increasing the 
sensitivity and can therefore allow for earlier detection of cancerous tissue.
108,112  
There are two types of contrast agent; T1 and T2, which act as either positive or negative 
contrast agents.  
T1, or positive contrast agents function by increasing the time it takes the hydrogen nuclei to 
recover along the main magnetic field via a direct interaction between the contrast agent and 
the  protons  in  the  tissue
111,124 The  T1 contrast  agents  have  a  low  ratio  of  r1/r2 and  this 
generates  a  positive  contrast,  hence,  a  positive  contrast  agent,  typically  paramagnetic 
gadolinium complexes, Figure 16.
111-112  
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Figure 16: An Image Showing the Positive Contrast Resulting from the Admission of a Gadolinium Contrast Agent 
 
T2, or negative contrast agents have a high r2/r1 ratio which results from a ‘remote effect that 
disturbs T2 relaxation with local magnetic field heterogeneity produced by T2 agents’.
111 This 
high ratio of r2/r1 results in dark areas in the T2 images and hence, is classified as a negative 
contrast agent, Figure 17.
112  
 
Figure 17: An Image Showing the Negative Contrast Resulting from the Admission of an Iron Oxide Contrast Agent 
 
The superparamagnetic properties of iron oxide MNPs make them excellent contrast agents 
owing  to  their  increased  magnetic  moment  and  ability  to  lose  net  magnetisation  in  the 
absence  of  an  external  magnetic  field.
26 Superparamagnetic  iron  oxide  MNPs  are  T2  or 
negative contrast agents but have the ability to shorten both T1 and T2 relaxation times and 
show an increased r1 and r2 compared to the paramagnetic gadolinium; 30 mmol
-11s
-1 (T1) 
and 100 mmol
-11s
-1 (T2) for iron oxide and 4 mmol
-11s
-1 (T1) and 6 mmol
-11s
-1 (T2) for the 
gadolinium complex Gd-DTPA at 37 °C and 0.47 T.
113  
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There are however challenges associated with the use of both iron oxide and gadolinium 
contrast  agents  such  as  ensuring  sufficient  concentration  at  site  of  interest,  instability  in 
biological media and potential toxic effects.
48 To overcome these issues faced by MRI both 
functionalisation  and  targeting  strategies  are  employed  ensuring  specific  and  sensitive 
imaging techniques. 
1.7.3 Positron Emission Tomography (PET)  
Positron emission tomography (PET) is a popular molecular imaging technique that offers 
detailed information about processes occurring at the early stage of disease, the extent of 
the disease including metastatic spread and determine the necessary therapeutic steps for 
treatment  whilst  remaining  a  non-invasive  imaging  technique.  PET  involves  the 
administration of radiolabelled compounds to a peripheral vein, these radioisotopes include; 
O
15, I
124, C
11 and F
18.  
Once  the  radiolabelled  compound  has  been  administered  in  vivo  it  emits  positrons  that 
undergo an annihilation event after interacting with an electron, which produces a pair a 
gamma  rays  in  a  180  degree  orientation.  Owing  to  the  time  of  flight  between  the  two 
detectors on either side of the 180 degree emission, the gamma rays can be detected by 
scintillation crystals on cameras and converted to electrical signals. A range of signals is 
collected that are characteristic of the annihilation event, which is determined by the uptake 
of the tracer due to the tissue environment, and the detected signals are interpreted by a 
computer that constructs an image of the measured plane, Figure 18.  The gamma rays 
produced  by  the  emission  of  the  positrons  have  sub-atomic  properties  but  the  spatial 
resolution of PET is limited to around 1mm by the detector hardware. 
114-116   55 
 
Figure 18: Schematic Illustration of a PET Scan Process (Reproduced from Reference 114 with permission from 
BMJ Publishing Group LTD) 
 
PET imaging is the most sensitive imaging technique with detection levels as low as 10
-11 
moles, permitting single cell detection. It is particularly popular in cancer diagnosis as it can 
help diagnose the stage of many cancers including lung and breast and determine whether 
or not the tumours are benign or malignant, eliminating the need for biopsies. PET imaging 
is primarily limited by its cost and the requirements for a nearby cyclotron to provide the 
radioisotopes. Another issue faced by PET imaging is the large dose of strongly ionising 
radiation,  which  can  cause  local  tissue  damage,  particularly  in  the  kidneys  owing  to  the 
pharmacokinetics. It is also necessary to combine the PET with another imaging technique 
such as computed tomography (CT) in order to give spatial resolution.
115,116  
Oku et al. reported the in vivo imaging of brain cancer by PET imaging with PEGylated 
liposomes labelled with 
18F and a fluorescent moiety. The labelled liposomes were not able 
to cross the blood brain barrier in normal tissue but it was possible to image the brain cancer 
owing to the different structure of the tumour vessels.
117  
 
1.7.4 Optical Imaging  
Optical  imaging  is  an  increasingly  important  and  popular  technique  in  which  a  single 
illumination source can offer imaging in multiple wavelengths and therefore colours, which 
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HOW DOES IT WORK?
Positron emission tomography
• Positron emission tomography (PET) is a
technique that measures physiological function
by looking at blood flow, metabolism,
neurotransmitters, and radiolabelled drugs.
PET offers quantitative analyses, allowing
relative changes over time to be monitored as
a disease process evolves or in response to a
specific stimulus. 
• The technique is based on the detection of
radioactivity emitted after a small amount of a
radioactive tracer is injected into a peripheral
vein. The tracer is administered as an
intravenous injection usually labelled with
oxygen-15, fluorine-18, carbon-11, or
nitrogen-13. The total
radioactive dose is
similar to the dose
used in computed
tomography.
• PET scans take 10-
40 minutes to
complete. They are
painless, and, as for
computed
tomography, the
patient is fully
clothed.
• A common use for
PET is to measure the
rate of consumption
of glucose in different
parts of the body.
Normal brain
Further reading: Positron Emission Tomography: Principles &
Practice, edited by Valk, Bailey, Townsend, and Maisey. London:
Springer-Verlag, 2002 (ISBN 1-85233-485-1)
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Abi Berger, science editor, BMJ
• Accumulation of the
radiolabelled glucose
analogue 18-
fluorodeoxyglucose
(FDG) allows
measurement of the
rate of consumption
of glucose. One
clinical use of this is
to distinguish
between benign and
malignant tumours
(malignant tumours
metabolise glucose at
a faster rate than
benign tumours).
Whole body scans are
often performed to
stage a cancer. 
• Other applications of PET include looking at
the blood flow and oxygen consumption in
different parts of the brain–for example, in
understanding strokes and dementia. Tracking
chemical neurotransmitters (such as
dopamine, in Parkinson’s disease) can also be
performed with this technique. 
• PET has further applications in cardiology (in
pretransplantation assessment of viable
myocardium), in distinguishing recurrent
tumours from radiation necrosis and surgical
scarring, and in a variety of cancers. 
1. The nucleus of the radioisotope
emits a positron (positive electron).
2. This collides with an electron in the
tissue and in the process converts
mass to energy (E=mc2) in the form
of two photons. 
3. The PET camera uses
scintillation crystals
placed around the
subject to detect these
photons.
4.The crystals absorb the
photons, producing light
that is converted into an
electrical signal.
Heart muscle with good blood flow Scan indicates restricted blood flow (causing the
pain of angina) 
A brain tumour demonstrated on the right (blue,
indicating poor blood flow at the area of tissue
damage or tissue death)
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can  be  visualised  immediately  by  eye.  It  is  an  extremely  important  laboratory  based 
technique,  particularly  in  clinical  histopathology  and  can  be  used  as  an  indicator  of 
therapeutic requirements. The set up and operation of an optical microscope with fluorescent 
capabilities is described in Section 2.7.8.  
A  number  of  molecules  have  been  developed  for  optical  imaging  and  these  include 
antibodies  and  proteins.  A  number  of  genes  have  been  developed  that  allow  for  the 
expression of fluorescent proteins, for example green fluorescent protein which has near-
infrared  fluorescent  imaging  capabilities  that  require  no  additional  administration  of 
fluorochromes.  
The  key  limiting  factor  of  optical  imaging  is  the  short  focal  lengths  that  result  in  a  poor 
imaging depth penetration of 1-2mm, rendering the technique unsuitable for in vivo imaging 
in  large  animals  and  more  importantly  humans.  Despite  the  technique  being  largely 
unsuitable for in vivo use in humans it remains an extremely popular technique in both in 
vitro and ex vivo imaging, especially in a histology setting. Optical imaging in both in vitro 
and  ex  vivo  settings  permits  cellular  staining  with  toxic  contrast  agents  and  can  provide 
useful  imaging  information  prior  to  employing  further  imaging  techniques  or  therapeutic 
treatment. 
112,115 
Matuszewski et al. reported the use of optical imaging techniques when loading different 
cancer cell lines with increasing amounts of carboxydextran functionalised iron oxide MNPs. 
The iron oxide loaded cells were stained with Prussian blue in order to visualise the iron 
present in the cells using optical techniques prior to measurement via MRI. Figure 19 shows 
the optical images obtained from staining the cells, where A is the native cells with no iron 
oxide MNPs and B, C, D showing the presence of increased amounts of iron oxide in the 
cells upon increasing the concentration of added MNPs.
17   57 
 
Figure 19: A Figure Showing the Use of Optical Imaging to Visualise Iron Oxide Loaded Cells Using Prussian Blue 
Staining Techniques (Reproduced from Reference 17 with permission from the Radiological Society of North 
America) 
 
The optical microscope used to image the transfected RFP expressing plasmid functioned 
as follows; a metal arc lamp (Prior Lumen 200) was used to produce light, which is then 
passed through an excitation filter that only allows set wavelengths of light produced by the 
lamp  pass  through.  The  light  that  is  passed  through  the  excitation  filter  is  then  passed 
through  to  the  dichroic  mirror,  which  works  by  reflecting  light  through  the  objective  and 
subsequently to the sample. Fluorescence emitted from the sample is passed back through 
to the dichroic mirror and this time it is passed to an emission filter that allows a select 
wavelength of fluorescence through and it is this emitted fluorescence which is passed to the 
camera to form an image.
 By using excitation and emission filters that encode for specific 
wavelengths it is possible to image a single sample in multiple fluorescent channels. 
118,119 
1.8 The Future of Cancer Diagnosis 
The  future  of  cancer  diagnosis  and  therapy  is  set  to  have  a  large  focus  on  the  further 
development of nanomedicine complexes. By further developing nanomedicine complexes it 
will one day be possible to provide personalised oncology to a patient whilst potentially being 
able to offer diagnosis and therapy simultaneously. The next generation of nanomedicine is 
set to offer dual, triple and quadruple modalities of imaging from a single multifunctional 
molecule that aims to exploit the availability of multiple imaging techniques and therapies 
such as a gene therapy and improved drug delivery. These multimodal molecules will be 
microscopy was performed by an experi-
enced board-certiﬁed pathologist (C.P.).
Quantitative Determination of
Intracellular Iron Uptake
Inductively coupled plasma atomic
emission spectrometry is a well-estab-
lished technique for elemental analysis
and was used to quantitatively determine
the intracellular iron uptake of CLL-185
cells. The technique is based on the mea-
surement of the emitted light of excited
iron atoms. The emitted wavelength is
characteristic for the material that is in-
vestigated. By measuring the intensities
of these wavelengths and comparing
them with those generated with known
standards, the concentrations of the dif-
ferent atoms (in this case iron) can be
determined.
For the analysis of inductively coupled
plasma atomic emission spectrometry, 1
million cells were prepared in 500  Lo f
phosphate-buffered saline. For measure-
ments, 100  Lo fc e l ls u s p e n s i o nw e r ed i s -
solved in 100  Lo fn i t r i ca c i da n dh y d r o -
gen peroxide and were diluted to 700  L
by adding distilled water. Iron counts were
calculated automatically as micrograms of
iron per liter of solution. Cell preparations
and inductively coupled plasma atomic
emission spectrometric (atomic absorption
spectrophotometer model 2380; Perkin-
Elmer, Ueberlingen, Germany) measure-
ments were performed by two authors
(L.M., M.F.).
MR Imaging Protocols
MR imaging was performed with a
1.5-T imager (Gyroscan Intera; Philips,
Best, the Netherlands) by using a stan-
dard extremity knee coil. For imaging of
cell phantoms, T2-weighted gradient-
echo (repetition time msec/echo time msec
of 250/13.81, 25° ﬂip angle, 410   512
matrix, 1.5-mm section thickness), spin-
echo (2500/100, 90° ﬂip angle, 193   512
matrix, 1.5-mm section thickness), and
turbo spin-echo (4000/100, 90° ﬂip an-
gle, echo train length of 15, 374   512
matrix, 1.5-mm section thickness) se-
quences were performed. The visibility of
iron oxide–labeled cells on MR images
was qualitatively assessed by two board-
certiﬁed radiologists (C.B., B.T.).
Statistical Analysis
All data are presented as mean   stan-
dard error of the mean. For statistical
evaluation, the effect of increasing iron
oxide concentrations in the medium and
the inﬂuence of particle size on cellular
iron uptake were compared by using an
analysis of variance with a Bonferroni-
corrected P value. Effects of lipofection
were compared by using a two-tailed Stu-
dent t test, in which cellular iron uptake
with TM was compared with that with-
out TM.
Moreover, the effect of iron labeling on
cell viability was analyzed by using an
unpaired two-tailed Student t test, in
which cells incubated with iron-free me-
dium were compared with cells incu-
bated with high iron concentrations (1
mg Fe/mL incubation medium). For all
tests, P   .05 was considered to indicate a
signiﬁcant difference. All calculations
were performed by two authors (L.M.,
C.B.) using a commercially available sta-
tistics software (GraphPad Prism, version
4; GraphPad, San Diego, Calif).
RESULTS
Cell Viability Assay and Label
Retention
The trypan blue exclusion assay
showed an averaged viability of 96.1%  
1.0 for the control cells. Even high iron
concentrations in the incubation me-
dium did not show any effect on cell
viability (1.0 mg Fe/mL in the medium,
96.8%   2.5; P   .05).
Findings of longitudinal studies showed
an exponential decrease of cellular iron
content in dividing CLL-185 cells. The av-
erage cellular iron content decreased from
4.29  g   0.6 Fe per 100 000 cells (100%)
at day 1 to 1.09  g   0.30 at day 4
(27.2%   4.1 of initial iron load). At day 8
after labeling, a 0.43  g   0.16 Fe per
100 000 cells (10.3%   1.3 of initial iron
load) was present within the cells. Three
weeks after cell labeling, the iron content
had returned to prelabeling baseline values
(0.08  g   0.02 Fe per 100 000 cells). The
dilution of cellular iron oxide over time
correlated well with the cell doubling time
of the CLL-185 cells, which ranged be-
tween 30 and 40 hours.
Light and Electron Microscopy
Light microscopy revealed an intracel-
lular uptake of iron oxides into the cy-
tosol. Both the use of TM and the increas-
ing concentration of iron oxides in the
medium substantially increased the in-
tracellular iron oxide load (Fig 1). Large
particles were taken up more efﬁciently,
compared with smaller iron oxides.
Electron microscopic studies revealed a
lysosomal deposition of iron oxides (Fig
2). In correlation with the trypan blue
exclusion experiments, no toxic effects of
the iron oxides could be observed at cel-
lular and subcellular levels.
Figure 1. Photomicrographs obtained at light microscopy of CLL-185 cells labeled with car-
boxydextran-coated iron particles (65 nm) in the presence of TM. Blue precipitate within the cells
represents incorporated iron particles. A, Native cells and cells incubated with, B, 0.01; C, 0.10;
and D, 1.00 mg Fe/mL. Note increasing intracellular iron uptake with higher doses of iron oxide
in the incubation medium. (Prussian blue stain; objective magniﬁcation,  40).
Volume 235   Number 1 Cell Tagging with Clinically Approved Iron Oxides   157
R
adiology  58 
able  to  circumvent in  vivo  clearance  systems  whilst  offering  biocompatibility  and  specific 
targeting to biomarkers and receptors found at the site of disease.
4,8,81 
Some recent publications in the literature have shown the emergence of nanomedicine as 
promising diagnostic and therapeutic tools and these include; 
Cho et al. showed a novel method for the delivery of iron oxide MNPs conjugated with a 
carcinoembryonic antigen into dendritic cells, cells that initiate and regulate antigen-immune 
specific responses, with the aim of working as a immunotherapeutic cancer technique with 
MRI  capability.  The  results  showed  both  immunotherapeutic  response  and  imaging 
capabilities in both ex vivo and in vivo settings showing promise for clinical trials.
120 
Silva et al. reported the incubation of the THP1 human macrophage cell line with citric acid 
functionalised iron oxide MNPs and the mTHPC drug, which is a fluorescent emitter to form 
‘therasomes’.  The  incubated  cells  were  magnetically  separated  and  then  MNP  and  drug 
containing  cells  were  subsequently  injected  in  vivo.  The  MNP  offers  an  MRI  imaging 
modality  and  the  fluorescent  drug  provides  a  means  for  photodynamic  therapy  and 
fluorescent optical imaging, Figure 20. The distinct advantage offered by this technique is 
the  encapsulation  into  a  human  cell  line,  which  exploits  the  natural  delivery  system  of 
macrophage cells avoiding clearance.
121 
 
 
Figure 20: Theranosomes Offering MRI, Photodynamic and Optical Imaging Capabilities (Reproduced from 
Reference 121 with permission from the American Chemical Society) 
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B
vectors present highly optimized functions in vivo,
such as natural stability in blood circulation, immuno-
tolerance,
8 natural targeting properties, and the capacity
to facilitate cell entry.
9 Moreover, most cell material
interactions are mediated by the cell membrane. In this
regard,designingatherapeuticvectorwithcellularorigin
may represent a challenging opportunity for drug deliv-
ery. Exosomes, the smallest subsets of cell-derived vesi-
cles,havebeen rstengineeredforgeneordrugdelivery.
Puri ed exosomes were electroporated in order to en-
capsulateshortinterfering(si)RNAforAlzheimer'sdisease
treatment.
10 Moreover, exosomes loaded with curcumin
byhydrophobicinteractionsweretestedinasepticshock
mouse model.
11 Here we propose an alternative
approach, following a top-down procedure, in which
cells serve as fabrication units to produce submicrom-
eter vesicles with speci c exogenous cargoes. Our
strategy aimed at exploiting the inherent properties
of cellular vesicles in order to design a new generation
of multifunctional theranostic vectors. For this pur-
pose, the parent cells were  rst engineered to enclose
both iron oxide nanoparticles and a therapeutic drug.
Then they were stimulated to generate nanovesicles
laden with both payloads. These cellular carriers were
named “theranosomes” in regard to their combination
of therapeutic and imaging properties (Scheme 1).
Indeed iron oxide nanoparticles are responsive to
magnetic  eld, allowing multiple functionalities such
as magnetic manipulation, remote heating,
12,13 and
tracking by magnetic resonance imaging (MRI).
14,15
Besides, the drug employed, a photosensitizer named
m-THPC, is clinically used and has been reported to be
one of the most active photosensitizers for photody-
namic therapy (PDT).
16 In addition to singlet oxygen
production, photosensitizers emit  uorescence, which
enables both detection and imaging of the drug. Yet,
the therapeutic outcome of PDT is currently weakened
bysuboptimalconcentrationatthetumorsiteandside
e ects related to unspeci c intake in healthy tissue.
Additionally, direct administration of most photosen-
sitizers such as m-THPC su ers important limita-
tions related to high hydrophobicity and subsequent
concentration-dependentaggregationinaqueousmedia.
Here the cellular membrane of cell-shed vesicles is
expected to act as a support carrier for the hydropho-
bic m-THPC drug, while the magnetic nanoparticles
provide MR detectability and allow magnetic manip-
ulations of such natural therapeutic nanovectors. Our
study reports the  rst proof of principle of designing
cell-derived multifunctional nanovectors, named ther-
anosomes, with applicability in cancer therapy.
RESULTS
Theranosome Production with Magnetic and Therapeutic
Cargo. The first step in theranosome production in-
volved an initial loading of parent cells with magnetic
nanoparticles and photosensitizer. Human macro-
phages, derived from the monocytic THP1 cell line,
were incubated with 8 nm citrate-coated iron oxide
nanoparticles together with the m-THPC photosensiti-
zer in RPMI culture medium, at a concentration below
the onset ofm-THPC aggregation. These nanoparticles
enter the cell by adsorptive endocytosis as previously
described.
17,18 Cellular internalization of nanoparticles
and efficient uptake of the photosensitizer were quan-
tified, corresponding to 30 pg of iron and 18 fmol of
m-THPCpercell,respectively.Toinducevesiclerelease,
theparentcellsweresubsequentlyculturedinserum-free
medium for two days. Membrane vesicles shed in the
extracellular medium were then sorted overnight on a
strongmagnet,inordertoselectthevesiclesloadedwith
ironoxidenanoparticles(SupplementaryFigure1).Trans-
mission electron microscopy (TEM) confirmed the isola-
tion of membrane-bound vesicles, most of them con-
tainingironoxidenanoparticlesintheirinternalcompart-
ment. A mean vesicle size of 332 ( 94 nm (n =3 0 )w a s
Scheme 1. Schematic representation of theranosome production from drug-loaded magnetic precursor cells and their
application for photodynamic therapy and dual-mode MRI and  uorescence imaging.
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Bamrungsap et al. reported conjugation of aptamers to the surface of iron oxide MNPs with 
the goal of using the aptamers for selective binding to the surface of cancer cells. Aptamers 
show  high  selectivity  and  affinity  for  receptors  and  can  be  designed  to  target  markers 
present on the surface cancer cells. The binding affinity of the aptamers to the cancer cells 
ensures the presence of iron oxide MNPs thus producing a reduction in the relaxation time 
when using the iron oxide MNPs as an MRI contrast agent. This research showed a method 
of highly selective biocompatible targeting of iron oxide MNPs to the site of disease to allow 
subsequent MRI imaging with the ability to distinguish between normal and cancerous cells. 
Multi-cancer imaging can also be explored through the functionalisation of different aptamers 
to the surface of the MNP.
12 
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2.0 Materials and Methods 
2.1  Bioconjugation  of  Poly(L)lysine  to  Commercially  Available  Iron 
Oxide Nanoparticles 
2.1.1. Materials 
3-(N-morpholino)propanesulfonic  acid,  (MOPS,  99.5%),  1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC, 99%) and sodium hydroxide pellets (NaOH, 99%) 
were purchased from VWR International (UK). Dextran coated iron oxide nanoparticles and 
carboxymethyldextran  coated  iron  oxide  nanoparticles  were  provided  by  Chemicell 
(Germany) and Micromod (Germany). Poly(L)lysine Hydrobromide (PLL;1-5, 30-70 and 150-
300  KDa),  sodium  periodate  (99.8%),  ethylene  glycol  (99.8%),  sodium  cyanoborohyride 
(NaCNBH4,  95%),  N-hydroxysuccinimide  (NHS,  98%),  tris(hydroxymethyl)aminomethane 
(tris base, 99.9%), glacial acetic acid (99.7%), hydrochloric acid (HCl, concentrated), uranyl 
acetate  dihydride  (98%),  sodium  hydrocarbonate  (NaHCO3,  95%)  and 
ethylenediaminetetraacetic acid (EDTA, 99%) were purchased from Sigma Aldrich, Germany. 
Slide-a-Lyzer dialysis cassettes with a 3,500Da Molecular Weight Cut off were purchased 
from Fisher Scientific, UK.  
2.1.2 Coating Dextran Coated Nanoparticles with PLL via Reductive Amination 
Iron oxide nanoparticles (1.25 mg, 5.40 µM) were added to an Eppendorf tube (1.5 ml). 
Sodium periodate (1.5 mg, 23.3 µM) was dissolved in dH2O (0.5 ml) and added to iron oxide 
sample, the sample was then made up to 1ml with dH2O. The sample was agitated in the 
dark for 1h at room temperature. After agitation, ethylene glycol (10 µl, 1.79 µM) was added 
to  terminate  the  oxidation  procedure  whereby  the  sample  was  subsequently  dialysed  in 
dH2O (2.5 l) using Slide-A-Lyzer cassettes with a 3,5000 MWCO, for 48 h (with a change in 
dH2O every 12 h).  
After the 48 h dialysis period, PLL (4 mg of each MW, 1-5 KDa PLL- 1.33 µM, 30-70 KDa- 80 
nM and 150-300 KDa- 17.8 nM) was dissolved in NaHCO3 (0.5 ml, 1 mM, pH 8.2). The iron 
oxide sample was split into 3 separate Eppendorfs (330 µl) and the different PLL added to 
the iron oxide sample (0.5 ml in each), the samples were then made up to 1 ml with NaHCO3 
(170 µl, 1 mM, pH 8.2). The samples were agitated for 1 h at room temperature. After the   73 
agitation, NaBH3CN (3 mg, 47 µM) was dissolved in dH2O (60 µl) and 20 µl was added to 
each sample, which were then agitated for 1 h at room temperature. The samples were 
subsequently dialysed (48 h in 2.5 l of dH2O). After washing, the samples were characterised 
using DLS, ZP, TEM, ICP-AES, FTIR and SQUID.
1 
2.1.3 Coating Carboxymethyldextran Coated Nanoparticles with PLL via Amide Bond 
Formation
 
Carboxymethyldextran coated MNPs (1.25 mg, 5.40 µM) were added to 3 Eppendorf tubes. 
Meanwhile, EDC (30 mg, 19.3 µM) was dissolved in MOPS buffer (300 µl, 50 mM, pH 6.5) 
and 100 µl was added to each sample. NHS (18 mg, 15.6 µM) was dissolved in MOPS buffer 
(300 µl, 50 mM, pH 6.5) and 100 µl was added to each sample. PLL (4 mg of each MW, 1-5 
KDa PLL- 1.33 µM, 30-70 KDa- 80 nM and 150-300 KDa- 17.8 nM) was dissolved in MOPS 
buffer (634 µl, 50 mM, pH 6.5) and this was added to the samples to give a total 2 mg of PLL 
per sample with a total volume of 1ml in each sample. The samples were agitated for 1h at 
room temperature. The samples were subsequently dialysed (48 h in 2.5 l of dH2O) using 
Slide-A-Lyzer cassettes with a 3,5000 MWCO, with a water change every 12 hours. After the 
washing process, the samples were kept refrigerated and characterised by FTIR, DLS and 
TEM. 
2 
 
2.2 Preparation and Condensation of Plasmid DNA 
2.2.1  Propagation  of  Plasmid  DNA  (pTagRFP-N1-TagRFP  and  pTagRFP-N1-hNIS-
TagRFP) 
Two different plasmids were prepared for condensation onto to the surface of the P@N; 
pTagRFP-N1-TagRFP and pTagRFP-N1-hNIS-TagRFP (prepared by Dr. Gilbert Fruhwirth, 
Kings College, London). Both plasmids contain the TagRFP gene, which encodes for the red 
fluorescent  protein  (RFP)  with  the  pTagRFP-N1-hNIS-TagRFP  containing  an  hNIS  group 
encoding for the human sodium iodide symporter. 
Briefly, aliquots of the E. Coli strain DH5α (25µl, Invitrogen) were thawed on ice (originally 
stored at -80° C). Existing plasmid stock (1 µl) was added to the DH5α aliquot and placed on 
ice (10 min). The resulting mixture was then heatshocked in a waterbath (42 °C, 45 s). After   74 
heatshocking, the samples were placed on ice (1 min) and subsequently added to LB broth 
(200 µl, Sigma) and placed in a shaking incubator at 37 °C (45 min). After shaking, the 
culture (50 µl) was spread on an agar plate with appropriate antibiotic resistance (in this 
instance, kanamycin) and incubated overnight to form bacterial colonies (37 °C). 
The following day, LB broth containing kanamycin (500X, 5 ml) was added to a falcon tube 
and to this a single colony from the agar plate was added and the resulting mixture was 
shaken (6 h, 37 °C). After shaking the mixture was added to LB broth containing kanamycin 
(500X, 250 ml) and incubated overnight with shaking (37 °C). After incubation the mixture 
was centrifuged (4000 g, 10 min, 4 °C) and the supernatant removed.  
After removal of the supernatant the resulting pellet was purified according to the Invitrogen 
PureLink HiPure Plasmid Filter Purification maxi-prep kit (Invitrogen).
3 Briefly, the column 
was equilibrated with Equilibration Buffer (30 ml) and the resulting pellet was re-suspended 
with Resuspension Buffer with RNase A (10 ml). Lysis buffer (10 ml) was then added to the 
re-suspended  pellet,  mixed  thoroughly  and  incubated  at  room  temperature  (5  min). 
Precipitation Buffer (10 ml) was subsequently added and the precipitated lysate transferred 
to  the  column.  After  filtration  the  inner  filtration  cartridge  was  removed  and  the  column 
washed  with  Wash  Buffer  (50  ml).  After  washing,  the  purified  DNA  was  eluted  from  the 
column using Elution Buffer and collected in a falcon tube and isopropanol (10.5 ml) was 
added. The mixture was centrifuged (12,000 g, 30 min, 4 °C), the supernatant discarded and 
the pellet re-suspended in ethanol (70%, 5ml). The mixture was centrifuged (12,000g, 5min, 
4 °C), the supernatant discarded and the pellet re-suspended in dH2O (500 µl) to give the 
purified  plasmid  DNA.  The  concentration  of  the  DNA was determined using a Nanodrop 
(Thermo Scientific, UK) with a typical yield of approximately 1000 µgµl
-1.  
2.2.2  Running  Agarose  Gels  to  Determine  the  DNA  Loading  Capacity  of  the 
Nanoparticles 
In order to determine the loading capacity of the MNP, the point at which no more DNA can 
be condensed onto the surface, gel shift assays using agarose gels were carried out. The 
rationale behind carrying out gel shift assays is that at ratios of DNA:MNP where all the DNA 
is  condensed,  the  heavy  weight  of  the  MNP  inhibits  it’s  movement  through  the  gel  and 
therefore  no  DNA  band  is  seen.  At  ratios  where  excess  DNA  is  present  (and  hence,   75 
uncondensed) it would be free to move up the gel and a band would be visible. Gel shift 
assays were carried out for the four different MNP types: Chemicell with 30-70KDa PLL, 
Chemicell with 150-300 KDa PLL, Micromod with 30-70 KDa PLL and Micromod with 150-
300 KDa PLL, with the pTagRFP-N1-TagRFP plasmid. To condense the plasmid DNA onto 
the  surface  of  the  MNPs,  the  anionic  DNA  solution  was  added  to  the  cationic  MNP 
dispersion in the same volume and at specific weight ratios, see Table 1. 
2.2.3 Preparing TAE Running Buffer (50X) 
Tris base (24.2 g) was dissolved in glacial acetic acid (5.71 ml) and added to a glass bottle 
(100 ml). Meanwhile, EDTA (1.6 g) was dissolved in dH2O (10 ml) and added to the tris base 
solution. The solution was made up to a final volume of 100 ml with dH2O and then pH 
adjusted to 7.4 (physiological pH). The running buffer was diluted to a 10X solution upon 
setting the gel and running the gel.  
2.2.4 Preparing 0.8% Agarose Gel 
Agarose (400mg) was dissolved in TAE buffer (1X, 50 ml) and microwaved until completely 
dissolved and ethidium bromide (150 µl) was added. The solution was poured into a gel tray, 
a comb added to form the lanes, ensuring no air bubbles were present and allowed to set (~ 
1h) 
2.2.5 Running 0.8% Agarose Gel 
Solutions containing the DNA, the MNPs and loading buffer were then loaded into the gel 
and the gel was run (1 h, 120 V). Upon completion the gel was soaked (20 min) in TAE 
buffer  (20  ml)  containing  ethidium  bromide  (2  ml).  The  gel  was  imaged  using  a  UV 
transilluminator. 
(N.B.  DNA  mass  remained  uniform  throughout  gel  with  an  alteration  in  MNP  mass  to 
determine the optimal loading concentration. A DNA control lane with no addition of MNPs 
was present in all gels to demonstrate its success.) 
In a typical experiment, the following conditions were used (see Table 1); 
Ratios of DNA to NP: 3:1, 5:1, 15:1, 30:1, 70:1, 140:1 
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Lane  Ratio 
(DNA:MNP)/Contents 
Amount of MNP (ng)  Amount of DNA (ng) 
1  Ladder (1 kbase)  n/a  n/a 
2  Control  n/a  100 
3  3:1  35  100 
4  5:1  175  100 
5  15:1  350  100 
6  30:1  875  100 
7  70:1  1750 (1.75µg)  100 
8  140:1  3500 (3.5µg)  100 
Table 1: A Table Showing the Typical Conditions for the Gel Shift Assay 
 
The gel was run at 120 V for 1h 20 and subsequently soaked in a 10X TAE solution with the 
addition of ethidium bromide (50 µl).  
 
2.3  Formulation  of  Liposomes  (L),  Lipopolyplexes  (L:P:Ds)  and 
Magnetoployplexes (L:D:P@Ns and L:P:D:Ns) 
2.3.1 Materials 
DOPE  (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine),  DOTMA  (1,2-di-O-octadecenyl-3-
trimethylammonium-propane),  DOTAP  (1,2-dioleoyl-3-trimethylammoniumpropane)  and 
Fluorescein  (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(carboxyfluorescein))  were 
purchased  from  Avanti  Polar  Lipids  (USA)  as  the  chloride  salts.  The  CH300  lipids  were 
synthesised at University College London by Dr. Nick Mitchell. 
2.3.2 Key to Lipid Structure Abbreviations  
Table 2 shows the abbreviations used when formulating the magnetolipopolyplexes where ‘:’ 
denotes  and  electrostatic  bond  and  ‘@”  denotes  a  permanent  bond  formed  through  bio-
conjugation. 
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Experiment Type  Formulation  Abbreviation 
Bioconjugation Formulation 
Nanoparticle  MNP/ N 
Peptide + Nanoparticle  P@N 
DNA + Peptide + Nanoparticle  D:P@N 
Lipid + DNA + Peptide + 
Nanoparticle 
L:D:P@N 
Electrostatic Formulation 
Nanoparticle  MNP/ N 
Lipid + DNA  L:D 
Lipid + Peptide + DNA  L:P:D 
Lipid + Nanoparticle  L:N 
Lipid + Peptide + DNA + 
Nanoparticle 
L:P:D:N 
Table 2: Key to Abbreviations Used in Chapter 2 
 
2.3.3 Lipid Structures 
In order to formulate the L:D, L:P:D, L:N, L:D:P@N and L:P:D:N structures, five types of 
lipids were used, four commercially available; DOPE, DOTMA, DOTAP and Fluorescein  and 
a  non-commercially  available  PEGylated  lipid,  CH300.  The  commercially  available  lipids 
were purchased as chloride salts. Figures 21-25 illustrates the chemical structures of the 
lipids and Tables 3 and 4 provide information on their molecular weight and the ratios in 
which they were used. 
 
Figure 21: DOPE Lipid 
 
 
Figure 22: DOTMA Lipid 
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Figure 23: DOTAP Lipid 
 
 
Figure 24: CH300 Lipid 
 
 
Figure 25: Fluorescein Lipid 
 
Lipid  Molecular Weight 
DOTMA  671 
DOTAP  699 
DOPE  744 
CH300  876 
Fluorescein  1136 
Table 3: Table Showing the Molecular Weight of the Lipids 
 
  Lipid Combination    Ratios (by weight) 
DOTMA/DOPE (D/D)  1:1 
CH300/DOPE (C/D)  1:1 
DOTAP/DOPE (DT/D)  1:1 
DOTMA/DOPE/Fluorescein  50:49:1 
CH300/DOPE/ Fluorescein  50:49:1 
Table 4: Average Molecular Weights of the Different Liposome Formulations 
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2.3.4 Peptide Structures 
A variety of peptide structures that code for EGF targeting sequences were synthesised by 
Dr.  Nick  Mitchell  following  previously  reported  work.  Three  different  targeting  sequences 
were used to determine if targeted delivery of the L:P:D:Ns would improve their transfection 
efficiency and delivery of iron oxide MNPs. Table 5 shows the peptide sequences used.
4,5,6 
Peptide Name  Peptide Sequence  Role of Peptide  Synthesised By 
Targeting Peptide 1 
(TP1) 
K16RVRRYHWYGYTPQNVI  DNA condensation and 
EGFR Targeting  
Dr. Nick Mitchell 
Targeting Peptide 2 
(TP2) 
K16RVRRLARLLT  DNA condensation and 
EGFR Targeting 
Dr. Nick Mitchell 
Targeting Peptide 3 
(TP3) 
YHWYGYTPQNVIRVRRK16  DNA condensation and 
EGFR Targeting 
Dr. Nick Mitchell 
Table 5: The Peptide Structures Used and their Role in L:P:D:N Formulation 
 
2.3.5  Formulation  of  Magnetolipopolyplexes  with  Bioconjugated  Commercially-
Available Nanoparticles (L:D:P@Ns) 
The lipids were prepared by adding the ratios of lipids in chloroform solution, typically 500µl 
of DOTMA (1 mM) or CH300 (1 mM) and 500µl of DOPE (1 mM) were added to a 5ml round-
bottomed flask. The chloroform was removed using a rotary evaporator to form a lipid film 
around  the  flask  and  this  was  placed  on  a  high-vacuum  system  (1  h)  to  remove  any 
remaining  chloroform.  The  corresponding  amount  of  D:P@N  solution  was  added  to  the 
round-bottomed flask and incubated overnight (4 °C). The solutions were probe-sonicated 
(25% power, 10 min) to form liposomes. Tables 6 and 7 illustrate the typical amounts made 
up for 30 transfections.  
Component / Ratio  5:2:1 (L:D:P@N) (µg)  10:2:1 (L:D:P@N) (µg)  20:5:1 (L:2:P@N) (µg) 
Lipid (L)  7.5  15.0  30.0 
pDNA (D)  3.0  3.0  3.0 
PLL@MNP (P@N)  1.5  1.5  1.5 
Table 6: Typical Formulation Amounts for the L:D:P@Ns at the Ratios 5:2:1, 10:2:1 and 20:2:1 
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Component / Ratio  5:5:1 (L:D:P@N) (µg)  10:5:1 (L:D:P@N) (µg)   20:5:1 (L:D:P@N) (µg) 
Lipid (L)  7.5  15.0  30.0 
pDNA (D)  7.5  7.5  7.5 
PLL@MNP (P@N)  1.5  1.5  1.5 
Table 7: Typical Formulation Amounts for the L:D:P@N at the Ratios 5:5:1, 10:5:1 and 20:5:1 
 
2.3.6  Formulation  of  Magnetoliposomes  (L:N),  Lipopolyplexes  (LPDs)  and 
Magnetolipopolyplexes (L:P:D:Ns) by Electrostatic Addition 
The lipids were prepared by adding the ratios of lipids in chloroform solution, typically 500 µl 
of DOTMA or CH300 and 500 µl of DOPE were added to a 5 ml round-bottomed flask. The 
chloroform was removed using a rotary evaporator to form a ‘lipid film’ around the flask and 
then this was placed on a high-vacuum system (1 h) to remove any remaining chloroform. 
The film was hydrated with dH2O (1 ml) and subsequently incubated (4 °C, 20 min). The 
solutions were then probe-sonicated (25% power, 10 min) to form liposomes.  
In order to formulate L:N samples, MNPs were added in a suitable weight ratio, typically 10:1 
L:N, to the liposome dispersion and then left to incubate overnight at 4 °C.  
To formulate L:P:D samples a peptide, usually K16 (molecular weight 2052.43), was used to 
condense the plasmid DNA at a ratio of 2:1 respectively. The anionic DNA is added to the 
cationic  peptide  solutions  in  equal  volume  through  addition  of  water,  this  is  then  left  to 
equilibrate (20 min, 25 °C). The P:D solution is then added to the liposome dispersion and 
left to equilibrate (30 min, 25 °C) typically at a ratio of 16:1 L:D. 
L:P:D:Ns were formulated by adding the corresponding amount (according to weight ratios) 
of  MNPs  to  the  lipid  dispersion  and  left  overnight  to  incubate  (4  °C).  After  incubation 
overnight, the samples were warmed to room temperature and the appropriate amount of 
DNA/K16 was added to the dispersion and left to equilibrate (30-45 min). Table 8 shows the 
typical  quantities  used  to  prepare  L:N,  L:P:D  and  L:P:D:N  samples  for  a  transfection 
experiment. In this case the lipid used is DOTMA/DOPE, the peptide is K16, the DNA is 
pTagRFP-N1-hNIS-TagRFP and the MNP is FluidmagCMX. 
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Formulation  Component  Amount (µg)  Amount (µl) 
L:N  
L  40  56.58 
N  4  4.00 
L:P:D 
L  40  56.58 
P  5  2.42 (in 2.58 µl dH2O) 
D  2.5  1.31 (in 3.69 µl dH2O) 
L:P:D:N 
L  40  56.58 
P  5  2.42 (in 2.58 µl dH2O) 
D  2.5  1.31 (in 3.69 µl dH2O) 
N  4  4 
Table 8: A Table Showing the Formulation Amounts for the L:N, L:P:D and L:P:D:N Formulations 
 
2.3.7 Preparation of Magnetolipopolyplexes (L:P:D:Ns) for Cell Uptake Experiments 
Typically  500,000  cells  were  seeded  per  experiment  (see  Section  2.6)  with  the  aim  of 
delivering 100 pg of iron oxide per cell, giving a total iron oxide amount of 50 µg. Table 9 
shows the formulation amounts for a cell uptake sample (L:P:D:N). For formulation protocol 
see Section 2.3.6. 
Component  Amount (µg)  Amount (µl) 
Lipid (L)/ DOTMA/DOPE  500.00  707.21 
Peptide (P)/ K16  62.50  30.21 (in 19.79 µl dH2O) 
DNA (D)/ pTagRFP-N1-hNIS-
TagRFP 
32.25  25.41 (in 24.59 µl dH2O) 
MNP (N)/ FluidmagCT  50.00  50 
Table 9: Formulation Amounts for the Cell Uptake Experiments 
 
2.4 In Vitro Cell Work 
2.4.1 Materials 
Dulbecco’s  modified  eagle  medium  (DMEM),  RPMI-1640,  Opti-MEM,  fetal  bovine  serum 
(FBS), Lipofectamine-2000 transfection agent and phosphate buffered saline (PBS) were all 
purchased from Life Technologies, UK. Fugene-6 and Fugene HD transfection agents were   82 
purchased  from  Roche  Applied  Science,  UK.  Dimethyl  sulfoxide  (DMSO,  99.9%)  was 
purchased from Sigma Aldrich, Germany.  
HCC1954,  MCF-7,  MDA-MB-231  and  264.7  (Parental)  cells  were  gifted  by  the  Randall 
Division of Cell and Molecular Biophysics, Kings College London.  
Cell lines were grown in vitro (37 °C, 5% CO2) in appropriate flasks (T25, T75, T175) to 
ensure sufficient quantities of cells were available for in vitro transfection and cell pelleting 
studies. Appropriate growth media was used to maintain cells; DMEM and RPMI-1640 with 
the addition of FBS (10%), L-glutamine (L-glu) and Penicillin/Streptomycin (Pen/Strep).  
 A variety of cell lines were used and they can be seen in Table 10. 
Cell Line  Cancer Type/Medium Used 
MDA-MB-231  Breast/DMEM 
MCF-7  Breast/DMEM 
HCC1954  Breast/RPMI 
264.7 (Parental)  Macrophage/DMEM 
Table 10: A Table Showing the Different Cancer Cell Lines Used in Transfection Experiments 
 
2.4.2 Cell Maintenance 
In  order  to  ensure  the  healthy  growth  of  cells,  cells  were  split  upon  reaching  70-80% 
confluency. Cells were passaged by removing the medium and cells were washed twice with 
PBS. Trypsin (sterile filtered, 1 ml T25 flask, 3 ml T75, 7 ml T175) was added and the cells 
were incubated (37 °C, 5% CO2, 5 min). After incubation the cells were removed with the 
addition of growth medium to stop the trypsin acting on the cells (3 ml T25, 9 ml T75, 21 ml T 
175) and the mixture was centrifuged to form a cell pellet (1.2 rpm, 4 min). The supernatant 
was removed and the cell pellet re-suspended in an appropriate amount of media for either 
splitting or for cell counting by haemocytometer or by an automated cell counter.  
In the case of the macrophage cell line (264.7) the cells were harvested using a cell scraper 
to remove the adherent cells from the bottom of the cell flask rather than trypsin.    83 
2.4.3 Freezing Cell Stocks 
The  cells  were  harvested  and  counted  and  pelleted  as  in  2.4.2.  The  supernatant  was 
removed and the cell pellet re-suspended in freezing medium (7ml, RPMI + 20% FBS, 10% 
DMSO, l-Glu and Pen/Strep) at a concentration of 1x10
6 cells/ml. Aliquots of the solution (1 
ml) were transferred to cryo-tubes and these were placed in a Nalgene freezing container 
and placed in a -80 °C freezer overnight. The following day the tubes were removed and 
subsequently stored in liquid nitrogen.  
2.4.4 Preparing Cells from Frozen 
In order to prepare cells from frozen, the cells were removed from liquid nitrogen storage 
and flash thawed in a waterbath (37 °C). The cell culture medium was removed and added 
to a falcon tube (15 ml), the cryo-tube was then washed with medium (1 ml) and added to 
the  falcon  tube  and  the  solution  was  centrifuged  (1  rpm,  5  min).  The  supernatant  was 
removed, the pellet re-suspended in freezing medium (4 ml) and added to a T25 flask. The 
cells were checked for adherence at approximately 6 hours and the medium changed to 
ensure that there was no remaining DMSO in the medium. 
 
2.5 In Vitro Transfection Studies  
2.5.1 Transfection protocol 
Cells were seeded into a 96 well plate at 10,000 cells per well and incubated overnight at 
37 °C in suitable growth medium, Table 11. The following day the liposome formulations 
(Table 11) were made so that 250 ng DNA was seeded per well alongside Lipofectamine 
and Fugene controls and the plate was incubated (37 °C, 4 h). After the incubation period 
medium containing 20% FBS was added to the wells at the same volume as the transfection 
mixture and the plate was then further incubated (37 °C, 42 h). The plate was then removed 
and the cells were fixed using 4% PFA by the method detailed in Section 2.5.5. After fixing 
the  cells  were  imaged  using  a  fluorescent  microscope  built  in-house  at  Kings  College 
London. The plate was imaged first in the Cy3 channel of the microscope to detect the RFP 
emission of the plasmid and then in the DAPI channel to image the Hoescht stained nuclei of 
the cells to provide information on cell viability.    84 
Table  11  shows  the  amounts  used  to  transfect  each  condition  in  a  typical  transfection 
experiment  and  Table  12  illustrates  the  schematic  layout  of  the  96-well  plate.  In  this 
particular example there is one control; Fugene and three different lipid formulations with 
and without nanoparticles. Due to limitations with the microscope used to analyse the plate, 
it is not possible to image the outer ring of wells and therefore the central 60 wells are used 
for transfections. 
Condition  Formulation  Amount Added to Each Well 
Fugene  See Section 2.5.2 for protocol  96µl of solution 
D/D (LPD)  Lipid: 56.58µl (40µg) 
Peptide: 2.42µl in 2.58µl dH2O (5µg) 
DNA: 1.31µl in 3.69µl dH2O (2.5µg) 
TOTAL: 66.58µl 
6.66µl LPD dispersion and 93.34µl 
Opti-MEM 
D/D (LPDN)  Lipid: 56.58µl (40µg) 
Peptide: 2.42µl in 2.58µl dH2O (5µg) 
DNA: 1.31µl in 3.69µl dH2O (2.5µg) 
NP: 4µl (4µg) 
TOTAL: 70.58µl 
7.06µl LPD dispersion and 92.94µl 
Opti-MEM 
DT/D (LPD)  Lipid: 55.48µl (40µg) 
Peptide: 2.42µl in 2.58µl dH2O (5µg) 
DNA: 1.31µl in 3.69µl dH2O (2.5µg) 
TOTAL: 65.48µl 
6.55µl LPD dispersion and 93.45µl 
Opti-MEM 
DT/D (LPDN)  Lipid: 54.48µl (40µg) 
Peptide: 2.42µl in 2.58µl dH2O (5µg) 
DNA: 1.31µl in 3.69µl dH2O (2.5µg) 
NP: 4µl (4µg) 
TOTAL: 69.48µl 
6.95µl LPD solution and 93.05µl 
Opti-MEM 
C/D (LPD)  Lipid: 49.38µl (40µg) 
Peptide: 2.42µl in 2.58µl dH2O (5µg) 
DNA: 1.31µl in 3.69µl dH2O (2.5µg) 
TOTAL: 59.38µl 
5.94µl LPD solution and 94.06µl 
Opti-MEM 
C/D (LPDN)  Lipid: 49.38µl (40µg) 
Peptide: 2.42µl in 2.58µl dH2O (5µg) 
DNA: 1.31µl in 3.69µl dH2O (2.5µg) 
NP: 4µl (4µg) 
TOTAL: 63.38µl 
6.34µl LPD dispersion and 93.66µl 
Opti-MEM   85 
Un-transfected Cells  n/a  100µl Opti-MEM 
Table 11: A Table Illustrating Typical Transfection Amounts 
 
 
Wells  2  3  4  5  6  7  8  9  10  11 
B  Fugene  D/D 
L:P:D 
D/D 
L:P:D:N 
C/D 
L:P:D 
C/D 
L:P:D:N 
DT/D 
L:P:D 
DT/D 
L:P:D:N 
Untransfected 
Cells 
Empty  Empty 
C  Fugene  D/D 
L:P:D 
D/D 
L:P:D:N 
C/D 
L:P:D 
C/D 
L:P:D:N 
DT/D 
L:P:D 
DT/D 
L:P:D:N 
Untransfected 
Cells 
Empty  Empty 
D  Fugene  D/D 
L:P:D 
D/D 
L:P:D:N 
C/D 
L:P:D 
C/D 
L:P:D:N 
DT/D 
L:P:D 
DT/D 
L:P:D:N 
Untransfected 
Cells 
Empty  Empty 
E  Fugene  D/D 
L:P:D 
D/D 
L:P:D:N 
C/D 
L:P:D 
C/D 
L:P:D:N 
DT/D 
L:P:D 
DT/D 
L:P:D:N 
Untransfected 
Cells 
Empty  Empty 
F  Fugene  D/D 
L:P:D 
D/D 
L:P:D:N 
C/D 
L:P:D 
C/D 
L:P:D:N 
DT/D 
L:P:D 
DT/D 
L:P:D:N 
Untransfected 
Cells 
Empty  Empty 
G  Fugene  D/D 
L:P:D 
D/D 
L:P:D:N 
C/D 
L:P:D 
C/D 
L:P:D:N 
DT/D 
L:P:D 
DT/D 
L:P:D:N 
Untransfected 
Cells 
Empty  Empty 
Table 12: Schematic Represention of a Typical 96-Well Plate Transfection Plan 
 
2.5.2 Transfection Controls 
Protocol as per manufacturer’s guidelines, adapted to seed 250 ng of DNA per well.  
Fugene 6  
In a particular experiment (in order to make a sufficient amount for 8 transfections), Fugene-
6 (4 µl) was added to Opti-MEM (without serum, 100 µl), this was then spun down (15 s) and 
then left to stand (5 min). Plasmid DNA (2 µg, 1.04 µl hNIS-RFP, 1.08 µl pTAG-RFP) was 
then added to the solution and this was spun down again (15 s) and left to stand (30 min). 
Opti-MEM (with serum, 666 µl) was then added and this was then added to the appropriate 
wells (96 µl).
8 
Fugene HD 
In a particular experiment (in order to make a sufficient amount for 8 transfections), pDNA (2 
µg, 1.04 µl hNIS-RFP, 1.08 µl pTAG-RFP) was added to Opti-MEM (84 µl) and incubated at 
room temperature (10-15 min). Fugene HD (6.32 µl) was subsequently added, the sample   86 
was thoroughly mixed by aspiration with a pipette and incubated at room temperature (30-45 
min). Following incubation the mixture was added to the wells (11.43 µl per well) alongside 
DMEM media containing serum (139.97 µl).
9 
Lipofectamine 2000 Control 
In a particular experiment (in order to make a sufficient amount for 8 transfections), pDNA (2 
µg, 1.04 µl hNIS-RFP, 1.08 µl pTAG-RFP) was added to Opti-MEM (without serum, 25.92 µl) 
and Lipofectamine (18.4 µl) was added to Opti-MEM (without serum, 33.12 µl). The two were 
combined, spun down (15 s) and then left to stand (15-45 min). The mixture was further 
diluted with Opti-MEM (without serum, 220.8 µl) and then 37 µl was added to each well 
alongside Opti-MEM (without serum, 37 µl).
10 
2.5.3 Cell fixing protocol 
Preparation of Paraformaldehyde 
Paraformaldeyde (PFA, 4 g) was added to PBS (100 ml) and thoroughly mixed. The mixture 
was then subsequently heated with moderate stirring until the solution turned from opaque to 
clear and all the paraformaldehyde was thoroughly dissolved (~3 h). Upon completion the 
solution was allowed to cool and stored at 4 °C. 
Cell Fixing Protocol 
The medium was removed from the plate and paraformaldehyde (PFA, 4%) was added to 
each well (100 µl) and left to incubate (25 °C, 15 min). The PFA solution was then removed 
and  replaced  with  the  DNA  stain  Hoechst  33342  (1  in  2500  dilution  (PBS),  100  µl)  and 
further incubated (25 °C, 10 min). The wells were then washed with PBS (200 µl, 5 min) and 
PBS added (100 µl) in order to store the plate. 
Hoechst 33342 is a DNA nuclear stain and by incubating the fixed cells with this stain it is 
possible to image the fixed viable cells to determine the amount of live cells at time of fixing, 
and thus by comparing with the amount of RFP transfection it is possible to determine the 
rate of transfection.    87 
 
2.6 Cell Uptake Experiments 
Performing uptake experiments by loading the cells with MNPs and L:P:D:Ns and then by 
subsequently measuring them using SQUID magnetometry it was possible to determine the 
average  amount  of  iron  oxide  per  cell.  The  amount  of  iron  oxide  per  cell  can  provide 
information  on  how  well  the  cells  take  up  the  MNPs  and  the  L:P:D:Ns  and  also  their 
suitability as MRI contrast agents by reaching a suitable amount of iron oxide per cell. The 
literature states that the limit of detection for T2
* measurements is 5 pg of iron oxide per cell 
for a 3 T magnet (120 x 10
3  cells/ml (2.4µg Fe/ml) in the brain and 385 x 10
3 cells/ml (8 µg 
Fe/ml) in the liver).
7 
2.6.1 Cell Uptake Protocol 
Cells were seeded into a 6 well plate at 500,000 cells per well and incubated overnight at 
37 °C in suitable growth medium (see Table 10). The appropriate transfection formulation 
was added to the cells and the final volume made up to 2 ml with Opti-MEM. The cells were 
incubated (37 °C, 24 h). After incubation the cells were washed with PBS (1 ml) to remove 
any  dead  cells  and  trypsin  (0.5  ml)  was  added  to  the  remaining  cells  where  they  were 
incubated (5 min, 37 °C). After incubation medium (1ml) was added and the solution was 
centrifuged (1.2 rpm, 5 min) to yield a cell pellet. This was re-suspended with PFA (4%, 1 ml, 
15 min) and centrifuged (1.2 rpm, 5 min). The supernatant was removed and the cell pellet 
was re-suspended with PBS (1 ml, 5min) and spun down (1.2 rpm, 5 min). The supernatant 
was  removed  and  the  cell  pellet  was  re-suspended  with  PBS  (1  ml)  and  the  cells  were 
counted  using  a  haemocytometer.  The  solutions  were  stored  at  4  °C  until  magnetic 
measurements taken. 
 
2.7 Instrumentation and Analysis Techniques 
2.7.1 X-Ray Powder Diffraction (XRD) 
Samples of MNPs were prepared for XRD analysis (XRD instrument: Panalytical X’Pert Pro) 
by first lyophilising the sample and mounting it on a silicon wafer sample holder. The sample 
was run between 20° and 100° as the significant peaks to identify the magnetite phase of   88 
iron oxide are found in this range. After running the sample it was compared to a magnetite 
reference spectrum in order to identify relevant peaks. 
2.7.2 Fourier Transform Infrared Spectroscopy (FTIR) 
Samples  were  first  lyophilised  and  measured  on  a  Perkin  Elmer  Spectrum  100  FT-IR 
Spectrometer, fitted with a Gd crystal, between wavelengths of 650 cm
-1 and 4000 cm
-1. 
2.7.3 Dynamic Light Scattering (DLS)  
Samples of MNPs were prepared by taking 5 µl of a 1 mgml
-1 sample and diluting it into 1ml 
of dH2O and added 500 µl to a standard cuvette. Samples containing lipid components were 
prepared by taking between 20-50 µl of a 1 mM sample and diluting it further in 1 ml of dH2O, 
this dispersion was then added to a capillary cell cuvette (DTS1070, Malvern Instruments, 
UK). The samples were run using the Malvern Zetasizer Nano (Malvern Instruments, UK) 
with an SOP designed for the particular sample type, the parameters can be seen in Table 
13. 
Sample  Material/ 
Dispersant 
Material Settings  Dispersant 
Settings 
Measurement 
Settings 
Iron oxide MNPs  Magnetite/ Water  Refractive Index: 
1.500 
Absorption: 0.50 
Temperature: 
25.0 °C 
Refractive Index: 
1.330 
Viscosity: 0.8872 cP 
Detection angle: 
173° 
Automatic no. of 
runs 
3 x measurements 
per sample 
Lipid containing 
samples 
Protein/ Water  Refractive Index: 
1.450 
Absorption: 0.00 
Temperature: 
25.0 °C 
Refractive Index: 
1.330 
Viscosity: 0.8872 cP 
Detection angle: 
173° 
Automatic no. of 
runs 
3 x measurements 
per sample 
Table 13: The SOP Parameters used for DLS Measurements 
 
2.7.4 Zetapotential (ZP) 
ZP samples were prepared by taking between 20-50 µl of a 1mM sample and diluting it 
further in 1 ml of dH2O, this solution was then added to a capillary cell cuvette (DTS1070,   89 
Malvern  Instruments,  UK).  The  samples  were  run  using  the  Malvern  Zetasizer  Nano 
(Malvern  Instruments,  UK)  with  an  SOP  designed  for  the  particular  sample  type,  the 
parameters can be seen in Table 14. 
Sample  Material Type/ 
Dispersant 
Material 
Settings 
Dispersant 
Settings 
Measurement 
Model Used 
Measurement 
Settings 
Iron oxide 
MNPs 
Magnetite/ 
Water 
Refractive 
Index: 1.500 
Absorption: 0.50 
Temperature: 
25.0 °C 
Refractive 
Index: 1.330 
Viscosity: 
0.8872  cP 
Dielectric 
Constant: 78.5 
Smoluchowski  Automatic no. of 
runs 
3 x 
measurements 
per sample 
Lipid containing 
samples 
Protein/ Water  Refractive 
Index: 1.450 
Absorption: 0.00 
Temperature: 
25.0 °C 
Refractive 
Index: 1.330 
Viscosity: 
0.8872 cP 
Dielectric 
Constant: 78.5 
Smoluchowski  Automatic no. of 
runs 
3 x 
measurements 
per sample 
Table 14: The SOP Parameters used for ZP Measurements 
 
2.7.5  Preparing  Samples  for  Inductively  Coupled  Plasma  –  Atomic  Emission 
Spectroscopy (ICP-AES) 
 
The concentration of MNP in solution of PLL@MNP (in mgml
-1) was determined using ICP-
AES, using a service provided Stanislav Strekopytov at the Natural History Museum, London. 
Samples  of  PLL@MNP  were  made  up  to  an  expected  final  concentration  of  10  mgl
-1 
(assuming stock solution concentration of 1 mgml
-1) with 2% acidity using HCl.  
A typical sampled was prepared as follows, PLL@MNP stock solution (200 µl) was added to 
a falcon tube (15 ml), ultrapure HCl (200 µl) was then added and the solution was left to 
digest (30 min), whereby the solution turned yellow in colour. This was then made up to 10   90 
ml with distilled water. A blank was also prepared in the same method without the addition of 
PLL@MNP. 
2.7.6 Transmission Electron Microscopy (TEM) 
2.7.6.1 TEM of MNPs and PLL@MNP  
Samples (1 µl) were added to the surface of a 200 mesh copper grid coated with holey 
carbon (Agar Scientific, UK). The samples were gently air dried to ensure all water had 
evaporated  and  imaged  using  a  Jeol  1010  Electron  Microscope  (Jeol,  Japan)  with  an 
acceleration voltage of 100 kV. 
2.7.6.2 TEM imaging of D:P@N and L:D:P@Ns 
The samples were stained using ‘on-grid’ negative staining where each sample (1 µl) was 
added to the surface of a Formvar-coated copper TEM grid and then stained with uranyl 
acetate (1 µl, 2%, 30 min). The uranyl acetate had previously been filtered using a Millipore 
filter capped syringe (2 µm cut off) and stored at 4 °C. The stained grids were then rinsed 3 
times with ddH2O and then gently dried over a small heater (2 min). The grids were then 
imaged using a Jeol 1010 Electron Microscope (Jeol, Japan) with an acceleration voltage of 
100 kV. 
2.7.7 Superconducting Quantum Interference Device (SQUID) Magnetometry 
2.7.7.1 Preparing Iron Oxide Nanoparticle Samples for SQUID analysis 
MNP samples were lyophilised and added to the appropriate polypropylene powder sample 
holder, which was then mounted into a brass trough sample rod. The mounted sample was 
then measured using a program called M(H) ultrafast 3 points, which works by measuring 3 
points at every field at 5 second time intervals at a 6mm oscillation height for 21 field points 
between  50,000  Oe  and  -50,000  Oe.  These  measurements  were  performed  using  a 
Quantum Design MPMS SQUID VSM. 
2.7.7.2 Preparing cell pellet samples for SQUID Analysis  
The fixed cells from the pelleting experiment were re-centrifuged (1.2rpm, 15 min) to yield a 
cell pellet. The supernatant was removed until a small amount remained (~20 µl) and the cell 
pellet  was  re-suspended  to  this  amount.  The  cell  suspension  was  then  added  to  a 
polycarbonate capsule (LOT, Germany) and allowed to dry (4 h, 37 °C). When the sample   91 
was completely dry the sample holders were mounted in straws ready for analysis. The 
mounted sample was then measured using a program called M(H) ultrafast 3 points, which 
works by measuring 3 points at every field at 5 second time intervals at a 6 mm oscillation 
height for 21 field points between 50,000 Oe and -50,000 Oe. These measurements were 
performed using a Quantum Design MPMS SQUID VSM. 
2.7.8 Imaging of Transfected Cells 
In order to image the transfection efficiency of the plasmid in its various formulations an in-
house microscope at Kings College, London was used. This is a fluorescent microscope that 
allows a 96-well plate to be imaged in the Cy3 channel (for RFP expression), FITC (for 
imaging the Fluorescein lipid and DAPI channel (for UV expression of the Hoescht 33342 
nuclear stain). In order to measure both the RFP expressing pDNA, the FITC expressing 
fluorescein  lipid  and  the  Hoescht  33342  stained  nuclei  different  fluorescence  filters  were 
used and these can be seen in Table 15. 
Cube  Properties 
Cy3 
Excitation minimum: 510 nm 
Excitation maximum: 560 nm 
Dichroic: 565 nm 
Emission minimum: 573 nm 
Emission maximum: 548 nm 
FITC 
Excitation minimum: 465 nm 
Excitation maximum: 495 nm 
Dichroic: 505 nm 
Emission minimum: 515 nm 
Emission maximum: 555 nm 
DAPI 
Excitation minimum: 355 nm 
Excitation maximum: 375 nm 
Dichroic: 410 nm 
Emission minimum: 410 nm 
Emission maximum: 510 nm 
Table 15: The Properties of the Fluorescent Cubes 
 
The microscope was set up to image an area of interest in the 96 well plate and the Cy3 
channel was imaged first in order to prevent quenching of the red fluorescence by the DAPI   92 
channel. Table 16 shows the microscope settings used to image the plate. Upon completion 
the images of the plates were then analysed using a software package called Image J where 
by  the  RFP  expression  per  well  was  measured  against  the  UV  expression  per  well 
(expressing cells vs. viable cells) thus giving information on transfection efficiency.
11 Cell 
viability could also be measured by the UV expression of a transfected well against the UV 
expression of un-transfected cells thus giving information on potential toxicity of the sample. 
The measurements obtained from the RFP expression and cell viability measurements are 
ratios of one expression to another and therefore produce arbitrary numbers as a means of 
comparison  between  conditions.  Statistical  analysis  of  two  data  sets  was  carried  out  by 
performing a paired, two-tailed t-test using Microsoft Excel. P values were calculated from 
the t-test results using an online statistical p value calculator, whereby the critical p value 
was  p<0.05.  When  comparing  multiple  data  sets  a  single  factor ANOVA  (Analysis  of 
Variance) was carried out using Microsoft Excel with the 'Analysis Toolpak Add-In'. Post 
tests  were  carried  out  by  performing  a  two  tailed  T-Test  assuming  equal  variance  and 
following this a Bonferroni correction was undertaken to remove any error associated with 
comparing multiple data sets. 
Cell Line  Cy3 Channel Settings  DAPI Channel Settings 
HCC1954 
MDA-MB-231 
SW1222 
MCF-7 
Gain: Full 
Exposure: 5.00 
Binning: 8 
Lamp Power: 10% 
Gain: Minimum 
Exposure: 5.00 
Binning: 8 
Lamp Power: 10% 
264.7 Parental  Gain: Full 
Exposure: 5.00 
Binning: 8 
Lamp Power: 100% 
Gain: Minimum 
Exposure: 5.00 
Binning: 8 
Lamp Power: 10% 
Table 16: Table Showing the Microscope Settings Used to Image the Different Cancer Cell Lines 
 
2.7.9 Transfection Efficiency Quantification 
In order to obtain quantitative transfection efficiencies it is necessary to set up a time-lapse 
experiment after imaging the 96 well plates, which allows the selection of various points of 
interest (i.e. where good RFP expression occurs) in the 96 well plate. It is then possible to 
image first in the Cy3 channel and then in the DAPI channel. By selecting points of interest   93 
images of individual cells in both channels are obtained, these images can then analysed 
using a cell counter tool in the Image J software. By counting the number of RFP expressing 
cells and comparing this to the number of UV expressing cells in the same area it is possible 
to work out a percentage transfection efficiency. Figures 26 and 27 show individual images 
taken  in  both  channels  with  the  cell  counts  shown  and  Table  17  shows  the  percentage 
transfection of the two images.  
 
Figure 26: A Time Lapse Experiment Image Showing the RFP Expression in Transfected HCC1954 Cells 
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Figure 27: A Time Lapse Experiment Image Showing UV Expression in Hoechst Stained HCC1954 Cells 
 
Expression  Cell Count  Percentage 
RFP  10  34.48% 
((10/129)*100)  UV  129 
Table 17: Table Showing Example Percentage Transfection Efficiency Calculations 
   95 
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3.0  The  Bio-conjugation  of  Peptides  to  Commercially 
Available  Nanoparticles,  their  Formulation  into 
Magnetolipopolyplexes and their use In Vitro 
 
3.1 Introduction 
In this chapter the bioconjugation of poly(L)lysine (PLL) to commercially available iron oxide 
MNPs, their subsequent functionalisation with plasmid DNA (pDNA) and encapsulation into 
liposomes will be discussed. At each stage of the MNP functionalisation and characterisation 
data was obtained in order to understand their structure and properties. In vitro transfection 
studies were carried out to determine the efficiency of the complexes by imaging the RFP 
encoded for by the pDNA.  
Two types of commercially available iron oxide MNPs were obtained; carboxymethyldextran 
(CDEX@MNP) and dextran coated MNPs (DEX@MNP) from two suppliers; Chemicell and 
Micromod. Three molecular weights of PLL were used; 1-5 KDa, 30-70 KDa and 150-300 
KDa to establish which would provide the best condensation of the plasmid DNA (pDNA) 
onto the surface of the MNP.  
Two  methods  of  bioconjugation  were  then  used  to  coat  the  MNPs  with  PLL;  reductive 
amination (DEX@MNP) and amide bond formation via EDC coupling (CDEX@MNP). The 
rationale behind conjugating PLL to the surface of the MNP was that the PLL coating would 
render the complex with a positive surface charge. This positive surface charge can then be 
utilised to electrostatically bind the negatively charged pDNA, leaving an overall negative 
surface  charge,  which  can  then  be  encapsulated  into  the  cationic  liposomes  forming  a 
magnetolipopolyplex. 
A  variety  of  characterisation  techniques  were  used  to  elucidate  the  size,  structure  and 
surface charge of the formulated compound including DLS, ZP, FTIR and TEM. Gel loading 
experiments  were  carried  out  in  order  to  determine  the  loading  capability  of  the  PLL   97 
functionalised nanoparticles. After characterisation the pDNA condensed MNPs (D:P@Ns) 
and magnetolipopolyplexes (L:D:P@Ns) were used to transfect various cell lines. 
The exact structure of the final complex is not known and Figure 28 shows the proposed 
final magnetolipopolyplex and the route to its formulation. The abbreviations for the various 
formulated structures can be seen in Table 18. 
Formulation  Abbreviation 
Nanoparticle  MNP or N 
PLL + Nanoparticle  P@N 
pDNA + PLL + Nanoparticle  D:P@N 
Lipid + pDNA + PLL + Nanoparticle  L:D:P@N 
Table 18: Key to Abbreviations Used in Chapter 3 
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Figure 28: A Figure Showing the Proposed Structure of the Magnetolipopolyplex (L:D:P@N)   99 
3.2 The Bio-conjugation of Poly(L)lysine to Commercially Available 
Nanoparticles 
3.2.1 Characterisation Data for Commercially Available Magnetic Nanoparticles  
Commercially available MNPs with dextran or carboxymethyl dextran were purchased from 
two  companies,  Chemicell  and  Micromod  and  their  properties  can  be  seen  in  Table  19. 
Figures  29-30  show  the  two  different  types  of  coating  with  the  point  where  conjugation 
occurs highlighted in red.  
MNP Name  Coating  Size  Core Component 
FluidmagCMX (Chemicell) 
1  Carboxymethyldextran  50 nm (HD)  Magnetite 
FluidmagD (Chemicell) 
2  Dextran  50 nm (HD)  Magnetite 
NanomagD-spio (plain) (Micromod) 
3  Dextran  20 nm (core)  Iron oxide (unspecified) 
NanomagD-spio (COOH) (Micromod) 
4  Carboxymethyldextran  20 nm (core)  Iron oxide (unspecified) 
Table 19: Commercially Available Nanoparticles Used and their Properties 
 
 
Figure 29: The Structure of a Carboxymethyldextran Coated MNP
1  
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Figure 30: The Structure of a Dextran Coated Iron Oxide MNP
2 
 
3.2.2 Bio-conjugation Reactions of Poly(L)lysine to Commercially Available 
Nanoparticles 
Both dextran and carboxydextran coated MNPs from Chemicell and Micromod were used to 
bioconjugate three different molecular weights of PLL (1,00-5,000kDa, 30,000-70,000kDa 
and 150,000-300,000kDa) via two different methods. The four different samples used in the 
bioconjugation experiments can be seen in Table 20. After functionalisation with PLL, the 
samples  were  fully  characterised  using  FTIR,  DLS,  ZP,  TEM,  SQUID  and  ICP-AES  to 
ensure successful coating had taken place. 
Commercial MNP Name  Sample Abbreviation  Bioconjugation Method Used 
Chemicell Fluidmag D  (cc)DEX@MNP  Reductive Ammination 
Chemicell Fluidmag CMX  (cc)CDEX@MNP  Amide Bond Formation 
Micromod D-SPIO-plain  (mm)DEX@MNP  Reductive Amination 
Micromod D-SPIO- COOH  (mm)CDEX@MNP  Amide Bond Formation 
Table 20: Sample List from Bioconjugation Experiments 
PLL has been shown to successfully condense pDNA owing to the interaction of positive 
charges on the PLL and negative charges on the pDNA and is typically used over other 
positive surface coatings owing to it being biodegradable.
5 Its biocompatibility is also very 
beneficial  over  other  surface  coatings  such  as  polyethylenimine  (PEI),  which  has  been 
shown  to  be  notably  cytotoxic.
6  The  structure  of  PLL  can  be  seen  in  Figure  31  and  its 
positive charge arises from the primary amine existing in the positively charged NH3
+ state at 
physiological pH.
7   101 
 
Figure 31: The Structure of PLL 
 
3.2.3 Functionalising Dextran Coated Nanoparticles with PLL via Reductive Amination 
In this reaction sodium periodate (NaIO4) is used to cleave vicinal diols to form an aldehyde 
or a ketone whereby it is possible to use reductive amination to conjugate an amine to the 
formed aldehyde or ketone group, giving a Schiff base. In order to selectively conjugate the 
terminal nitrogen to the aldehyde or ketone functional groups, protecting groups can be used. 
This Schiff base can then be further reduced with sodium cyanoborohydride (NaBH3CN) to 
form an alkylamine bond, which is extremely stable.
8 
In this case the vicinal diols on the dextran surface coating of the MNP (illustrated in red in 
Figure 32) are cleaved to form an aldehyde, which is then reduced with NaBH3CN to form a 
link between the dextran coating and the PLL. This method was carried out with both brands 
of  commercially  available  MNPs  and  all  molecular  weight  (MW)  ranges  of  PLL,  the 
mechanism can be seen in Figure 32.  
 
Figure 32: Mechanism for the Bioconjugation of PLL to Dextran Coated MNPs 
O
O
O
OH
OH
OH
+ I
O
O -O
O
Na+
O
O O
HO
O
O
RI H
H2N RII +
O-
RI
H
N
H
RII
[H+]
RI
H
N
H
RII
OH2
+
NaCNBH3
RI N
H+
RII
H- + RI N
H
RII  102 
 
Figure 33 shows the final structure of the PLL functionalised MNP, where R’’ denotes the 
PLL chain. 
 
Figure 33: The Structure of PLL Functionalised Dextran Coated MNP 
 
The  outcome  of  this  experiment,  in  all  weights  of  PLL  and  both  MNP  types,  yielded  an 
opaque dark brown solution (characteristic of magnetite), which showed no visible evidence 
of aggregates.
9 This indicated that the conjugation experiment had been successful and thus 
further  characterisation  experiments  could  be  performed  to  confirm  this  and  obtain 
information on the properties of the functionalised MNP. 
3.2.4 Functionalisation of Carboxymethyldextran Coated Nanoparticles with PLL via 
Amide Bond Formation 
Carbodiimides  can  be  used  to  bioconjugate  an  amine  to  a  carboxylate  group  via  the 
formation  of  an  amide  bond.  In  this  case  1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDC was used to link the carboxymethyl dextran coating of the MNP to the PLL, which 
contains  an  –NH2  functional  group.
8  This  method  was  carried  out  with  both  brands  of 
commercially available MNPs and all molecular weight (MW) ranges of PLL, the mechanism 
can be seen in Figure 34. 
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Figure 34: Mechanism for the Bioconjugation of PLL to Carboxymethyldextran Coated MNPs 
 
Figure 35 shows the structure of the PLL functionalised FluidmagCMX MNPs where the PLL 
chain is indicated in red. 
 
Figure 35: The Structure of PLL Functionalised Carboxymethyldextran Coated MNP 
 
In  all  weights  of  PLL  and  both  MNP  types  a  dark  brown  precipitate  was  present,  which 
showed visible evidence of aggregates and could be identified as the MNPs. This indicated 
that the conjugation experiment had been unsuccessful. Attempts to lyophilise the solution 
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for FTIR analysis were also unsuccessful with a clear oily solution being obtained, which 
could be a result of cross-linking between MNPs or contamination present in the EDC. It was 
decided that no further experiments would be carried out with the CDEX@MNP samples. 
3.2.5 X-Ray Diffraction (XRD) 
XRD  analysis  was  carried  out  on  the  lyophilised  unmodified  MNPs  to  ensure  their 
composition was magnetite by elucidating the crystal structure of the sample. Figures 36 and 
37  show  the  diffractograms  for  both  the  Chemicell  and  Micromod  MNPs  alongside  the 
reference pattern characteristic of the crystal structure of magnetite. XRD reference patterns 
were obtained from the International Centre for Crystal Diffraction Data (ICCD Database) 
and the magnetite reference pattern (reference code: 01-075-1609) was used. Park et al. 
reported the use of XRD to elucidate the crystal structure of synthesised iron oxide MNPs to 
confirm their constitution as magnetite.
10 
Figure 36 shows that the Chemicell sample is predominantly magnetite with the majority of 
the peaks matching the reference diffractogram. It is, however, possible to note that there is 
the presence of another phase in the diffractogram (the peaks unmatched to the reference), 
this  could  be  attributed  to  a  contaminant  present  in  the  commercial  MNPs  themselves. 
Figure  37  also  shows  that  the  Micromod  MNPs  are  a  good  match  for  magnetite  when 
comparing the diffractogram obtained to the reference pattern. As in Figure 36 there is again 
the presence of another phase and this could be contamination in the sample. The broad 
peak between 20° and 30° also suggests the presence of an amorphous region in the MNPs. 
A variety of reference patterns were compared to the unmatched peaks in both Chemicell 
and Micromod MNPs to attempt to decipher a possible cause for the contamination but this 
proved unsuccessful even when comparing to other possible phases of iron oxide including 
haematite.    105 
 
Figure 36: XRD Diffractogram of Chemicell MNPs with a Magnetite Reference Pattern 
 
   
Figure 37: XRD Diffractogram of Micromod MNPs with a Magnetite Reference Pattern 
 
3.2.6 Fourier Transform Infrared Analysis (FTIR) 
FTIR  was  performed  on  the  conjugated  samples,  which  had  been  lyophilised,  to  ensure 
successful coating had taken place. It is expected that a characteristic peak in the region of 
1650 to 1590 cm
-1 would be present upon successful conjugation of PLL to the MNP surface, 
denoting the presence of a primary amine functional group. There is also an N-H stretch 
found between 3500 to 3300 cm
-1, which is typically masked by the O-H stretch found in the 
same region. The O-H stretch has been found to be more intense than that of the N-H group 
owing to its ability to form stronger hydrogen bonds.
11 Sun et al. reported the use of FTIR to 
confirm the conjugation of PEG and folic acid groups to the surface of iron oxide MNPs. 
They highlighted the presence of a peak at 1645 cm
-1,
 which is characteristic of a primary   106 
amine group and thus confirmed the successful conjugation of PEG-NH2 onto the surface of 
the  MNP.
12  Babič  et  al.  also  reported  a  characteristic  peak  around  1650cm
-1  when 
successfully functionalising iron oxide MNPs with PLL.
13 
The FTIR spectra for the DEX@MNP showed good evidence of PLL conjugation in the three 
MW of PLL for both the Chemicell and Micromod MNP types. A characteristic peak was 
seen around 1650 cm
-1 in the PLL conjugated MNPs confirming the presence of a primary 
amine functional group. This was further confirmed when comparing the results from the 
conjugated MNPs to the spectra of the ‘bare’ MNPs, which showed no peak present around 
1650 cm
-1. The full peak list for the Chemicell and Micromod MNPs can be seen in Table 21 
indicating the presence of the primary amine peak in the conjugated sample. There should 
not be any free PLL present in the FTIR samples owing to the rigorous dialysis washing step 
when bioconjugating the PLL to the surface of the MNPs.  
MNP Type  List of Peaks (cm
-1) 
Chemicell ‘Bare’  3338, 1366, 1151, 1079, 1028, 654 
Chemicell with 1-5 KDa PLL  3349, 1648, 1364, 1040 
Chemicell with 30-70 KDa PLL  3291, 2933, 1652, 1545, 1311, 1048, 654 
Chemicell with 150-300 KDa PLL  3291, 2933, 1651, 1545, 1310, 656 
Micromod ‘Bare’  3297, 1559, 1411, 1015, 655 
Micromod with 1-5 KDa PLL  3358, 2920, 1646, 1348, 1152, 1105, 916, 764 
Micromod with 30-70 KDa PLL  3330, 2927, 1649, 1545, 1340, 1152, 1106, 916, 654 
Micromod with 150-300 KDa PLL  3331, 1649, 1031, 645 
Table 21: Peak list for the FTIR spectra of (mm)DEX@PLL and (cc)DEX@PLL 
 
3.2.7 Dynamic Light Scattering and Zetapotential Analysis  
After  initial  analysis  with  FTIR  to  determine  if  the  coating  was  successful,  it  was  then 
necessary to investigate the hydrodynamic size and the size distribution of the MNPs using 
DLS. DLS is a popular technique for characterising the size and polydispersity of MNPs and 
Babič et al. reported its use when characterising PLL functionalised iron oxide nanoparticles, 
whereby they reported a hydrodynamic diameter of ~60 nm after functionalisation.
13 
Figure 38 shows the DLS size distribution graph for (mm)DEX@PLL with 1-5 KDa PLL. Here, 
it is evident that an extremely polydisperse sample is present judging from the shape of the   107 
size distribution and this in turn suggests that conjugation of this MW of PLL to the MNPs is 
not suitable.  
 
 
Figure 38: DLS size distribution of Micromod MNPs coated with 1-5KDa PLL 
 
Figure 39 shows the size distribution of the (mm)DEX@PLL with 150-300 KDa PLL and in 
this particular example it is possible to conclude that a uniform size distribution is present 
around 50 nm. 
 
 
Figure 39: DLS size distribution of Micromod MNPs coated with 150-300KDa PLL 
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Size Distribution by Intensity   108 
MNP and coating  Average size (nm)  Polydispersity Index (PDI) 
Unmodified Chemicell  26.0  0.333 
Chemicell with 1-5 KDa PLL  Not possible to get measurement  N/A 
Chemicell with 30-70 KDa PLL  32.4  0.178 
Chemicell with 150-300 KDa PLL  39.5  0.208 
Unmodified Micromod  44.0  0.172 
Micromod with 1-5 KDa PLL  Not possible to get measurement  N/A 
Micromod with 30-70 KDa PLL  49.0  0.279 
Micromod with 150-300 KDa PLL  52.4  0.245 
Table 22: DLS sizing data for the PLLFunctionalised Micromod and Chemicell MNPs (values taken as an average of 
three replicates) 
 
From looking at Table 22 it is possible to see that the unmodified MNPs have the smallest 
hydrodynamic diameter and as the MW of the PLL increases so too does the hydrodynamic 
diameter  of  the  MNPs.  The  modified  Chemicell  MNPs  were  smaller  in  size  than  the 
Micromod  MNPs  but  underwent  a  larger  increase  in  hydrodynamic  diameter  when 
bioconjugating the PLL. A size increase of 6.4 nm and 13.5 nm was seen for the Chemicell 
MNPs  when  conjugating  the  MNP  with  30-70  kDa  and  150-300  kDa  PLL  respectively 
compared to a size increase of 5 nm and 8.4 nm for the Micromod MNPs. It was not possible 
to obtain a suitable measurement for the 1-5 KDa PLL coated MNPs for both the Chemicell 
and Micromod MNPs, which could be attributed to the presence of free PLL in the solution 
interfering with the measurement or an inconsistency in the coating. This was not rectified by 
further washing of the sample via dialysis.  
After the DLS measurements the ZP was measured to determine the surface charge. By 
knowing the surface charge it is possible to elucidate not only the stability of the solution but 
if successful coating had taken place. Thielbeer et al. reported the use of ZP to determine 
the  success  of  a  reaction  when  modifying  the  surface’s  functionalisation  of  both 
nanoparticles and microparticles by measuring changes to surface charges.
14  
If the MNP is coated with PLL there should be a positive surface charge owing to the free 
amine groups present on the PLL and the unmodified DEX@MNP should have a negligible 
surface charge as dextran is neutrally charged. Table 23 shows the ZP measurements for   109 
the unmodified MNPs (no PLL) and the MNPs coated with the 3 different MWs of PLL for 
both Chemicell and Micromod MNPs.  
MNP  Surface Charge (mV)  Standard Deviation (mV) 
Chemicell (unmodified)  -1.02  12.7 
Chemicell + 1-5 kDa PLL  27.0  13.0 
Chemicell + 30-70 kDa PLL  64.5  16.0 
Chemicell + 150-300 kDa PLL  48.0  24.1 
Micromod (unmodified)  -1.05  12.2 
Micromod + 1-5 kDa PLL  12.8  12.3 
Micromod + 30-70 kDa PLL  22.0  7.3 
Micromod + 150-300 kDa PLL  24.6  8.5 
Table 23: Zetapotential Results for the PLL modified Dextran coated MNPs (values taken as an average of three 
replicates) 
 
Both the unmodified Chemicell and Micromod MNPs showed a negligible surface charge, 
which was expected, as DEX itself is uncharged. The MNPs modified with PLL all showed a 
positive surface charge, which was expected as the PLL is positively charged and confirms 
along with the FTIR results that the MNPs have been successfully coated. It is essential that 
they  be  positively  charged  so  that  the  pDNA  (which  is  negatively  charged)  can  be 
electrostatically bound to the surface of the modified MNPs. The low positive surface charge 
associated with the 1-5 kDa PLL in the Micromod (around 12 mV) suggest instability of the 
MNP@PLL and therefore could explain the inability to acquire DLS results for these samples, 
this  is  however  not  the  case  for  the  Chemicell  MNPs.  A  more  likely  explanation  is  the 
presence of free PLL, which has not been removed via the washing steps preventing the 
accurate measurement of the 1-5 kDa PLL functionalised MNPs.  
3.2.8 Transmission Electron Microscopy (TEM) 
TEM images were taken of the MNPs to examine their size and the possible presence of 
cross-linking in the PLL coated MNPs. Figures 40 to 47 show a selection of TEM images for 
both the unmodified and PLL modified MNPs.  
From examining the TEM images it is possible to see that the core size of the MNPs was 
around 10-20 nm for both the unmodified Chemicell and Micromod samples. The best TEM   110 
results were seen in the lower MW of 1-5 kDa in both MNP types. Increasing aggregation of 
the MNPs can be seen when increasing the MW of PLL. This could be a result of either 
cross-linking of the PLL chains, which would be more common in higher MW PLL or as a 
result  of  the  sample  preparation  for  TEM.  When  preparing  the  TEM  grids  the  sample  is 
completely dehydrated and this can lead to aggregation of the organic components in the 
sample. The DLS results confirm that there is no large-scale aggregation occurring in the 
larger MWs of PLL coated MNPs and therefore the ‘clumping’ seen in the TEM images can 
be attributed to the drying artefacts resulting from sample preparation.  
   
Figure 40: TEM Images Showing Unmodified Chemicell MNPs 
   
Figure 41:  TEM Images Showing Chemicell MNPs Functionalised with 1-5 KDa PLL 
   
Figure 42: TEM Images Showing Chemicell MNPs Functionalised with 30-70 KDa PLL   111 
   
Figure 43: TEM Images Showing Chemicell MNPs Functionalised with 150-300KDa PLL 
   
Figure 44: TEM Images Showing Unmodified Micromod MNPs 
   
Figure 45: TEM Images Showing Micromod MNPs Functionalised with 1-5 KDa PLL 
   
Figure 46: TEM Images Showing Micromod MNPs Functionalised with 30-70 KDa PLL   112 
   
Figure 47: TEM Images Showing Micromod MNPs Functionalised with 150-300 KDa PLL 
 
3.2.9 SQUID Magnetometry Data 
The magnetic properties of lyophilised samples were measured at 300 K using a super-
conducting quantum interference device (SQUID). The magnetisation (M) as a function of 
field (H) was measured, producing an M(H) curve, which gives information on the magnetic 
properties of the sample, an example of this can be seen in Figure 48. When the curve 
begins to plateau the sample is said to be saturated and it is the saturation magnetisation 
that gives the maximum value of magnetisation.
15 Thomas et al. reported the use of SQUID 
measurements to determine the magnetic properties of iron oxide MNPs functionalised with 
ligands containing carboxylic acid functional groups. The shape of the M(H) curve seen in 
Figure 48 is characteristic of a superparamagnetic material such as an iron oxide MNP.
16    113 
 
Figure 48: An Example of an M(H) Curve for Chemicell MNPs coated with 30,000-70,000 KDa PLL 
 
Table 24 shows the magnetisation values obtained from both the Chemicell and Micromod 
samples (DEX@MNP and P@N). 
Sample  Mass (g)  Average Saturation (emu)  emu/g 
Chemicell (unmodified)  0.002  0.0083  44.2 ± 11 
Chemicell with 1-5 KDa PLL  0.001  0.0194  38.8 ± 19 
Chemicell with 30-70 KDa PLL  0.001  0.0125  10.3 ± 5 
Chemicell with 150-300 KDa PLL  0.002  0.0188  9.4 ± 2 
Micromod (unmodified)  0.002  0.0170  8.5 ± 2 
Micromod with 1-5 KDa PLL  0.002  0.0114  7.6 ± 2 
Micromod with 30-70 KDa PLL  0.001  0.00782  7.8 ± 4 
Micromod with 150-300 KDa PLL  0.003  0.0133  4.8 ± 1 
Table 24: Magnetisation values for Unmodified and PLL Functionalised MNPs 
 
It is evident from the obtained results that the Chemicell MNPs exhibit a larger saturation 
magnetisation than that of the Micromod MNPs. The values for the unmodified MNPs are 
also lower than that of uncoated magnetite (around 80-100 emu/g), with the Micromod MNPs 
being substantially lower than the Chemicell ones, 8.50 emu/g and 44.14 emu/g respectively. 
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An M(H) Curve for Chemicell MNPs with 30-70 KDa PLL   114 
From the value of uncoated magnetite and the value obtained experimentally it is possible to 
conclude that around 50% of the Chemicell MNP by weight is the iron oxide core and as little 
as 10% of the Micromod MNP is the iron oxide core, these MNPs must therefore have a 
large amount of dextran coating present.  
From analysing the results obtained from the PLL modified samples it is possible to see that 
the larger lengths of PLL have a smaller magnetisation value and as a result have a larger 
presence of the PLL coating. For example, the emu/g of the Chemicell MNPs with 150-300 
KDa PLL is 9.40, 20% of the value of the unmodified Chemicell MNPs and from this is it is 
possible to conclude that around 80% of the sample is the PLL coating. The 1-5 KDa PLL 
has the largest magnetisation value in both the Chemicell and Micromod MNPs with the 
percentage  of  coating  being  approximately  10%  in  both  cases.  The  percentage  of  PLL 
coating present in the samples can be seen in Table 25. It is also possible to conclude that 
the Micromod samples have a smaller percentage of PLL coating than the Chemicell MNPs, 
which  is  not  what  you  would  expect  owing  to  the  reduced  emu/g  associated  with  the 
Micromod MNPs.  
Sample  Magnetisation Value  Percentage of PLL 
Coating 
Chemicell (unmodified)  44.2 ± 11  n/a 
Chemicell with 1-5 KDa PLL  38.8 ± 19  12.1 ± 6 
Chemicell with 30-70 KDa PLL  10.3 ± 5  76.8 ± 35 
Chemicell with 150-300 KDa PLL  9.4 ± 2  78.7 ± 20 
Micromod (unmodified)  8.5 ± 2  n/a 
Micromod with 1-5 KDa PLL  7.6 ± 2  10.6 ± 3 
Micromod with 30-70 KDa PLL  7.8 ± 4  8.0 ± 4 
Micromod with 150-300 KDa PLL  4.8 ± 1  44.1 ± 7 
Table 25: The Mass Percentage of PLL Coating Present on Commercial MNPs 
 
3.2.10 Inductively Coupled Plasma – Atomic Emission Spectroscopy (ICP-AES) 
ICP-AES was carried out to determine the exact concentration of iron oxide MNP in the 
P@N  samples.  It  was  necessary  to  determine  the  exact  concentration  of  iron  oxide  in 
solution to provide an accurate weight ratio of iron oxide to DNA when condensing the pDNA   115 
to the surface of the MNP. Briley-Saebo et al. reported the use of ICP-AES to determine the 
total iron concentration of iron oxide MNP samples to confirm the concentration prior to the 
in vivo administration of MNPs for MRI in rats.
17 
Twelve  different  samples  of  both  Chemicell  and  Micromod  MNPs  were  measured  with 
different  molecular  weights  of  PLL  and  different  ages  of  sample.  The  rationale  behind 
measuring the samples at different ages was to determine whether or not any degradation of 
the MNP occurred after a given time period, giving information on the stability of the sample. 
The approximate experimental concentration of iron oxide was calculated to be 1 mgml
-1 and 
the samples for ICP-AES analysis were prepared at an estimated concentration of 10 mgl
-1. 
Table 26 shows the results from the ICP-AES analysis. 
Weight of PLL (Da)  Fe Concentration of P@N 
Micromod Samples at 0 / 6 / 12 
months (mgml
-1) 
Fe Concentration of P@N 
Chemicell Samples at 0 / 6 / 12 
months (mgml
-1) 
30,000-70,000  2x10
-3 ± 5x10
-5 / 5x10
-3 ± 1x10
-4 /           
4x10
-3 ± 1 x10
-4 
7x10
-3 ± 2 x10
-4 / 9x10
-3 ± 2 x10
-4 /          
10x10
-3 ± 3 x10
-4 
150,000-300,000  2 x10
-3 ± 5 x10
-5 / 6x10
-3 ± 2x10
-4 /        
4x10
-3 ± 1x10
-4 
7x10
-3 ± 2 x10
-4 / 7x10
-3 ± 2x10
-4 /          
10x10
-3 ± 3x10
-4 
Table 26: ICP-AES Analysis Results of P@N Samples 
 
It is evident that the measured concentrations of stock solutions are lower than the expected 
1 mgml
-1, which can be accredited to the washing procedure when conjugating the PLL to 
the surface of the MNPs. There are two stages of dialysis where it is likely that MNPs can be 
lost, reducing the concentration.  
3.3 Preparation and Characterisation of Plasmid DNA 
Two different plasmids were prepared for condensation onto to the surface of the P@N; 
pTagRFP-N1-TagRFP and pTagRFP-N1-hNIS-TagRFP (prepared by Dr. Gilbert Fruhwirth, 
Kings College, London). Both plasmids contain the TagRFP gene, which encodes for the red 
fluorescent protein (RFP). Initial experiments were carried out with the pTagRFP-N1-hNIS-
TagRFP  plasmid  to  establish  the  method  for  both  encapsulation  and  transfection  with 
subsequent experiments carried out using the pTagRFP-N1-hNIS-TagRFP plasmid.   116 
Fluorescent proteins are increasingly popular for the in vitro imaging of cancer cells owing to 
their  long  excitation  wavelength,  which  reduces  the  photobleaching  associated  with 
fluorescent  dyes  that  were  conventionally  used  to  image  cells.  The  high  extinction 
coefficients and quantum yields of fluorescent proteins enable the high resolution imaging of 
the cells. By incorporating the TagRFP group into a plasmid it allows the transfection of the 
protein into cells whereby it undergoes transcription and translation, which results in the 
expression  of  the  red  fluorescent  protein.  By  subjecting  the  cells  to  the  appropriate 
wavelength of light, the RFP fluoresces and therefore can be imaged.
18,19  
The  pTagRFP-N1-hNIS-TagRFP  also  contains  a  region  encoding  for  the  human  sodium 
iodide symporter (hNIS). The hNIS is a hydrophobic membrane protein that is responsible 
for the active transport of iodide into the thyroid, lactating mammary, stomach and salivary 
glands  and  is  driven  by  the  electrochemical  gradient  of  sodium  (intracellular  vs 
extracellular).
20,21 By cloning the hNIS group into the TagRFP to make a bicistronic plasmid it 
can be transfected into cancer cells where it can mimic the iodide uptake associated with 
relevant glands and the subsequent administration of radiotracers permits the imaging of the 
cancer cells via SPECT (Tc
99m, 
123I or
 131I) 
 or PET (
124I).
21,22,23 A distinct advantage of using 
the hNIS group is that it is a human gene so no activation of the immune system occurs and 
thus allows the facile introduction into cells.
22 
Figures 49 and 50 show the plasmid maps for the two plasmids whereby the pTagRFP-N1-
TagRFP is 4.73 kbp in size and the pTagRFP-N1-hNIS-TagRFP is larger at 6.67 kbp.    117 
 
Figure 49: The Plasmid Map for the pTagRFP-N1-TagRFP Plasmid 
 
Figure 50: The Plasmid Map for the Bicistronic pTagRFP-N1-hNIS-TagRFP Plasmid 
 
3.3.1 Plasmid DNA concentration 
Plasmid  DNA  was  prepared  according  to  the  methods  described  in  Section  2.2.  After 
preparing  and  purifying  the  plasmid  DNA,  the  concentrations  of  both  plasmids  were 
measured using a Nanodrop (Thermo, UK) and the results can be seen in Table 27. 
Plasmid DNA Sample  Concentration (µgml
-1) 
pTagRFP-N1-TagRFP  1837 
pTagRFP-N1-hNIS-TagRFP  1914 
Table 27: A Table Showing Plasmid DNA Concentrations   118 
 
3.3.2 Determining the Loading Capacity of MNPs  
Gel shift assays were carried out for the four different MNP types with the pTagRFP-N1-
TagRFP  plasmid:  Chemicell  with  30-70  KDa  PLL,  Chemicell  with  150-300  KDa  PLL, 
Micromod with 30-70 KDa PLL and Micromod with 150-300 KDa PLL. 
It was expected that the larger molecular weight of PLL (150-300 KDa) would condense a 
larger amount of DNA than that of the lower molecular weight PLL (30-70 KDa), owing to the 
presence of more positive charges on the PLL.  
Figure 51 shows examples of the gel shift assays for both the Micromod and Chemicell 
MNPs functionalised with 30-70kDa and 150-300kDa PLL, the key to the different conditions 
can be seen in Table 28.  
Lane Number  Contents of Lane 
1  Ladder (1kBase) 
2  Control (no MNPs) 
3  3:1 (pDNA:MNP) 
4  5:1 (pDNA:MNP) 
5  15:1 (pDNA:MNP) 
6  30:1 (pDNA:MNP) 
7  70:1 (pDNA:MNP) 
8  140:1 (pDNA:MNP) 
Table 28: Key to Lanes in Gel Shift Assay 
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Figure 51: a) Gel Shift Assay for the pDNA Loading of Chemicell MNPs Functionalised with 30-70kDa PLL, b) Gel 
Shift Assay for the pDNA Loading of Chemicell MNPs Functionalised with 150-300kDa PLL, c) Gel Shift Assay for 
the pDNA Loading of Micromod MNPs Functionalised with 30-70kDa PLL and d) Gel Shift Assay for the pDNA 
Loading of Micromod MNPs Functionalised with 150-300kDa PLL 
 
 
Nanoparticle type  Maximum loading ratio (pDNA:MNP) 
Chemicell + 30-70 KDa PLL  5:1 
Chemicell + 150-300 KDa PLL  5:1 
Micromod + 30-70 KDa PLL  5:1 
Micromod + 150-300 KDa PLL  15:1 
Table 29: Table Showing the Loading Capacity of Different P@N Samples 
 
From examining the results in Table 29 it is possible to see that for (cc)DEX@PLL with both 
MWs of PLL that the maximum loading of pDNA is at a ratio of 5:1 pDNA:MNP before free 
DNA is seen on the gel. When all the pDNA is bound to the MNP no band should be seen as 
a result of the heavy weight of the MNP preventing its movement through the gel. In the case 
of the (mm)DEX@PLL the lower MW of 30-70 KDa shows a loading maximum of 5:1 like the 
Chemicell  MNPs,  however  at  the  higher  PLL  MW  of  150-300  KDa  there  is  a  maximum 
loading of 15:1 (pDNA:MNP). The higher MW of PLL can explain this higher loading of DNA 
onto the surface of the MNP by being able to condense more pDNA than the lower weight 
owing to its longer lysine chain. 
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3.3.3 Characterisation of D:PLL@MNP (D:P@N) by DLS and Zetapotential 
It was hypothesised that in order to successfully encapsulate the D:P@N into the cationic 
liposomes a negative surface charge would be required and therefore sufficient pDNA was 
required  to  be  condensed  on  the  surface  of  the  MNP  to  overcome  the  positive  charge 
resulting from the PLL. DLS was used to measure the hydrodynamic diameter and ZP for the 
surface charge. Tables 30 and 31 shows the sizes and surface charge that result from the 
condensation  of  pDNA  (in  this  case  pTagRFP-N1-TagRFP)  onto  the  surface  of  the 
Micromod MNPs functionalised with 150-300 KDa PLL.  
Ratio of DNA:MNP  Size (nm)  Polydispersity Index (PDI) 
MNP (no DNA)  76.5  0.190 
1:1  148.5  0.289 
1.5:1  251.1  0.443 
1.75:1  243.9  0.140 
2:1  244.0  0.383 
Table 30: DLS Results of DNA Loaded MNPs (values taken as an average of three replicates) 
 
Ratio of MNP:DNA  Surface charge (mV)  Standard Deviation (mV) 
MNP with no DNA  35.7  4.4 
1:1  35.4  10.3 
1.5:1  32.9  7.1 
1.75:1  31.0  5.3 
2:1  -21.6  11.3 
Table 31: Zetapotential Results of DNA Loaded MNPs (values taken as an average of three replicates) 
 
As expected there is an increase in size upon the addition of the pDNA (1:1, D:N) (from 76.5 
nm to 148.5 nm). As more pDNA is added the size increases to around 250 nm at the ratios. 
1.5:1, 1.75:1 and 2:1 (D:N). With the increased addition of pDNA onto the surface of the 
MNP  there  is  a  decrease  in  the  surface  charge  whereby  the  surface  charge  becomes 
negative at the 2:1 ratio.  
The DLS and ZP results for the ratios 1:1 and 2:1 (D:P@N) for the other D:P@N types can 
been seen in Table 32.   121 
D:P@N Type/Ratio D:P@N  DLS Results (nm)/PDI  Zeta Potential Results/SD (mV) 
(cc)DEX@PLL (30-70 KDa) / 1:1  170.6 nm/0.281  12.5 mV/6.70 
(cc)DEX@PLL (30-70 KDa) / 2:1  145.4 nm/0.227  -8.09 mV/4.9 
(cc)DEX@PLL (150-300 KDa) / 1:1  208.4 nm/0.255  31.6 mV/4.7 
(cc)DEX@PLL (150-300 KDa) / 2:1  235.3 nm/0.281  -15.1 mV/5.0 
(mm)DEX@PLL (30-70 KDa) / 1:1  202.9 nm/0.491  14.5 mV/4.5 
(mm)DEX@PLL (30-70KDa) / 2:1  298.7nm/0.737  -13.1mV/4.2 
Table 32: DLS and ZP for DNA Loaded MNPs (values taken as an average of three replicates) 
 
3.3.4 Characterisation of D:P@N by Transmission Electron Microscopy (TEM) 
TEM imaging was performed on the D:P@N complexes in order to further ascertain their 
structure. The complexes were stained with uranyl acetate prior to imaging so that the pDNA 
could be visualised. Uranyl acetate acts as a negative stain, which allows the visualisation of 
DNA in electron microscopy via the binding of uranyl ions to the phosphate groups present in 
the DNA.
24 Xiao et al. demonstrated the use of uranyl acetate staining when visualising gold 
nanoparticles  bound  with  DNA  crystals  for  use  as  programmable  molecular  scaffolds.
25 
Figure 52 (i-iii) shows the TEM images for (mm)DEX@PLL (150-300 KDa PLL). TEM images 
of unmodified Micromod MNPs can be seen in Figure 44.  
 
Figure 52: TEM micrographs of DNA loaded MNPs 
 
From examining the TEM images the presence of the P@N structures with DNA wrapped 
around the outside can be seen. Owing to the uranyl acetate staining of the pDNA, this 
appears  as  a  dark  grey  network  surrounding  the  black  spherical  P@N  structures.  This 
confirms the DLS and ZP results in Section 3.3.3 that show the successful condensation of 
pDNA on the surface of the P@N particle. 
(i)  (ii)  (iii) 
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3.4 Encapsulation of D:P@N in to Liposomes to form 
Magnetolipolyplexes (L:D:P@Ns)  
3.4.1 Characterisation of Magnetolipopolyplexes (L:D:P@N) by DLS and Zetapotential  
Initial L:D:P@N formulations were carried out with the Chemicell MNPs as characterisation 
data  obtained  from  SQUID  and  DLS/ZP  measurements  indicated  that  the  P@Ns  and 
D:P@Ns had been successfully formed.  
Characterisation measurements with these L:D:P@Ns did not yield successful results when 
formulated with the PLL functionalised Chemicell MNPs. It was not possible to obtain DLS or 
ZP measurements as the sample underwent precipitation upon encapsulation into liposomes. 
Further sonication of the sample did not improve the precipitation and the samples were too 
polydisperse to obtain either DLS or ZP measurements. After formulation into liposomes the 
Chemicell containing L:D:P@N complexes were further dialysed to determine whether DLS 
and ZP measurements could be obtained but this too proved unsuccessful when measuring 
both the DLS and ZP.   
There  was  more  success  seen  when  encapsulating  the  D:P@N  complexes  containing 
Micromod MNPs and 30-70 KDa PLL into L:D:P@Ns. L:D:P@Ns were formulated initially in 
the ratios (by weight) 5:2:1, 10:2:1, 20:2;1 and 50:2:1 ((mm)DEX@PLL (30-70 KDa PLL) and 
pTagRFP-N1-TagRFP). The encapsulations were attempted at these ratios to ensure that an 
excess of lipid to pDNA would be present. These different formulations were measured using 
DLS and ZP results can be seen in Table 33. 
  Ratio (L:D:P@N)  DLS Results (nm) / PDI  ZP Results (mV)/ SD 
(mV) 
L:D:P@N (D/D) 
5:2:1  469.5 nm/ 0.377  -0.3 mV/ 3.7 
10:2:1  389.0 nm/ 0.262  -2.6 mV/ 3.7 
20:2:1  586.5 nm/ 0.567  -25.1 mV/ 7.8 
50:2:1  713.9 nm/ 0.514  -33.6 mV/ 16.8 
L:D:P@N (C/D) 
5:2:1  429.9 nm/ 0.658  -40.0 mV/ 4.0 
10:2:1  489.1 nm/ 0.405  -50.1 mV/ 4.3 
20:2:1  566.8 nm/ 0.156  -52.7 mV/ 4.6 
50:2:1  717.2 nm/ 0.353  -40.5 mV/ 4.7 
Table 33: DLS and ZP Results for the L:D:P@Ns with a 2:1 ratio of D:P@N (values taken as an average of three 
replicates)   123 
It was hypothesised that the more lipid excess present, the higher the surface charge as the 
D:P@N particle is more likely to be encapsulated. The results in Table 33 show this not to be 
the case as large sizes and negative surface charges are present in both lipid combinations, 
at all ratios. In both the D/D and C/D lipid formulations, the increase in lipid to MNP ratio in 
fact causes an increase in the size of the MNP, 469.5 nm (5:2:1, D/D) to 713.9 nm (50:2:1, 
D/D) and 429.9 nm (5:2:1, C/D) to 717.2 nm (50:2:1, C/D). There is also no increase in the 
surface charge upon the increase of lipid to MNP ratio, in fact in the case of the D/D lipid 
formulations the increase in lipid amount appears to decrease the surface charge of the 
formulation further.  
This clearly shows that the L:D:P@N formulation has been unsuccessful and this could be 
explained by the surface charge of the D:P@N compound seen in Table 33. The surface 
charge of the (mm)DEX@PLL (30-70 KDa PLL) is only -13.1 mV at a ratio of 2:1 D:P@N 
and it was considered that a larger ratio of D:P@N would provide an increased negative 
charge and therefore aid successful formulation of L:D:P@Ns. 
To try and overcome the issues faced with the previous ratios, new ratios of 5:5:1, 10:5:1, 
20:5:1 and 50:5:1 were measured by DLS and ZP. Table 34 shows the results obtained 
using  the  (mm)DEX@PLL  MNPs  with  30-70  KDa  PLL  and  the  pTagRFP-N1-TagRFP 
plasmid. 
Formulation  Ratio (L:D:P@N)  DLS Results (nm) / PDI  ZP Results (mV) / SD 
(mV) 
L:D:P@N (D/D) 
5:5:1  176.7 nm/ 0.397  -25.7 mV/ 6.8 
10:5:1  251.2 nm/ 0.353  -23.7 mV/ 5.3 
20:5:1  268.1 nm/ 0.504  -31.2 mV/ 6.0 
50:5:1  705.3 nm/ 0.348  -15.28 mV/ 7.0 
L:D:P@N (C/D) 
5:5:1  294.4 nm/ 0.408  -32.6 mV/ 8.5 
10:5:1  238.7 nm/ 0.307  -22.2 mV/ 4.7 
20:5:1  239.2 nm/ 0.468  -28.9 mV/ 7.3 
50:5:1  747.8 nm/ 0.724  -48.7 mV/ 2.9 
Table 34: DLS and ZP Results for the L:D:P@Ns with a 5:1 ratio of D:P@N (values taken as an average of three 
replicates) 
   124 
The results seen in Table 34 show a similar trend to those in Table 33; an increase in the 
ratio of lipid to D:P@N results in an increase in the size of the formulated L:D:P@N. For the 
D/D formulations the ratio of 5:5:1 gave a size increase of 176.7 nm to 705.3 nm for 50:5:1 
ratios and in the case of the C/D formulations the size increases from 294.4 nm (5:5:1) to 
747.8 nm (50:5:1).  There is no change in the surface charge of L:D:P@N complexes to 
positive values, with the 50:5:1 ratios in the D/D and C/D formulations being -15.28 mV and -
48.7 mV respectively.  
It  is  clearly  evident  from  the  results  in  Tables  33  and  34  that  the  formulation  of  the 
L:D:P@Ns has not been successful. An explanation for this could be that the sonication and 
subsequent collapse of the lipid film around the D:P@Ns did not work as expected. As the 
D:P@Ns are negatively charged they could be electrostatically binding the lipid in between 
them  and  hence,  explaining  why  the  L:D:P@N  is  not  formulated  properly.  An  alternative 
explanation could be that the liposomes are forming and the negatively charged D:P@N 
particles are electrostatically bonding to the outside of the positively charged liposomes, this 
could also explain their large sizes seen in Table 33. 
 
3.4.2  Transmission  Electron  Microscopy  Analysis  of  Magnetolipopolyplexes 
(L:D:P@N) 
To  further  investigate  the  structure  of  the  L:D:P@Ns,  TEM  analysis  was  performed  with 
uranyl  acetate  staining  so  that  the  pDNA  can  be  imaged.  Figure  53  (i-iii)  shows  the 
L:D:P@Ns formulated with D/D and Figure 54 (i-iii) shows the L:D:P@Ns formulated with 
C/D.  
 
Figure 53: TEM micrographs of L:D:P@Ns Formulated with D/D 
 
0.75µm 
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Figure 54: TEM micrographs of L:D:P@Ns Formulated with C/D 
 
From  examining  Figure  53  (i),  there  appears  to  be  structures  that  look  like  formulated 
liposomes with MNPs and pDNA around the surface. These structures can also be seen in 
Figure 53 (ii) and (iii) and further add to the theory that the D:P@Ns are electrostatically 
binding to the outside of liposomes. However, these structures are not seen in Figure 54 (i-
iii) where there are no lipid like structures appearing and it simply appears that the D:P@N 
structures  are  present.  This  could  give  evidence  to  the  first  hypothesis  that  the  D:P@N 
structures are in fact condensing the positively charged lipids within the negative D:P@N.  
It is not possible to obtain detailed images of complex samples such as liposomes through 
conventional TEM owing to the sample preparation method. The samples are prepared by 
dehydrating the sample on the TEM and thus the dehydration is detrimental to the delicate 
liposome  structure.  To  further  examine  the  structures  by  TEM  it  would  be  necessary  to 
perform  cryoTEM  analysis,  which  would  allow  for  the  delicate  liposome  structure  to  be 
imaged in detail and thus could confirm the exact structure of the L:D:P@N compound. 
 
3.5 In Vitro Transfection Experiments 
L:D:P@Ns were used in in vitro transfection experiments to determine their suitability as 
imaging agents. In the first instance three EGF positive breast cancer cell lines were used; 
MDA-MB-231 (M), HCC1954 (H) and MCF-7 (MC) to provide a measure of the ability of the 
L:D:P@Ns  to  transfect  different  cell  lines.  A  similar  method  of  in  vitro  transfection  was 
reported by Mustapa et al. whereby a luciferase encoding plasmid was encapsulated into a 
lipopolyplex  and  used  to  transfect  MDA-MB-231  breast  cancer  cells,  the  subsequent 
transfection  efficiency  was  measured  by  the  expression  of  the  plasmid.
26  In  these 
(i)  (ii)  (iii) 
0.5µm   126 
experiments  the  pTagRFP-N1-TagRFP  plasmid  was  used  owing  to  its  improved 
fluorescence  over  the  pTagRFP-N1-hNIS-TagRFP  plasmid  where  the  large  hNIS  group 
hinders the fluorescence of the TagRFP.
26 
Initially transfection experiments were performed with both the functionalised Chemicell and 
Micromod MNPs. The transfection of Chemicell L:D:P@Ns were unsuccessful with no RFP 
expression seen as a result of complete cell death in L:D:P@N and as a result of these 
preliminary transfection experiments further experiments were carried out with the Micromod 
MNPs. 
3.5.1  In  Vitro  Transfection  of  L:D:P@Ns  in  MDA-MB-231,  HCC1954  and  MCF-7  Cell 
Lines 
Initial L:D:P@N transfection experiments were performed with the ratios 5:2:1, 10:2:1 and 
20:2:1 (lipid:pDNA:P@N) and compared to a transfection control, Fugene. It was decided 
that the 50:2:1 condition from Table 33 would be omitted owing to its extremely large size 
and negative surface charge.  
Figures 56 and 57 show the RFP expression and the cell viability for the L:D:P@Ns in the 
three cell lines. The RFP expression is measured as a ratio of RFP expressing cells against 
the Hoechst stained viable cells for the same parameter, giving a means of showing the 
expression of RFP in the viable cells. The cell viability is measured by obtaining the ratio of 
transfected  Hoechst  stained  cells  against  un-transfected  cells  also  stained  with  Hoechst, 
giving  an  indication  of  the  toxicity  induced  by  a  given  parameter.  Both  of  these 
measurements are ratios of one parameter to another and therefore yield arbitrary numbers 
that  can  be  used  to  provide  a  means  of  comparison  rather  than  quantitative  values  of 
expression. In this transfection experiment the D/D lipid formulation was used alongside the 
30-70KDa P@Ns.   127 
 
Figure 55: RFP Expression of L:D:P@Ns in MDA-MB-231 (M), HCC1954 (H) and MCF-7 (MC) Cells with 30-70KDa 
PLL and pTagRFP-N1-TagRFP 
 
Figure 56: Cell Viability of L:D:P@Ns in MDA-MB-231 (M), HCC1954 (H) and MCF-7 (MC) Cells  with 30-70KDa 
PLL and pTagRFP-N1-TagRFP 
 
Figure 55 shows the RFP expression in the three cell lines and it is evident that the Fugene-
6 control was successful across the three cell lines. In each of the three cell lines there is a 
significant  difference  (p<0.05)  between  the  Fugene-6  control  and  each  of  the  different 
conditions whereby the control showed a marked increase in RFP expression. Transfection 
was solely in the 5:2:1 condition for the MDA-MB-231 cell line with the HCC1954 cell line 
showing with no RFP expression in the 10:2:1 and 20:2:1 conditions. RFP expression was 
seen  in  the  HCC1954  cell  line  with  the  10:2:1  and  20:2:1  conditions  although  minimal 
0 
20 
40 
60 
80 
100 
120 
140 
160 
180 
200 
R
a
t
i
o
 
o
f
 
R
F
P
 
E
x
p
r
e
s
s
i
n
g
 
C
e
l
l
s
 
v
s
 
H
o
e
c
h
s
t
 
S
t
a
i
n
e
d
 
V
i
a
b
l
e
 
C
e
l
l
s
 
RFP Expression of L:D:P@Ns in MDA-MB-231, HCC1954 and MCF-7 
Cells with 30-70KDa PLL and pTagRFP-N1-TagRFP 
0 
20 
40 
60 
80 
100 
120 
Fugene 
(M) 
5:2:1 
(M) 
10:2:1 
(M) 
20:2:1 
(M) 
Fugene 
(H) 
5:2:1 
(H) 
10:2:1 
(H) 
20:2:1 
(H) 
Fugene 
(MC) 
5:2:1 
(MC) 
10:2:1 
(MC) 
20:2:1 
(MC) 
R
a
t
i
o
 
o
f
 
H
o
e
c
h
s
t
 
S
t
a
i
n
e
d
 
T
r
a
n
s
f
e
c
t
e
d
 
C
e
l
l
s
 
v
s
 
H
o
e
c
h
s
t
 
S
t
a
i
n
e
d
 
U
n
t
r
a
n
s
f
e
c
t
e
d
 
C
e
l
l
s
 
 
Cell Viability of L:D:P@Ns in MDA-MB-231, HCC1954 and MCF-7 
Cells  with 30-70KDa PLL and pTagRFP-N1-TagRFP 
   128 
transfection was seen in the 5:2:1 condition. The MCF-7 cell line also shows a small amount 
of transfection in the 20:2:1 condition but no notable transfection in the 5:2:1 and 10:2:1 
conditions.  
There was no significant difference (p>0.05) in the cell viability across the HCC1954 and 
MCF-7 cell lines when comparing the different ratios of L:D:P@N to the Fugene-6 control, 
Figure 56. A toxic effect was seen in the MDA-MB-231 cell line, Figure 56, with each of the 
three conditions, however this was not significantly different statistically with p>0.05. 
The low levels of transfections seen at these ratios can be attributed to their large sizes 
469.5nm, 389.0nm and 586.5nm for the 5:2:1, 10:2:1 and 20:2:1 conditions respectively, 
Table 33. The relatively high level of transfection in the 5:2:1 condition in the MDA-MB-231 
cells compared to other can be attributed to loss of cell viability. The transfection efficiency is 
measured as a ratio of RFP expression vs. UV expression of the viable cells, if there is a 
detrimental effect to the cell viability there will be a decrease in viable cells and thus if the 
remaining viable cells are expressing RFP it gives a high measure of RFP expression which 
can be deemed as a false positive measurement and can therefore be discounted. 
From the DLS and ZP results seen in Table 34, the ratios 5:5:1, 10:5:1 and 20:5:1 appeared 
to give smaller sizes than the 5:2:1, 10:2:1 and 20:2:1 ratios and it was thought that these 
could potentially improve the transfection ability of the L:D:P@Ns. A transfection experiment 
was  carried  out  with  the  D/D  lipid  formulation,  the  pTagRFP-N1-TagRFP  pDNA  and  30-
70kDa P@Ns, Figures 57 and 58 show the RFP expression and cell viability respectively.   129 
 
Figure 57: RFP Expression of L:D:P@Ns in MDA-MB-231 (M), HCC1954 (H) and MCF-7 (MC) Cells with 30-70KDa 
PLL, D/D Lipid Formulation and pTagRFP-N1-TagRFP 
 
Figure 58: Cell Viability of L:D:P@Ns in MDA-MB-231 (M), HCC1954 (H) and MCF-7 (MC) Cells with 30-70KDa PLL, 
D/D Lipid Formulation and pTagRFP-N1-TagRFP 
 
As  in  the  previous  transfection  experiment,  there  is  good  RFP  expression  seen  in  the 
controls, in this instance the Lipofectamine and Fugene-6, across the three cell lines, Figure 
57. There is no RFP expression of the L:D:P@Ns seen in the MDA-MB-231 and MCF-7 cell 
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at all three ratios of L:P:D@N. Transfection is seen in each of the ratios in the HCC1954 cell 
line with no statistical significance (p>0.05) between the L:D:P@Ns and the Lipofectamine 
and  Fugene-6  controls.  The  improved  RFP  expression  with  the  5:5:1,  10:5:1  and  20:5:1 
ratios  over  the  previous  ratios  can  be  explained  by  their  smaller  sizes,  177  nm  (5:5:1), 
251nm (10:5:1) and 268 nm (20:5:1) compared to 470 nm (5:2:1), 389 nm (10:2:1) and 587 
nm (20:2:1), Table 34.  
Figure 58  shows that there is a no notable effect  the cell viability in the  three cell lines 
(p>0.05) indicating that the L:D:P@Ns do not exhibit a marked toxic effect. The new ratios 
showed an improvement in the viability of L:D:P@Ns in the MDA-MB-231 cell line when 
compared to the previous viability measurements, Figure 56. 
Following  the  success  seen  with  5:5:1,  10:5:1  and  20:5:1  ratios  seen  with  the  D/D  lipid 
formulation, the transfection was repeated with the C/D lipid formulation. It was hoped that 
comparable  transfection  would  be  seen  with  the  C/D  lipid  formulations  as  ultimately  the 
PEGylation on the CH300 lipid should improve in vivo circulation times should the L:D:P@Ns 
be used in in vivo transfection experiments. Figures 59 and 60 show the RFP expression 
and cell viability respectively. 
 
Figure 59: RFP Expression of L:D:P@Ns in MDA-MB-231 (M), HCC1954 (H) and MCF-7 (MC) Cells with 30-70KDa 
PLL, C/D Lipid Formulation and pTagRFP-N1-TagRFP 
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Figure 60: Cell Viability of L:D:P@Ns in MDA-MB-231 (M), HCC1954 (H) and MCF-7 (MC) Cells with with with 30-
70KDa PLL, C/D Lipid Formulation and pTagRFP-N1-TagRFP 
 
Figure 59 shows that RFP expression is present in the three ratios for the L:D:P@Ns in the 
HCC954 cell line and as in Figure 57, the 5:5:1 ratio provides the best RFP expression. In 
this instance there is a slight reduction in the 10:5:1 ratio, although there is no reduction in 
the  cell  viability  concluding  that  the  decreased  RFP  expression  is  not  a  result  of  the 
L:D:P@N exhibiting a toxic effect on the cells. There are no significant differences (p>0.05) 
however between the controls and the three different ratios of L:D:P@Ns in the HCC1954 
cell line suggesting comparable transfection of the different rations and the controls. 
As  in  the  case  with  the  D/D  formulations  there  is  no  transfection  in  all  three  ratios  of 
L:D:P@Ns in the MDA-MB-231 cell line and in the 10:5:1 and 20:5:1 conditions of the MCF-7 
cell line. There is a large amount of RFP expression in the 5:5:1 condition in the MCF-7 cell 
line providing an anomalous result. This result is subject to an extremely large error bar, 
especially compared to the other conditions, and it can therefore be concluded that this is 
not a viable measurement, which have resulted from contamination or an artefact in the 
imaging process.  
Figure 60 shows that there is no significant effect to the cell viability in all three cell lines 
after the addition of the L:D:P@Ns formulated with the C/D lipid combination. There is no 
0 
20 
40 
60 
80 
100 
120 
140 
160 
R
a
t
i
o
 
o
f
 
H
o
e
c
h
s
t
 
S
t
a
i
n
e
d
 
T
r
a
n
s
f
e
c
t
e
d
 
C
e
l
l
s
 
v
s
 
H
o
e
c
h
s
t
 
S
t
a
i
n
e
d
 
U
n
t
r
a
n
s
f
e
c
t
e
d
 
C
e
l
l
s
 
 
Cell Viability of L:D:P@Ns in MDA-MB-231, HCC1954 and MCF-7 
Cells with with with 30-70KDa PLL, C/D Lipid Formulation and 
pTagRFP-N1-TagRFP   132 
statistical difference (p>0.05) between the controls and the L:D:P@N formulations in each of 
the three cell lines suggesting that no notable toxicity is exhibited by these formulations. 
Overall the HCC1954 cell line proved to the most successful across the range of conditions, 
showing transfection ability in the L:D:P@Ns with the different ratio types. The HCC1954 cell 
line  also  has  a  well-established  tumour  model,  which  would  prove  extremely  beneficial 
should in vivo work be performed.
27,28,29 Less success was seen in the MDA-MB-231 and 
MCF-7 cell lines, with limited results and contingency between the conditions and it was 
decided that these two cell lines would not be used in further experiments.   
3.6 Chapter Summary 
It is possible to conclude that a viable method for producing PLL modified MNPs has been 
established with FTIR, DLS, ZP and SQUID measurements all confirming the presence of 
the  PLL  coating.  Further  characterisation  techniques  such  as  TEM  and  XRD  provide 
information of the size and crystal structure of the MNPs establishing their composition as 
magnetite  and  their  size  as  approximately  10-20  nm.  The  SQUID  measurements  also 
confirmed the magnetic properties of the samples.  
When functionalising the P@N complexes with pDNA it is possible to see a large increase in 
the  size  of  the  MNPs  and  a  reduction  in  their  surface  charge  confirming  the  successful 
condensation of pDNA onto the MNPs surface.  
However, when encapsulating these MNPs into liposomes to form the L:D:P@N complex the 
results were not as expected. When considering the DLS and ZP measurements it is evident 
that successful encapsulation of the D:P@Ns has not taken place owing to their large sizes 
and negative surface charge. If the D:P@Ns were successfully encapsulated there should 
be a positive surface charge owing to the cationic lipids coating the D:P@N. A possible 
hypothesis for this is that the D:P@N complexes are too large to be coated by the lipids; at a 
ratio of 10:5:1 there is a hydrodynamic diameter of 251.2 nm. As a negative charge exists for 
the  L:D:P@Ns  it  is  also  possible  to  conclude  that  the  D:P@N  complex  may  be 
electrostatically bound to the formulated lipids, giving rise to the negative charge.   133 
Alongside  the  poor  formulation  results,  the  transfection  results  proved  to  have  poor 
reproducibility, which could be accredited to their large size and low surface charge. In most 
cases there was no significant effect to the cell viability upon the addition of the L:D:P@N 
complexes  ultimately  indicating  that  the  reduced  transfection  was  not  a  direct  result  of 
toxicity to the cells.  
In order to overcome the issues faced with the formulation of the L:D:P@Ns and their poor 
transfection  ability  an  alternative  method  of  formulation  must  be  considered  that  yields 
magnetolipopolyplexes with smaller hydrodynamic diameters and positive surface charges.  
     134 
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4.0 The Electrostatic Formulation of Magnetolipopolyplexes 
and their use In Vitro 
4.1 Introduction  
As a result of the lack of success seen with the L:D:P@Ns in Chapter 3.0 it was decided that 
a new approach to formulating magnetolipopolyplexes would be investigated. In the previous 
L:D:P@N  formulations,  the  large  size  of  the  D:P@N  complex  prevented  its  effective 
encapsulation into liposomes to form the resulting L:D:P@Ns. 
To  overcome  this  it  was  decided  that  a  successful  method  reported  in  the  literature  to 
formulate lipopolyplexes would be modified in order to produce new magnetolipopolyplexes 
(L:P:D:Ns). In this work they show a method of formulating L:P:Ds by first formulating the 
liposome and then subsequently adding the peptide and pDNA components.
1-10 
It was hypothesised that there were two possible routes to formulation of the L:P:D:Ns;  
1)  Hydration of lipid film with MNPs, followed by the formulation of L:N complex and 
then the addition of peptide DNA (pDNA) and peptide (Sonication Method) 
2)  Formulation  of  liposome  and  subsequent  addition  of  MNP,  pDNA  and  peptide 
components  (Diffusion Method) 
The successful L:P:D:N formulation would then be used in in vitro transfections to establish 
their  efficiency  as  transfection  agents  by  measuring  the  RFP  expression  of  the  pDNA. 
SQUID  magnetometry  data  would  give  information  on  their  potential  as  MRI  agents  by 
measuring the amount of iron oxide taken up by cells. In order to determine the formulation 
with  the  greatest  degree  of  success  a  variety  of  different  conditions  were  investigated, 
including  different  sizes  of  nanoparticles,  targeting  peptides  and  different  liposome 
formulations.  
Figure 61 shows the proposed outcome of the formulation and Table 35 summarises the 
abbreviations for the various formulations.    138 
 
Figure 61: Picture Showing the Proposed Outcome when Formulating the L:P:D:Ns 
Formulation  Abbreviation 
Nanoparticle  MNP or N 
Lipid + Nanoparticle  L:N 
Lipid + Peptide + pDNA  L:P:D 
Lipid + Peptide + pDNA + Nanoparticle  L:P:D:N 
Table 35: Key to Abbreviations Used in Chapter 4 
 
It has been shown in the literature that the use of targeting peptides greatly improves the 
delivery of liposomes when targeting a specific site, Section 1.5. In this case the HCC1954 
(L)  (N) 
(P)   139 
cells are known to be positive for the epidermal growth factor receptor (EGFR) and therefore 
by preparing peptides that target the EGF receptor it was hypothesised that this method 
would increase both the transfection efficiency and the iron oxide uptake in cells.
11-14 Table 
36 shows the three different targeting peptides. 
Targeting Peptide  Peptide Sequence 
Targeting Peptide 1 (TP1)  K16RVRRYHWYGYTPQNVI 
Targeting Peptide 2 (TP2)  K16RVRRLARLLT 
Targeting Peptide 3 (TP3)  YHWYGYTPQNVIRVRRK16 
Table 36: Table Showing the Various Targeting Peptides Used and their Sequences 
 
4.2 Characterisation Data for Commercially Available Magnetic 
Nanoparticles  
Commercially  available  MNPs  were  purchased  from  Chemicell  with  a  range  of  coatings 
including dextran and citric acid. Their properties can be seen in Table 37 and Figures 62-64.  
MNP Name  Coating  Size  Core Component 
FluidmagCMX (Chemicell) 
15  Carboxymethyldextran  50 nm (HD)  Magnetite 
FluidmagD (Chemicell) 
16  Dextran  50 nm (HD)  Magnetite 
FluidmagCT (Chemicell) 
17  Citric Acid  50 nm, 100nm 
(HD) 
Magnetite 
Table 37: Commercially Available Nanoparticles Used and their Properties 
 
 
Figure 62: The Surface Structure of the Chemicell FluidmagCMX MNPs 
15 
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Figure 63: The Surface Structure of Chemicell FluidmagD MNPs 
16 
 
 
Figure 64: The Surface Structure of Chemicell FluidmagCT MNPs 
17 
 
4.3 Characterisation of Lipopolyplexes (L:P:Ds), Magnetoliposomes 
(L:Ns) and Magnetolipopolyplexes (L:P:D:Ns)  
4.3.1 Dynamic Light Scattering and Zetapotential Characterisation of Lipopolyplexes, 
Magnetoliposomes and Magnetolipopolyplexes 
When investigating the new method of formulating the magnetolipopolyplexes (L:P:D:Ns) it 
was necessary to fully characterise them by DLS and ZP in order to gather information on 
their  size  and  surface  charge  and  therefore  understand  if  their  formulation  had  been 
successful.  
Cationic  liposomes  were  primarily  made  up  with  either  DOTMA/DOPE  (D/D)  or 
CH300/DOPE (C/D) formulations alongside the pDNA and the K16. In order to successfully 
formulate  the  L:P:D:Ns,  it  was  hypothesised  that  a  negatively  charged  MNP  would  be 
-OOC
H2
C C
H2
C
COO-
COO-
COO-Na+
Na+
Na+
Na+  141 
required and it was for this reason that FluidmagCMX was chosen for initial experiments. For 
relative sizes and surface charges see Table 38. The fluorescein lipid was included in the 
formulations  when  measuring  the  transfection  efficiency  of  magnetoliposomes  (L:Ns).  By 
formulating the liposomes with the Fluorescein lipid (F) it allows the internalised liposomes to 
be  imaged  in  the  FITC  fluorescence  region  of  the  microscope  as  there  is  no  pDNA  to 
express RFP and hence, the fluorescence must be detected by another means. 
Formulation  DLS Result  ZP Result 
FluidmagCMX  62.9 nm, PDI: 0.412  -36.8 mV, SD: 17.8 
D/D  128.8 nm, PDI: 0.243  53.1 mV, SD: 7.33 
C/D  143.7 nm, PDI: 0.210  65.8 mV, SD: 17.8 
D/D/F  216.8 nm, PDI: 0.490  63.1 mV, SD: 5.34 
C/D/F  166.5 nm, PDI: 0.251  59.9 mV, SD: 7.33 
Table 38: DLS and ZP Data for Commercial MNPs and Formulated Liposomes (values taken as an average of three 
replicates) 
 
Initially  L:P:Ds  were  formulated  following  the  work  published  by  Kudsiova  et  al.  with  the 
pTagRFP-N1-TagRFP  plasmid  and  K16  with  varying  weight  ratios  of  lipid:pDNA  to 
determine the ideal formulation.
4 The surface charges and hydrodynamic diameters were 
measured for each of the different ratios with both the D/D and C/D lipid formulations and the 
results can be seen in Table 39. In both D/D and C/D formulations the 16:1 ratio proved to 
be the most successful with the most positive surface charges for the smallest size; 172.6 
nm and +48.6 mV and 141.3 nm and +50.3 mV respectively. 
Formulation/ L:D Ratio  DLS Result  ZP Result 
L:P:D (D/D)/ 2:1  148. nm, PDI: 0.155  -28.8 mV, SD: 26.1 
L:P:D (D/D)/ 4:1  161.9 nm, PDI: 0.232  -14.8 mV, SD: 16.8 
L:P:D (D/D)/ 8:1  313.8 nm, PDI: 0.307  34.2 mV, SD: 4.25 
L:P:D (D/D)/ 16:1  172.6 nm, PDI: 0.178  48.6 mV, SD: 7.31 
L:P:D (C/D)/ 2:1  178.9 nm, PDI: 0.143  -30.6 mV, SD: 8.16 
L:P:D (C/D)/ 4:1  189.1 nm, PDI: 0.132  -25.0 mV, SD: 6.10 
L:P:D (C/D)/ 8:1  160.0 nm, PDI: 0.169  47.9 mV, SD: 7.36 
L:P:D (C/D)/ 16:1  141.3 nm, PDI: 0.178  50.3 mV, SD: 6.61 
Table 39: DLS and ZP Data for the Formulation of L:P:Ds with Varying Ratios of Lipid to pDNA (values taken as an 
average of three replicates) 
 
After formulating the L:P:D complexes, L:Ns were prepared in order to establish the ideal 
ratio of lipid:MNP. They were made up following two different methods; hydration of lipid film   142 
with MNP solution followed by sonication (Sonication Method)
18-20  and the formulation of 
liposomes with the subsequent addition of MNPs ensuring an excess of lipid:MNP (Diffusion 
Method)
21. Table 40 shows the DLS and ZP results following the Sonication Method. 
Formulation/ L:N Ratio  DLS Result  ZP Result 
D/D:N/ 5:1  539.5 nm. PDI: 0.478  -6.43 mv, SD: 6.18 
C/D:N/ 5:1  460.7 nm, PDI: 0.467  10.4 mV, SD: 4.82 
D/D:N/ 10:1  392.0 nm, PDI: 0.696  -10.2 mV, SD: 4.93 
C/D:N/ 10:1  541.6 nm, PDI: 0.883  -16.8 mV, 8.47 
Table 40: DLS and ZP Data for the Formulation of L:Ns with the Sonication Method (values taken as an average of 
three replicates) 
 
From examining the results from the sonication method, Table 41, it is possible to see that 
the L:Ns were not formulated successfully as they have large hydrodynamic diameters and 
polydispersity  indexes.  The  surface  charges  also  suggest  that  they  have  not  been 
successfully formulated as they range between -10.2 mV and +10.4 mV. In order to form 
L:Ns  the  surface  charge  must  be  positive  to  confirm  the  cationic  lipid  coating  of  the 
negatively charged MNP, and to ensure fully stabilised formulations the surface charge must 
exceed +30 mV. The subsequent addition of pDNA and K16 did not improve the outcome of 
the sonication formulation rendering the samples too polydisperse to obtain either DLS or ZP 
measurements. 
Formulation/ L:N Ratio  DLS Result  ZP Result 
L:N (D/D)/ 5:1  313.1 nm, PDI: 0.754  25.2 mV, SD: 16.07 
L:N (C/D)/ 5:1  345.4 nm, PDI: 0.694  22.7 mV, SD: 4.90 
L:N (D/D)/ 10:1  149.1 nm, PDI: 0.222  35.0 mV, SD: 7.03 
L:N (C/D)/ 10:1  188.6 nm, PDI: 0.365  37.5 mV, SD: 5.04 
L:P:D:N (D/D)/ 5:1  305.4 nm, PDI: 0.638  -21.8 mV, SD: 6.57 
L:P:D:N (C/D)/ 5:1  342.4 nm, PDI: 0.619  - 28.7 mV, 8.73 
L:P:D:N (D/D)/ 10:1  159.1 nm, PDI: 0.254  42.5 mV, SD: 7.25 
L:P:D:N (C/D)/ 10:1  213.3 nm, PDI: 0.355  45.7 mV, SD: 6.48 
L:P:D:N (D/D) (1 week stability test)/ 
10:1 
213.5 nm, PDI: 0.465  43.9 mV, SD: 4.48 
L:P:D:N (C/D) (1 week stability test)/ 
10:1 
237.9 nm, PDI: 0.384  51.1 mV, SD: 5.76 
Table 41: DLS and ZP Data for the Formulation of L:P:D:Ns with Different L:N Ratios Using Diffusion Method 
(values taken as an average of three replicates) 
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The diffusion method of formulation proved to be more successful for the formulation of L:Ns 
with a small size and positive surface charge, Table 41. The best results were seen at a ratio 
of 10:1 (L:N) for both D/D and C/D conditions with sizes of 149.1 nm and 188.6 nm and 
surface charges of 35.0 mV and 37.5 mV respectively.  
The success of the L:N formulations meant that it was possible to add the pDNA and K16 
components to formulate the L:P:D:N compound. In both L:N rations of 5:1 and 10:1, the 
pDNA and K16 was added at a ratio of 16:1 (D:L) (with a pDNA to K16 ratio of 2:1). As 
before, the 10:1 L:N gave the best results for both D/D and C/D lipid formulations with sizes 
of 159.1 nm and 213.3 nm and surface charges of 42.5 mV and 45.7 mV respectively. The 
positive  surface  charge  of  the  L:P:D:N  formulations  and  small  standard  deviation  (SD) 
measurements suggest that the MNP, pDNA and K16 components are encapsulated in the 
cationic lipid coating.  
4.3.2 TEM Analysis of Lipopolyplexes (L:P:Ds), Magnetoliposomes (L:Ns) and 
Magnetolipopolyplexes (L:P:D:Ns) 
L:P:D:Ns were formulated using the Diffusion Method and were imaged by TEM with uranyl 
acetate staining to permit visualisation of the pDNA, Figure 65. TEM images of unmodified 
Chemicell MNPs can be seen in Figure 40. 
 
Figure 65: TEM Images of DOTMA/DOPE Magnetolipopolyplexes Formed by the Diffusion Method 
 
The TEM images in Figure 65 show round structures that are dark in colour and these can 
be identified as the liposomes containing pDNA, with the pDNA responsible for the dark 
colour owing to the negative staining properties of uranyl acetate.
22 Upon closer examination 
of  the  large  circular  structures  it  is  also  possible  to  see  smaller  circular  nanoparticles 
500nm  500nm 
magnetolipopolyplex 
1μm 
Magnetolipopolyplex   144 
enclosed  within  them,  confirming  the  presence  of  both  MNPs  and  pDNA  inside  the 
liposomes.  
4.4 In Vitro Transfection of Lipopolyplexes (L:P:Ds), Magnetoliposomes 
(L:Ns) and Magnetolipopolyplexes (L:P:D:Ns)  
4.4.1 In Vitro Transfection of Lipopolyplexes (L:P:Ds) 
Initially experiments were carried out to measure the transfection ability of the L:P:Ds with 
both the pTagRFP-N1-TagRFP plasmid and the pTagRFP-N1-hNIS-TagRFP. Both D/D and 
C/D liposomes were formulated and to both of these co-condensed pDNA and K16 was 
added in a weight ratio of 16:2:1 (L:P:D), the formulated L:P:D was then used to transfect 
HCC1954 cells.  
Figure 66 shows the transfection efficiency of the L:P:Ds formulated with the pTagRFP-N1-
TagRFP plasmid. There was similar transfection capabilities seen in both L:P:D formulations 
(with D/D and C/D) which were only slightly lower than that of both transfection controls; 
Fugene-6 and Lipofectamine. By examining Figure 67 it is possible to see that there was 
also no effect on the cell viability upon the addition of the L:P:D formulations to the cells. In 
fact there is less effect on the viability of the cells when adding the L:P:Ds than seen with the 
Lipofectamine, which exhibits a larger toxic effect to the cells. The L:P:Ds formulated with 
D/D  and  C/D  however  showed  statistically  similar  results  (p>0.05)  to  the  Fugene-6  and 
Lipofectamine controls in both the RFP expression and the cell viability indicating similar 
results between the L:P:Ds and control transfection agents.   145 
   
Figure 66: RFP Expression of L:P:Ds Formulated with D/D and C/D in HCC194 Cells with pTagRFP-N1-TagRFP 
pDNA and Figure 67: Cell Viability of L:P:Ds Formulated with D/D and C/D in HCC1954 Cells with pTagRFP-N1-
TagRFP pDNA 
Upon repeating the experiment with both D/D and C/D lipid formulations with the pTagRFP-
N1-hNIS-TagRFP  plasmid,  similar  transfection  was  seen  in  in  both  L:P:D  formulations, 
Figure  68.  The  cell  viability  measurements  show  a  promising  result  with  a  slight 
improvement to viability in the L:P:D conditions compared to those of the two controls, see 
Figure 69. There is no statistically significant difference seen between the two formulations 
of the L:P:Ds and the controls in both the RFP expression and the cell viability. 
   
Figure 68: RFP Expression of L:P:Ds Formulated with D/D and C/D in HCC194 Cells with pTagRFP-N1-hNIS-
TagRFP pDNA and Figure 69: Cell Viability of L:P:Ds Formulated with D/D and C/D in HCC1954 Cells with 
pTagRFP-N1-hNIS-TagRFP pDNA 
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4.4.2 In Vitro Transfection of Magnetoliposomes (L:Ns) 
Owing  to  the  successful  outcome  seen  with  the  L:P:Ds,  the  toxicity  of  the  L:Ns  was 
measured alongside their ability to be internalised in the cells. Liposomes were formulated 
using the Fluorescein lipid alongside the regular D/D and C/D formulations, for composition 
see Section 2.3, and to these liposomes FluidmagCMX was added at a ratio of 10:1 (L:N). 
By formulating the liposomes with the Fluorescein lipid it allows the internalised liposomes to 
be  imaged  in  the  FITC  fluorescence  region  of  the  microscope  as  there  is  no  pDNA  to 
express RFP and hence, the fluorescence must be detected by another means. 
   
Figure 70: FITC Fluorescence of L:Ns Containing Fluorescein Lipid in HCC1954 Cells and Figure 71: Cell Viability 
of L:Ns Containing Fluorescein Lipid in HCC1954 Cells 
 
From  looking  at  Figure  70  it  is  possible  to  see  that  there  is  fluorescence  in  both  L:N 
conditions,  which  is  comparable  in  magnitude.  The  cell  viability  measurement  shows  a 
comparable toxicity to the cells in the presence of the L:Ns when compared to the viability of 
the  cells  when  they  are  only  exposed  to  the  MNP,  Figure  71.  There  is  no  statistically 
significant difference seen between the two formulations of the L:P:Ds in the RFP expression 
and the cell viability. 
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4.4.3 In Vitro Transfection of Magnetolipopolyplexes (L:P:D:Ns) Formulated with 
FluidmagCMX 
By investigating the transfection efficiency of the L:P:Ds and L:Ns and their effects on cell 
viability it was possible to conclude that it was feasible to carry out similar experiments with 
the formulated L:P:D:Ns. Initially, transfection efficiency was investigated with both D/D and 
C/D lipid formulations, FluidmagCMX  MNPs  and  the  pTagRFP-N1-TagRFP  plasmid.  The 
transfection  was  carried  out  at  250  ng  of  pDNA  per  10,000  cells  and  also  1000  ng  per 
10,000 cells with the aim to determine if a larger concentration of DNA had a significant 
effect on transfection efficiency and cell toxicity from the L:P:D:Ns. 
 
Figure 72: RFP Expression of L:P:Ds and L:P:D:Ns Formulated with D/D and C/D in HCC1954 Cells with Different 
Amounts of DNA with pTagRFP-N1-TagRFP pDNA and FuidmagCMX 
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Figure 73: Cell Viability of L:P:Ds and L:P:D:Ns Formulated with D/D and C/D in HCC1954 Cells with Different 
Amounts of DNA  with pTagRFP-N1-TagRFP pDNA and FluidmagCMX 
 
From Figures 72 and 73 it is possible to deduce that transfection was seen in both 250ng of 
pDNA per 10,000 cells and 1000ng of pDNA per 10,000 cells. When comparing the RFP 
transfection  of  the  formulations  containing  250ng  of  pDNA  per  10,000  cells  the  only 
statistically significant improvement of RFP expression compared to the control occurs in the 
L:P:D:N complex with D/D whereby p<0.05. When the concentration of pDNA was increased 
to 1000ng of pDNA per 10,000 cells, both the L:P:D:N formulations did not give not notably 
different RFP expression compared to the Fugene-6 control.  
When  considering  the  toxicity  of  the  formulations  to  the  cells  there  was  no  significant 
difference (p>0.05) in the toxicity at both the lower and higher concentrations of pDNA in the 
formulations without MNPS. Interestingly there is a decrease in cell viability in the L:N and 
L:P:D:N conditions that is not seen in the MNP alone suggesting that the toxicity is a result of 
the  formulated  compound  as  opposed  to  the  MNP  itself.  In  the  lower  concentration  it 
appears that there is an increase in transfection efficiency for the L:P:D:Ns compared to the 
controls and L:P:Ds. However, when considering the cell viability it is possible to suggest 
that the increased value is also due to there being fewer viable cells but those that are 
present are expressing RFP which gives a higher ratio of expression to viable cells and 
hence, a higher value. 
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The transfection was repeated with the pTagRFP-N1-hNIS-TagRFP plasmid and both D/D 
and C/D lipids and the RFP expression and cell viability can be seen in Figures 74 and 75. 
 
Figure 74: RFP Expression of L:P:Ds and L:P:D:Ns Formulated with D/D and C/D in HCC1954 Cells with Different 
Amounts of DNA with pTagRFP-N1-hNIS-TagRFP pDNA and FuidmagCMX 
 
 
Figure 75: Cell Viability of L:P:Ds and L:P:D:Ns Formulated with D/D and C/D in HCC1954 Cells with Different 
Amounts of DNA  with pTagRFP-N1-hNIS-TagRFP pDNA and FluidmagCMX 
 
Upon repeating the experiment with the pTagRFP-N1-hNIS-TagRFP plasmid it is evident 
from Figure 74 that greater transfection was seen in the formulation with 250 ng of pDNA per 
10,000  cells  than  the  conditions  with  1000  ng  of  pDNA  per  10,000  cells.  There  was  a 
significant  reduction  in  RFP  expression  when  comparing  the  conditions  with  1000ng  of 
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pDNA per 10,000 cells to the Fugene-6 control (p<0.05). The cell viability, Figure 75, shows 
only  a  minimal  reduction  upon  the  addition  of  the  L:Ns  and  L:P:D:Ns  with  cell  toxicity 
comparable to the L:P:Ds (p>0.05). Greater transfection is seen in with the pTagRFP-N1-
TagRFP  compared  to  the  larger  pTagRFP-N1-hNIS-TagRFP  as  the  larger  pTagRFP-N1-
hNIS-TagRFP resides in the plasma membrane whereas the pTagRFP-N1-TagRFP is found 
within the cytosol, which allows for greater expression of RFP. 
When considering the results and that the ultimate goal is to use the pTagRFP-N1-hNIS-
TagRFP for radiolabelling and subsequent PET imaging it was decided that continuing with a 
pDNA concentration of 250 ng per 10,000 cells would be advantageous as this proved to 
give the best RFP expression when compared to 1000 ng per 10,000 cells of pDNA.  
4.4.4 Cell Uptake with Different Commercial Nanoparticles  
Cell  uptake  experiments  were  performed  in  order  to  determine  the  concentration  of  iron 
oxide  present  in  the  cells,  which  indicates  their  potential  as  MRI  contrast  agents.  Initial 
experiments  to  determine  the  iron  oxide  uptake  of  L:P:D:Ns  with  both  pDNA  types  and 
FluidmagCMX proved to be unsuccessful with cell death seen when uptake experiments 
were  performed.  This  led  to  a  need  to  establish  suitable  parameters  for  the  uptake 
experiments and it was decided that two experiments would be carried out determining both 
ideal  incubation  time  and  maximum  loading  amount.  It  was  also  decided  that  the 
FluidmagCMX MNPs would be tested alongside FluidmgD and FluidmagCT to determine 
which coating produced the best uptake results. It was hypothesised that FluidmagCMX and 
FluidmagCT would be the most successful owing to their negative surface charges and that 
there would be minimal uptake seen when using FluidmagD as a result of the neutral surface 
charge (see Table 42 for DLS and ZP results).  
Nanoparticle  DLS Results  ZP Results 
FluidmagD  48.1 nm, PDI: 0.145  10.1 mV, SD: 19.9 
FluidmagCT  52.1 nm, PDI: 0.144  -48.4 mV, SD: 11.9 
FluidmagCMX  62.9 nm, PDI: 0.412  -36.8 mV, SD: 12.3 
Table 42: DLS and ZP Results for the Commercial MNPs Used in Formulations (values taken as an average of 
three replicates) 
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Nanoparticle Type/Incubation Time  Amount of Iron Oxide per Cell (pg) 
FluidmagCMX (1h)  0.8 ± 0.1 
FluidmagCMX (2h)  0.1 ± 0.02 
FluidmagCMX (4h)  0.3 ± 0.04 
FluidmagCMX (24h)  Negligible 
FluidmagCT (1h)  0.3 ± 0.06 
FluidmagCT (2h)  0.2 ± 0.01 
FluidmagCT (4h)  7.9 ± 2.8 
FluidmagCT (24h)  5.6 ± 1.1 
FluidmagD (1h)  Negligible 
FluidmagD (2h)  0.7 ± 0.3 
FluidmagD (4h)  Negligible 
FluidmagD (24h)  Negligible 
Table 43: Time Course Cell Uptake for Different Commercial Nanoparticles 
 
Initially a time-course experiment was carried out with the three different MNP types at a 
concentration of 200 pg of MNP per cell with a total of 500,000 cells per formulation, Table 
43.  As  expected,  there  was  minimal  uptake  seen  with  FluidmagD  with  no  noticeable 
superparamagnetic contribution in the SQUID measurements. FluidmagCT provided the best 
uptake results with almost 8pg per cell of MNP after a 4 h incubation period. Conversely, 
there  was  minimal  uptake  with  the  FluidmagCMX,  which  was  unexpected  owing  to  its 
negative surface charge; a maximum uptake was seen after only 1 h of incubation with just 
under 1  pg of MNP per cell. Riegler et al. used SQUID magnetometry to determine the 
uptake of different commercially available iron oxide nanoparticles in mesenchymal  stem 
cells  (MSCs)  where  they  showed  an  uptake  of  57±18  pg  per  cell  when  incubated  with 
Chemicell’s FluidmagD, conversely there was minimal uptake seen when incubated with a 
carboxydextran coated MNP, Ferucarbotran.
23 These results indicate that different cell types 
take  up  different  MNPs  at  varying  rates  and  that  FluidmagD  MNPs  are  better  suited  for 
uptake in MSCs as opposed to the HCC1954 cell line. 
It was decided that both the FluidmagCT and FluidmagCMX would be used in subsequent 
concentration dependent cell loading experiments to see how much MNP could be taken up 
and if an increased amount of MNP per cell could improve the uptake with FluidmagCMX. In 
this experiment MNPs were added to the cells in varying concentrations and incubated for 
4h.   152 
Nanoparticle Type/Incubation Amount per Cell  Amount of Iron Oxide per Cell (pg) 
FluidmagCMX (40 pg)  Negligible 
FluidmagCMX (200 pg)  0.2 ± 0.06 
FluidmagCMX (1000 pg)  0.2 ± 0.02 
FluidmagCMX (2000 pg)  0.4 ± 0.05 
FluidmagCMX (4000 pg)  0.8 ± 0.15 
FluidmagCT (40 pg)  0.3 ± 0.07 
FluidmagCT (200 pg)  3.6 ± 0.28 
FluidmagCT (1000 pg)  71.9 ± 11.63 
FluidmagCT (2000 pg)  Cell Death 
FluidmagCT (4000 pg)  Cell Death 
Table 44: Concentration Dependent Cell Uptake for Different Commercial Nanoparticles 
 
Table 44 showed that despite the increased amount of FluidmagCMX added to the cells, 
uptake remained minimal with under 1 pg per cell upon the addition of the equivalent of 4 µg 
of MNP per cell. There was much better uptake however, seen in the FluidmagCT MNPs 
with a maximum uptake of around 70 pg per cell of MNP when loading the equivalent of 1µg 
per cell of MNP. At the higher MNP loading concentrations of 2 µg and 4 µg per cell of 
FluidmagCT there was cell death seen due to overloading the cells with iron oxide. From 
previous  results  and  lower  concentrations  it  is  possible  to  deduce  that  FluidmagCT  is 
internalised well by the HCC1954 cells and could have taken up too much in these higher 
concentrations and thus this has led to cell death.  
It was decided that both FluidmagCT and FluidmagCMX would be used in further cell uptake 
experiments  to  provide  a  comparison  between  the  two  but  also  to  see  with  the  newly 
established uptake conditions whether there was uptake in the encapsulated MNPs.  
4.4.5 In Vitro Transfection of Magnetolipopolyplexes (L:P:D:Ns) Formulated with 
FluidmagCT  
Transfection efficiency and cell viability measurements were carried out with the FluidmagCT 
MNPs following their successful internalisation. Both pDNA concentrations of 250 ng and 
1000  ng  per  10,000  cells  were  examined  with  the  pTagRFP-N1-hNIS-TagRFP  plasmid, 
Figures 76 and 77.   153 
 
Figure 76: RFP Expression of L:P:Ds and L:P:D:Ns Formulated with D/D and C/D in HCC1954 Cells with Different 
Amounts of DNA with pTagRFP-N1-hNIS-TagRFP pDNA and FuidmagCT 
 
 
Figure 77: Cell Viability of L:P:Ds and L:P:D:Ns Formulated with D/D and C/D in HCC1954 Cells with Different 
Amounts of DNA  with pTagRFP-N1-hNIS-TagRFP pDNA and FluidmagCT 
 
Transfection is seen in all conditions in both concentrations, including in both the D/D and 
C/D  formulated  L:P:D:Ns  with  a  notable  increase  in  the  transfection  in  D/D  formulations 
compared to those with a C/D lipid combination. The formulations containing D/D did not 
give a statistically significant difference in RFP expression when compared to the control 
(p>0.05), however the formulations contacting C/D showed a notable decrease in the RFP 
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expression compared to the Fugene-6 control (p<0.05). A higher rate of transfection is seen 
in the higher concentration of 1000 pg of pDNA for the complexes formulated with C/D but 
there is still notable transfection in the lower concentration. As previously noted, there is a 
slight  reduction  in  the  cell  viability  upon  the  addition  of  the  L:Ns  and  L:P:D:Ns  when 
compared  to  the  L:P:Ds  but  overall  a  comparable  cell  viability  between  the  two 
concentrations of pDNA is seen for the L:P:D:Ns.  
It was decided that as in the case of the FluidmagCMX encapsulated L:P:D:Ns that future 
transfections  with  the  FluidmagCT  containing  formulations  would  be  carried  out  with  the 
lower concentration of 250 ng of pDNA per 10,000 cells. 
4.4.6 Comparing the Transfection Efficiency of the pTagRFP-N1-TagRFP and 
pTagRFP-N1-hNIS-TagRFP Plasmids  
After  establishing  that  both  L:P:D:N  formulations  with  the  different  MNP  types  produced 
good  transfection  efficiencies  with  minimal  effect  to  cell  viability  compared  to  Fugene 
controls a transfection experiment was performed whereby the two pDNA types and the two 
MNP types were compared in L:P:D and L:P:D:N complexes against the Fugene control, see 
Figures 78 and 79.  
 
Figure 78: RFP Expression of L:P:Ds and L:P:D:Ns Formulated with D/D with pTagRFP-N1-TagRFP and pTagRFP-
N1-hNIS-TagRFP pDNA and Fluidmag CMX and Fluidmag CT MNPs 
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Figure 79: Cell Viability of L:P:Ds and L:P:D:Ns Formulated with D/D with pTagRFP-N1-TagRFP and pTagRFP-N1-
hNIS-TagRFP pDNA and Fluidmag CMX and Fluidmag CT MNPs 
 
From Figure 78 it is evident that there is greater RFP expression seen in the conditions that 
have  the  pTagRFP-N1-TagRFP  as  opposed  to  those  containing  the  pTagRFP-N1-hNIS-
TagRFP.  The  RFP  expression  is  significantly  lower  in  the  conditions  containing  the 
pTagRFP-N1-hNIS-TagRFP  pDNA  (with  the  exception  of  the  L:P:D:Ns  formulated  with 
Fluidmag CT) when compared to the conditions containing the pTAGRFP-N1-TagRFP pDNA 
(p<0.05).  As  previously  mentioned  the  larger  pTagRFP-N1-hNIS-TagRFP  resides  in  the 
plasma  membrane  whereas  the  pTagRFP-N1-TagRFP  is  found  within  the  cytosol,  which 
allows for greater expression of RFP.
24 When considering the cell viability, Figure 79, as in 
previous  conditions  there  is  a  slight  reduction  seen  in  those  conditions  containing  the 
L:P:D:Ns with no effect to viability in conditions where just the MNP or lipid is present.  
4.4.7 Cell Uptake in L:P:D:Ns 
Upon  establishing  that  both  FluidmagCMX  and  FluidmagCT  containing  L:P:D:Ns  could 
successfully  transfect  the  HCC1954  cells,  the  iron  oxide  concentration  in  the  cells  was 
determined by performing an uptake experiment. In order to establish suitable protocols for 
these  experiments,  L:P:D:Ns  were  formulated  with  D/D  lipid  formulations  owing  to  their 
commercial availability and widespread use in the literature.
1-5, 21,26 
Experiment parameters were adopted from the loading experiments in Section 4.4.4, with an 
incubation time of 4 h and a loading concentration of 1000 pg per cell of MNP. Unfortunately 
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these initial experiments yielded no results as they caused cell death in both the FluidmagCT 
and FluidmagCMX. This can be attributed to the large amount of lipid added to the cells in 
the L:P:D:N mixture when adding 1000 pg of MNP per cell, as the L:P:D:Ns have a ratio of 
10:1 L:N by adding 1000  pg/1µg of MNP this in turn means that 10 µg of lipid is therefore 
added. Various lower concentrations were also tried; 750 pg, 500 pg and 250 pg per cell of 
MNP which all again resulted in cell death and eventually a concentration was found that did 
not lead to cell death; 100 pg per cell of MNP. 
L:P:D:N/Incubation Amount per Cell  Amount of Iron Oxide per Cell (pg) 
L:P:D:N (D/D, FluidmagCMX)/20 pg  0.3 ± 0.2 
L:P:D:N (D/D, FluidmagCMX)/50 pg   0.3 ± 0.1 
L:P:D:N (D/D, FluidmagCMX)/100 pg  0.5 ± 0.3 
L:P:D:N (D/D, FluidmagCT)/20 pg  0.5 ± 0.3 
L:P:D:N (D/D, FluidmagCT)/50 pg  1.1 ± 0.4 
L:P:D:N (D/D, FluidmagCT)/100 pg  0.8 ± 0.2 
MNP, FluidmagCMX/ 100 pg  0.4 ± 0.1 
MNP, FluidmagCT/ 100 pg  5.0 ± 0.5 
Table 45: Cell Uptake Experiment for L:P:D:Ns Formulated with FluidmagCMX and FluidmagCT 
 
In both the FluidmagCMX and FluidmagCT L:P:D:N formulations there is a low uptake of iron 
oxide  per  cell  with  a  maximum  of  1.1  pg  per  cell  achieved  when  incubated  with  the 
equivalent of 50 pg of CT MNPs. When considering the FluidmagCMX MNPs there is no 
notable difference in uptake between the encapsulated MNPs and the MNPs themselves 
leading  to  the  conclusion  that  the  encapsulation  of  these  MNPs  in  the  L:P:D:Ns  neither 
affects nor improves their cellular uptake.  
In  the  case  of  the  FluidmagCT  MNPs  the  uptake  of  iron  oxide  is  reduced  6-fold  upon 
encapsulation in the L:P:D:Ns. Possible reasoning for such a reduction could be owing to its 
toxic effect on the cells at the elevated uptake concentrations. For example it could in fact be 
internalised well when encapsulated, as transfection data suggests from its RFP expression, 
but  owing  to  the  toxic  effect  of  both  the  MNPs  and  the  DNA  upon  the  cells  this  could 
ultimately result in cell death. Thus only the cells which have taken up minimal amounts of 
the L:P:D:N formulation remain and hence, have a lower uptake. At these low amounts of 
iron oxide per cell it would not be possible to use this L:P:D:N formulation as an MRI agent. 
The effective amounts of iron oxide needed have been shown to be 5pg per cell.
25   157 
As the FluidmagCMX MNPs have limited success in cellular iron oxide uptake when both 
added  alone  and  encapsulated  in  the  L:P:D:N  formulation  it  was  decided  that  further 
transfection and uptake results would be explored with the FluidmagCT MNPs alone. 
4.4.8 Transfection and Cell Uptake of L:P:D:Ns with Different Size MNPs  
The poor uptake of the L:P:D:Ns led to a variety of potential variations for improvement 
being tested. The first of these was to carry out a repeat transfection and uptake experiment 
with a FluidmagCT MNP with a larger core. It was hypothesised that the larger core would 
contain  a  larger  magnetic  domain  and  therefore  improve  the  magnetic  response  when 
measuring  the  uptake  of  the  L:P:D:Ns.  Initial  experiments  were  carried  out  using 
FluidmagCT MNPs with a 50nm hydrodynamic diameter, Figures 80 and 81 and Table 47 
show the results from both the transfection and iron oxide uptake experiments when using 
FluidmagCT with a hydrodynamic diameter of 100 nm compared to the 50 nm MNPs. Figure 
82 and Table 46 show the percentage uptake of the L:P:D:Ns with different sized MNPs 
compared to L:P:Ds and a Fugene-6 control. 
   
Figure 80: RFP Expression of L:P:D:Ns in HCC1954 Cells Formulated with Different Sized FluidmagCT MNPs, D/D 
Lipids and pTagRFP-hNIS-TagRFP and Figure 81: RFP Expression of L:P:D:Ns in HCC1954 Cells Formulated with 
Different Sized FluidmagCT MNPs, D/D Lipids and pTagRFP-hNIS-TagRFP 
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Figure 82: Quantification of Transfection of L:P:D:Ns with Different Sized FluidmagCT MNPs 
 
Formulation  Percentage Transfection 
Fugene  10.42 ± 4.48 
L:P:D  21.25 ± 21.8 
L:P:D:N (50nm)  28.45 ± 26.89 
L:P:D:N (100nm)  20.08 ± 15.91 
Table 46: Percentage Transfection of L:P:D:Ns Containing Different Size MNPs 
 
When  comparing  the  transfection  efficiency  of  the  L:P:D:Ns  with  the  larger  and  smaller 
MNPs, Figure 80, it is possible to evaluate that they are in fact similar in their ability to 
transfect the HCC1954 cells. As previously seen, there is a slight reduction in cell viability 
upon addition of the L:P:D:Ns in both the larger and smaller MNP conditions but there is no 
notable difference between the two different formulations  (p>0.05). When quantifying the 
percentage of transfected cells, Figure 82 and Table 46, the L:P:D:N formulation with the 50 
nm  FluidmagCT  MNP  has  a  slightly  better  average  transfection  percentage  of  28% 
compared to 20% for the 100 nm FluidmagCT MNP. It is important to note the large error 
margins present when quantifying the transfection, Figure 82. As previously mentioned in 
Section 2.7.9, when measuring the percentage transfection and three images per condition 
are taken at different points in the well in both the Cy3 channel and the DAPI channel and a 
ratio of the number of transfected cells and viable cells is calculated giving a measure of the 
percentage  transfection.  The  large  error  margins  suggest  there  are  large  areas  of 
transfection and then areas where there is little to no transfection taking place which leads to 
the conclusion that perhaps the L:P:Ds and L:P:D:Ns do not have a uniform mechanism of 
action throughout the well in which the cells are seeded. 
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By examining Table 47 it is possible to deduce that increasing the size of the MNP in the 
L:P:D:N  has  no  distinguishable  improvement  on  cellular  uptake  of  iron  oxide  and  other 
means of improvement are therefore required in order to establish a suitable level of uptake. 
L:P:D:N/ MNP Size   Amount of Iron Oxide per Cell (pg) 
L:P:D:N/ 50 nm  0.8 ± 0.06 
L:P:D:N/ 100 nm  0.7 ± 0.08 
Table 47: Cell Uptake with L:P:D:Ns using Different Size FluidmagCT MNPs 
 
4.4.9 Transfection and Cell Uptake of L:P:Ds and L:P:D:Ns with Different Lipid 
Formulations  
As no improvement to the iron oxide uptake was made when using a larger MNP in the 
L:P:D:N formulation it was hypothesised that trying different lipid formulations might improve 
the  uptake.  Alongside  the  D/D  formulations  of  L:P:Ds  and  L:P:D:Ns  both  DT/D  and  C/D 
combinations were also attempted. The DOTAP lipid was chosen as it has been shown in 
the literature that DT/D provides an improved transfection of 2 to 4- fold when compared to 
D/D formulations.
26 As discussed in Section 1.3.3, using a PEGylated lipid such as CH300 
improves the uptake and length of time in vivo owing to its ability to evade uptake by the 
reticuloendothelial system (RES).
21  
Table 48 shows the DLS and ZP results for the L:P:D and L:P:D:N formulations with the 
DT/D  and  C/D  lipid  combinations.  When  examining  the  results  for  the  DT/D  lipids  the 
liposomes alone gave a large hydrodynamic diameter of 289.0 nm and a surface charge of 
43.3 mV. The addition of MNPs to form the L:Ns causes a reduction in size to 140.4 nm and 
a surface charge of 62.7 mV indicating the successful formation of the L:N. The reduction in 
size can be attributed to the addition of the negative MNP causing the positively charged 
lipids to condense tighter around the surface of the MNP.  
A smaller size is also seen in the L:P:D:Ns, 205.9 nm with a surface charge of 56.4 mV, 
which again confirms the successful formulation of the L:P:D:Ns. The L:P:D:Ns also produce 
a smaller hydrodynamic diameter and higher surface charge than the L:P:Ds. Similar results 
are seen with the C/D formulation whereby the addition of the MNP causes a reduction in 
size from 123.3 nm to 108.7 nm with the L:N maintaining a positive surface charge. The   160 
L:P:D:Ns  with  the  C/D  lipids  have  a  hydrodynamic  diameter  of  197.0  nm  and  a  surface 
charge of 45.3 mV confirming a successful formulation of the L:P:D:Ns. 
Formulation  DLS Result  Zetapotential Result 
DT/D (L)  289.0 nm, PDI: 0.380  43.3 mV, SD: 5.11 
L:N (DT/D)  140.4 nm, PDI: 0.247  62.7 mV, SD: 13.2 
L:P:D (DT/D)  315.4 mV, PDI: 0.367  36.9 mV, SD: 12.4 
L:P:D:N (DT/D)  205.9 nm, PDI: 0.446  56.4 mV, SD:12.1 
C/D (L)  123.3 nm, PDI: 0.267  65.2 mV, SD: 7.06 
L:N (C/D)  108.7 nm, PDI: 0.243  64.3 mV, SD: 8.27 
L:P:D (C/D)  203.2 nm, PDI: 0.562  48.2 mV. SD: 12.0 
L:P:D:N (C/D)  197.0 nm, PDI: 0.386  45.3 mV, SD: 6.58 
Table 48: DLS and ZP Data for the DT/D and C/D Lipid Formulations (values taken as an average of three 
replicates) 
 
L:P:D  and  L:P:D:N  formulations  with  both  the  DT/D  and  C/D  lipid  combinations  were 
transfected along with the L:P:Ds and L:P:D:Ns formulated with D/D, Figures 83 and 84. The 
percentage  transfection  of  the  different  lipid  formulations  was  also  carried  out  to  further 
assess the transfection efficiency of the different formulations, Figure 85 and Table 49. 
 
 
Figure 83: RFP Expression in HCC1954 Cells of L:P:Ds and L:P:D:Ns Formulated with Different Lipid Combinations, 
pTagRFP-N1-hNIS-TagRFP pDNA and Fluidmag CT 
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Figure 84: Cell Viability in HCC1954 Cells of L:P:Ds and L:P:D:Ns Formulated with Different Lipid Combinations, 
pTagRFP-N1-hNIS-TagRFP pDNA and Fluidmag CT 
 
 
Figure 85: Quantification of Transfection in HCC1954 Cells of L:P:Ds and L:P:D:Ns Formulated with Different Lipid 
Combinations, pTagRFP-N1-hNIS-TagRFP pDNA and Fluidmag CT 
 
Formulation  Percentage Transfection 
Fugene  6.0 ± 0.9 
L:P:D (D/D)  5.3 ± 1.4 
L:P:D:N (D/D)  4.2 ± 1.0 
L:P:D (DT/D)  9.3 ± 0.6 
L:P:D:N (DT/D)  9.3 ± 2.8 
L:P:D (C/D)  3.2 ± 0.5 
L:P:D:N (C/D)  2.2 ± 0.3 
Table 49: Percentage Transfection of L:P:Ds and L:P:D:Ns Formulated with Different Lipid Combinations 
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Figures  63  and  64  show  the  RFP  expression  and  the  cell  viability  of  the  different  lipid 
formulations in comparison to the Fugene-6 transfection control. In both the RFP expression 
and cell viability there is no statistically significant difference (p>0.05) between the three 
different  lipid  formulations  both  with  the  L:P:Ds  and  L:P:D:Ns  and  the  Fugene-6  control 
suggesting comparable transfection efficiencies. In the quantification of transfection, Figure 
85 and Table 49 the DT/D L:P:Ds and L:P:D:Ns have a larger percentage transfection than 
the D/D and C/D formulations.  
The  increased  percentage  transfection  seen  with  the  DT/D  lipid  combination  was  not 
however mirrored in the iron oxide uptake results, Table 50, with an uptake of 0.3 pg per cell 
compared to 0.8 pg per cell with the D/D lipid formulations. The C/D lipid combination also 
did not elucidate an improvement in uptake with an average of 0.4 pg per cell. These levels 
of uptake are still not sufficiently high enough that MRI imaging could be performed with the 
L:P:D:Ns. 
L:P:D:N/ Lipid Formulation/Concentration Added per 
Cell 
Amount of Iron Oxide per Cell (pg) 
L:P:D:N / DT/D/ 100 pg  0.3 ± 0.07 
L:P:D:N / C/D/ 100 pg  0.4 ± 0.1 
Table 50: Cell Uptake for L:P:Ds and L:P:D:Ns with Different Lipid Formulations 
 
4.4.10 Transfection and Cell Uptake with Targeting Peptides 
L:P:D:Ns were formulated with the D/D lipid combination alongside the pTagRFP-N1-hNIS-
TagRFP pDNA and FluidmagCT MNPs but in place of the K16, a targeting peptide was used, 
see Table 36. L:P:Ds and L:P:D:Ns were formulated with the different targeting peptides and 
their transfection efficiency measured alongside their effect on cell viability and iron oxide 
uptake. Table 51 shows the DLS and ZP characterisation data for the L:P:Ds and L:P:D:Ns 
formulated with the three targeting peptides. It is evident to see that the L:P:Ds are all large 
in size ranging between 250 nm with TP3 and 400 nm with TP2, although they show positive 
surface  charges  suggesting  that  the  formulation  was  successful.  The  large  sizes  of  the 
L:P:Ds formulated with these targeting peptides is responsible for their large polydispersity 
index values, with the L:P:D formulated with TP1 having a PDI value of 0.617. The L:P:D:Ns   163 
show smaller sizes (between 150  nm and 250  nm) and higher surface charges and the 
smaller size can be accredited to the presence of the extra negative charge when the MNP 
is present causing the cationic liposome structure to condense tighter around the MNP, the 
pDNA and the peptide.  
Formulation  DLS Result  Zetapotential Result 
L:P:D with TP1  324.0 nm, PDI: 0.617  28.6 mV, SD: 15.9 mV 
L:P:D:N with TP1  162.6 nm, PDI: 0.241  37.2 mV, SD: 19.3 mV 
L:P:D with TP2  396.0 nm, PDI: 0.405  28.2 mV, SD: 8.69 mV 
L:P:D:N with TP2  259.2 nm, PDI: 0.395  51.0 mV, SD: 11.2 mV 
L:P:D with TP3  254.0 nm, PDI: 0.441  43.8 mV, 12.0 mV 
L:P:D:N with TP3  145.5 nm, PDI: 0.178  46.4 mV, 16.1 mV 
Table 51: DLS and ZP Data for L:P:Ds and L:P:D:Ns Formulated with Different Targeting Peptides (values taken as 
an average of three replicates) 
 
Figure 86: RFP Expression in HCC1954 Cells of L:P:Ds and L:P:D:Ns with Different Targeting Peptides, D/D Lipids, 
pTagRFP-N1-TagRFP pDNA and FluidmagCT 
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Figure 87: Cell Viability in HCC1954 Cells of L:P:Ds and L:P:D:Ns with Different Targeting Peptides, D/D Lipids, 
pTagRFP-N1-TagRFP pDNA and FluidmagCT 
 
From looking at Figure 86 it is evident that there is not a remarkable improvement (p>0.05) 
to  the  RFP  expression  upon  the  inclusion of the three targeting peptides  in  the  L:P:D:N 
formulations in comparison to the L:P:DNs formulated with K16 alone. There was also no 
statistically  significant  difference  (p>0.05)  between  the  L:P:D:Ns  formulated  with  the 
targeting  peptides  and  the  L:P:D:Ns  formulated  with  the  K16  when  considering  the  cell 
viability. The results from the RFP expression and cell viability indicate that the L:P:D:Ns 
formulated with the different targeting peptides are comparable to the L:P:D:Ns formulated 
with the K16 peptide. 
L:P:D:N  Amount of Iron Oxide per Cell (pg) 
L:P:D:N with K16  1.2 ± 0.2 
L:P:D:N with TP1  1.7 ± 0.2 
L:P:D:N with TP2  Negligible 
L:P:D:N with TP3  1.1 ± 0.3 
Table 52: Cell Uptake Results with Different Targeting Peptides 
 
Iron oxide uptake experiments also show no remarkable difference between the L:P:D:Ns 
formulated with K16 and the L:P:D:Ns formulated with TP1 and TP3, with the TP2 showing 
no superparamagnetic contribution when magnetic measurements performed, Table 51.  
Despite using targeting peptides there was no improvement to cellular uptake of iron oxide 
suggesting  that  perhaps  there  is  a  key  factor  hindering  the  uptake  of  iron  oxide  when 
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encapsulated in the L:P:D:N formulation that cannot be overcome by changing parameters 
of the formulation alone. 
4.4.11 Transfection and Cell Uptake with Separate Addition of Nanoparticles 
As a result of the poor iron oxide uptake with the L:P:D:Ns experiments were undertaken 
where the FluidmagCT MNPs were administered separately to the L:P:D compound to see if 
any  effect  to  either  transfection  of  iron  oxide  uptake  took  place.  Initial  transfection 
experiments were carried out where the L:P:Ds were formulated with D/D and the pTagRFP-
N1-hNIS-TagRFP plasmid and the FluidmagCT was added in the same amount that would 
ordinarily be added to the L:P:D:N formulation but administered to the cells separately. The 
cells were incubated with L:P:Ds with the separate addition of MNPs at different time frames 
after  the  L:P:D  addition;  0  min,  30  min  and  1  h  and  these  parameters  were  measured 
against the L:P:D and L:P:D:N formulations. 
 
Figure 88: RFP Expression in HCC1954 Cells of L:P:Ds and L:P:D:Ns Formulated with D/D Lipids, pTagRFP-N1-
hNIS-TagRFP pDNA and FluidmagCT with Separate MNP Addition 
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Figure 89: Cell Viability in HCC1954 Cells of L:P:Ds and L:P:D:Ns Formulated with D/D Lipids, pTagRFP-N1-hNIS-
TagRFP pDNA and FluidmagCT with Separate MNP Addition 
 
From examining Figures 88 and 89 it is evident that the separate addition of MNP alongside 
the  L:P:D  formulation  has  comparable  transfection  to  both  the  L:P:D  and  L:P:D:N 
formulations. There is however, a significant reduction in RFP expression for each of the 
different conditions when compared to the Fugene-6 control in this experiment. There is also 
no  notable  effect  to  cell  viability  with  comparable  results  across  the  L:P:D,  L:P:D:N  and 
L:P:D + MNP parameters (p>0.05).  
Interestingly however, when adding the MNP separately to the L:P:Ds a dramatic increase in 
iron  oxide  uptake  took  place  with  the  amount  per  cell  rising  5  fold.  In  this  particular 
experiment there was 0.5pg per cell obtained with the L:P:D:Ns but when the MNPs were 
added separately there was an increase in iron oxide uptake to around 2.5pg per cell, see 
Table 53. Figure 90 shows the cell pellets produced from the iron uptake experiment and 
from examining the different cell pellets it is possible to conclude that the separate addition 
of MNPs (2-4) shows a much darker cell pellet than seen in the L:P:D:N pellet (1).  
Particle Type/ Concentration Added per Cell of Iron 
Oxide (pg)/ Incubation Time (h) 
Amount of Iron Oxide per Cell (pg) 
L:P:D:N/ 100 pg/ 4h (1)  0.5 ± 0.05 
L:P:D + NP/ 100 pg/ 4 h L:P:D, 4h NP (2)  2.3 ± 0.2 
L:P:D + NP/ 100 pg/ 4 h L:P:D, 3h NP (3)  1.9 ± 0.3 
L:P:D + NP/ 100 pg/ 4 h L:P:D, 2h NP (4)  1.5 ± 0.1 
Table 53: Cell Uptake Results of L:P:D:N Compared to L:P:D with Separate Addition of MNP 
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Figure 90: Cell Pellets In Eppendorf Tubes Illustrating the Uptake Difference Upon Separate Addition of MNPs and 
L:P:Ds 
 
As a result of the higher iron oxide loading capabilities achieved when separately adding the 
MNPs to the L:P:D complexes a further uptake experiment was performed whereby again 
the MNPs were added separately to the L:P:Ds but this time in differing amounts; 100pg, 
200pg, 400pg and 800pg of iron oxide per cell. From Table 54 it is evident that it is possible 
to add far more MNPs separately to the L:P:Ds than when encapsulated with no drastic 
effect to cell viability. When adding the equivalent dose of 800 pg of iron oxide per cell it was 
possible  to  achieve  an  uptake  of  13  pg  per  cell,  which  is  a  sufficient  level  for  MRI 
measurements. Figure 91  shows the colour differences of the various loading conditions 
following aspiration of the cell pellet. It is quite evident that there is more iron oxide present 
in (4) where 800 pg per cell of MNP was loaded compared to that of (1) where 100 pg of 
MNP was added.  
Particle Type/ Concentration Added per Cell of Iron 
Oxide(pg) 
Amount of Iron Oxide per Cell (pg) 
L:P:D + NP/ 100 pg (1)  2.5 ± 1.2 
L:P:D + NP/ 200 pg (2)  2.8 ± 1.0 
L:P:D + NP/ 400 pg (3)  4.5 ± 2.2 
L:P:D + NP/ 800 pg (4)  12.9 ± 8.2 
NP/ 400 pg  4.9 ± 1.2 
Table 54: Cell Uptake Amounts when MNPs Loaded are Separately to L:P:Ds 
 
(1)  (2)  (3)  (4)   168 
 
Figure 91: Cell Pellet Solutions when Different Amounts of MNPs are Loaded Separately to L:P:Ds 
 
4.4.12 Transfection and Cell Uptake in the Macrophage Line 264.7 (Parental)  
As a consequence of the low iron oxide uptake seen with the L:P:D:Ns in the HCC1954 cell 
line despite various different alterations to the method it was hypothesised that perhaps this 
could be a result of the cell line itself and perhaps using a different cell line could circumvent 
the low uptake issues. It was decided that transfection and iron oxide uptake experiments 
would be tried with the macrophage cell line 264.7 (Parental). Macrophages are classified as 
phagocytic cells and these cells work by undergoing phagocytosis, which is the process of 
binding solid particles to the surface and then internalising them (a form of endocytosis) 
where they are later broken down. The primary role of the macrophages in the body is to 
protect the body from infection but in this case its ability to engulf the iron oxide nanoparticle 
proves to be beneficial for increased uptake.
27-28 
Initially  cell  uptake  experiments  were  performed  with  the  un-encapsulated  MNPs; 
FluidmagCMX and FluidmagCT to determine the maximum loading with no toxic effect to the 
cells. Table 55 shows the iron oxide uptake per cell when varying concentrations of MNP 
were added to the macrophage cells.  
Nanoparticle Type/ Amount of Iron Oxide Seeded 
per Cell 
Amount of Iron Oxide per Cell (pg) 
FluidmagCMX/ 50 pg  Negligible 
FluidmagCMX/ 100 pg  1.3 ± 0.1 
FluidmagCMX/ 250 pg  2.5 ± 0.9 
FluidmagCMX/ 500 pg  5.9 ± 0.3 
FluidmagCMX/ 1000 pg  8.7 ± 0.3 
(1)  (2)  (3)  (4)   169 
FluidmagCT/ 50 pg  0.9 ± 0.04 
FluidmagCT/ 100 pg  6.40± 1.1 
FluidmagCT/ 250 pg  13.9 ± 4.1 
FluidmagCT/ 500 pg  298 ± 10.6 
FluidmagCT/ 1000 pg  419 ± 66.9 
Table 55: Iron Oxide Uptake in Macrophages with Different MNPs 
 
Much like in the HCC1954 cell line it is evident that there is a much greater uptake in the 
cells  with  the  FluidmagCT  MNPs  compared  to  that  of  the  FluidmagCMX  MNPs.  When 
adding the equivalent of 1000pg of FluidmagCMX to the macrophage cells it was possible to 
achieve a loading value of 6 pg per cell of iron oxide but with the FluidmagCT a loading of 
400 pg per cell was achieved. This increased uptake compared to the HCC1954 cell line is 
according to the properties exhibited by the macrophage cell line and their ability to take up 
increased amounts of iron oxide.
 
After  successfully  determining  the  loading  of  the  macrophage  cells,  a  transfection  was 
performed with the L:P:D and L:P:D:N formulations made up with D/D lipids, FluidmagCT 
and pTagRFP-N1-hNIS-TagRFP, Figure 92 and 93. 
 
 
Figure 92: RFP Expression of L:P:Ds and L:P:D:Ns Formulated with D/D Lipids, FluidmagCT and pTagRFP-N1-
TagRFP pDNA in Macrophage Cells 
Figure 93: Cell Viability of L:P:D:Ns in HCC1954 Cells Formulated with Different Sized FluidmagCT MNPs, D/D 
Lipids and pTagRFP-hNIS-TagRFP 
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Figures 92 and 93 show the transfection efficiency and cell viability of the various conditions 
used to transfect the macrophages. It is evident that there is transfection in all cases with 
Lipofectamine  showing  the  best  RFP  expression  and  the  L:P:D  and  L:P:D:N  conditions 
having comparable expression to Fugene HD (p>0.05). There is no significant effect to cell 
viability (p>0.05) when the L:P:Ds and L:P:D:Ns were added to the macrophage cell lines 
suggesting that the L:P:Ds and L:P:D:Ns have comparable toxicity to the controls. The low 
transfection seen could perhaps be attributed to the properties of the macrophages, they 
exhibit the ability to internalise particles that are bound to the surface of the cell and once 
internalised  the  macrophage  begins  to  break  down  the  particle.  Once  internalised  in  the 
macrophages,  the  L:P:D:N  formulation  are  subject  to  being  broken  down  and  the  poor 
transfection  could  be  explained  by  the  facile  breakdown  of  the  lipid,  pDNA  and  peptide 
components.
27-28 
After measuring the transfection efficiency of the L:P:Ds and L:P:D:Ns their cellular uptake of 
iron oxide was measured. Table 56 shows that much like the results seen with the HCC1954 
cells  there  is  a  poor  level  of  uptake  with  a  maximum  of  0.3  pg  per  cell  seen,  which  is 
concordant with the transfection results where there is a poor level of transfection. 
Particle Type/ Amount of Iron Oxide Seeded Per Cell  Amount of Iron Oxide per Cell (pg) 
L:P:D:N (D/D), 100 pg  0.3 ± 0.1 
Table 56: Cell Uptake of L:P:D:N in Macrophages 
 
The poor levels of RFP expression and iron oxide uptake confirm that the macrophage line 
does  not  provide  an  improvement  over  the  HCC1954  cell  line  when  administering  the 
L:P:D:Ns,  despite  the  macrophage  line  providing  a  vastly  improved  uptake  of  iron  oxide 
MNPs when added without the lipid, peptide and pDNA components.  
4.5 Chapter Summary  
It is possible to conclude that the successful formulation of L:P:D:Ns has been achieved 
using  the  diffusion  method,  which  involves  first  formulating  the  liposomes  and  then 
subsequently  adding  the  MNPs,  pDNA  and  peptides.  DLS  and  ZP  characterisation  data 
confirm  that  the  formulation  has  been  successful  by  showing  an  increase  in  the 
hydrodynamic diameter from around 130 nm to 210 nm upon the addition of the MNP, pDNA   171 
and peptide components. The surface charge remains positive, around 45 mV, when all the 
components  are  encapsulated  confirming  that  they  are  not  electrostatically  bound  to  the 
surface and have been incorporated into the liposomes.  
In vitro transfection data shows the ability of the L:P:D:Ns to be used as optical imaging 
agents in vitro with RFP expression seen in the HCC1954 cell line upon the addition of the 
L:P:D:Ns, with minimal effect to cell viability. SQUID measurements were used to determine 
the concentration of MNPs within the cell providing information on both cellular uptake and 
encapsulation  efficiency.  Unfortunately  the  SQUID  measurements  showed  a  low 
concentration of around 1 pg of iron oxide per cell for the L:P:D:Ns, which is not sufficient for 
use as contrast agents in MRI. Work in the literature has shown a minimum of 5 pg of iron 
oxide MNP per cell is required for use as a contrast agent.
25 The low concentration of MNPs 
taken up into the cells can be attributed to the amount encapsulated when formulating the 
L:P:D:N. In order to successfully form the L:P:D:N a weight ratio of 10:1 lipid:MNP must be 
observed, if the amount of MNP added to the cells increased so too is the amount of lipid 
which has a large negative effect to cell viability owing to increased amount of lipid present. 
Section 4.4.11 confirms that the low concentration issue is due to poor encapsulation as the 
separate addition of MNPs and lipopolyplexes yields a higher concentration of iron oxide per 
cell when compared to the addition of L:P:D:Ns containing the same amount of MNPs. 
In order to try and improve the concentration of MNPs in the cells a range of modifications to 
the L:P:D:Ns were made including; the use of different lipid formulations, targeting peptides 
and MNPs with a larger hydrodynamic diameter. However, even with these modifications, a 
low concentration of around 1pg per cell of iron oxide was still obtained indicating that these 
L:P:D:Ns would still be unsuccessful for use a MRI contrast agents. In order to use the 
L:P:D:Ns as MRI contrast agents a method for increasing the amount of MNPs encapsulated 
in the L:P:D:Ns would need to be established.  
Despite  the  issues  faced  by  the  low  concentration  of  MNPs  per  cell  the  successful 
formulation  of  a  multimodal  diagnostic  agent  has  been  reported  that  encapsulates 
multifunctional  pDNA  and  MNPs  with  the  possibility  of  site  selective  targeting  with  the 
incorporation of targeting peptides.     172 
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5.0 Conclusion and Future Work 
The aim of the work presented was to develop a method for the formulation of a multimodal 
cancer-imaging  agent,  a  magnetolipopolyplex.  MNPs,  pDNA  and  targeting  peptides  were 
encapsulated in shielding lipids to produce an agent that has potential as both an MRI, PET 
and optical imaging agent.  
Chapter 3 presented a method of magnetolipopolyplex formulation (L:D:P@N) whereby PLL 
was conjugated to dextran coated MNPs. Following the conjugation of PLL to the MNPs, 
pDNA  was  condensed  onto  the  surface  of  the  MNP  and  this  was  then  subsequently 
encapsulated into shielding lipids. DLS and ZP data showed the formulated L:D:P@N had 
large sizes and negative surface charges, Tables 33 and 34. These large sizes and negative 
charges led to poor transfection of the pDNA and poor cell viability in HCC1954, MDA-MB-
231 and MCF-7 cancer cell lines.  
In Chapter 4 a new approach to the formulation of the magnetopolyplexes was investigated 
in  order  to  overcome  the  poor  transfection  and  loss  to  cell  viability  with  the  L:D:P@Ns 
formulated in Chapter 3. Here, liposomes were pre-formulated and MNPs and pDNA co-
condensed with peptides were subsequently added in order to form an L:P:D:N. DLS and ZP 
confirmed the successful formulation of the L:P:D:N with an increase in the hydrodynamic 
diameter from 130 nm (D/D lipid alone) to 210 nm when formulated. The surface charge 
remained positive with an overall surface charge of around 45 mV for the formulated L:P:D:N, 
confirming the encapsulation of the MNPs into the liposomes and also indicating the stability 
of the formulation. In vitro transfection data showed good transfection of the pDNA in the 
HCC1954 cell line with minimal toxic effect to the cells.  
Despite the success of the formulation as a transfection agent poor cell uptake was seen 
with the L:P:D:Ns. When encapsulated into the L:P:D:Ns a low concentration per cell of iron 
oxide MNP was achieved, typically around 1pg per cell, which is too low for use as an MRI 
contrast agent. Several attempts to improve the uptake were tried including increasing the 
size of MNP from 50 nm to 100 nm and using targeting peptides to improve the delivery of 
the L:P:D:Ns to the cells but these however, did not increase the concentration of iron oxide 
in the cells.    177 
Despite endeavours to improve the concentration of iron oxide delivered to the cell it was not 
possible and therefore limited the L:P:D:N’s success as an MRI contrast agent. The lack of 
success can be attributed to the complex nature of the formulation. In order to achieve a 
suitable concentration of iron oxide in the cell a large amount of L:P:D:N would need to be 
administered  to  the  cells.  This  would  ultimately  result  in  cell  death  owing  to  the  high 
concentration of L:P:D:N present, which has a toxic effect to the cell. When the MNPs were 
administered separately to the cells alongside L:P:Ds, an increase in the concentration of 
iron oxide to 2.5 pg per cell was seen confirming that the complex nature of the L:P:D:Ns 
hinders the uptake of the MNPs into the cell.  
The overcomplicated nature of this formulation prohibits further improvement to the uptake of 
the MNPs negating its use as an MRI contrast agent and subsequently as a multimodal 
contrast agent. A simplistic approach to the formulation of a multimodal agent has been 
shown to be successful in the literature and an example of which is the work published by 
Silva et. al. Here they reported the formulation of a bimodal contrast agent, which combines 
both  MRI  imaging  and  photodynamic  therapy  by  incubating  the  human  macrophage  line 
THP1 with iron oxide MNPs and the fluorescent drug mTHPC. The MNP and fluorescent 
drug  loaded  macrophage  cells  are  then  administered  in  vivo  providing  a  biocompatible 
means  to  deliver  these  moieties  owing  to  its  ability  to  circumvent  the  body’s  clearance 
mechanisms.
1 Further discussions of future work can be seen in Section 1.8. 
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